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Abstract  
Arterial occlusion accounts for high rates of mortality in the western world. Strategies to 
bypass an occlusion by activating collateral vessels could reduce the consequences of 
arterial diseases. This thesis investigates the genes involved in collateral vessel remodelling 
in the chick embryo to gain insight into the process. Ligation of the right proximal vitelline 
artery of HH st 17 chick embryos occluded blood flow to the right hand side of the extra-
embryonic tissue and vitelline vessel network. Collateral vessels were seen to develop from 
the pre-existing, left (unligated) vitelline artery and extended across the midline to carry 
arterial blood to the un-perfused side of the extra-embryonic tissue. The remodelling 
process was active over 48 hours and developed many small collateral vessels into a few, 
main conducting arteries.  The number of collateral vessels peaked at 12 hours post tied-
ligation and then decreased, whilst collateral vessel diameter continued to increase over 
the time period. 
Analysis of the global transcriptional profile of collateral vessels in the chick embryo was 
assessed following ligation, during early stages of collateral vessel development (4 hours), 
at the point of pruning and remodelling of the collateral network (12 hours). Collateral 
vessel formation in the chick embryo was found to be associated with a unique and specific 
gene expression profile. Phosphodiesterase 10A (PDE10A), an cAMP hydrolysing enzyme, 
was upregulated in tied-ligated embryos at 4 hours post tied-ligation and hypothesised to 
play a role in the remodelling process. To study PDE10A papaverine hydrochloride was 
used to inhibit the enzyme. Papaverine had no effect on normal vessel development but 
significantly impaired collateral vessel diameter from 6 hours post-ligation. This effect was 
rescued by co-treatment with Protein Kinase A inhibitor, Rp-8-Br-cAMPS. To begin an 
assessment of the role of PDE10A in collateral vessel remodelling, proliferation was 
investigated, in vivo. However, a mechanism of action for PDE10A has yet to be elucidated. 
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Chapter 1 
Introduction 
1.1 Atherosclerosis and the clinical relevance of arterial occlusion 
Arterial occlusion accounts for high rates of morbidity and mortality in the Western world 
(Aschwanden et al., 2014).  Commonly, occlusion of the coronary or cerebral arteries 
results in myocardial infarction or stroke (Schaper., 1971, Helisch and Schaper., 2003).  
Arterial occlusion can also occur in the major conducting arteries or peripheral vasculature 
(Fung and Helisch, 2012). In most cases, arterial occlusion is caused by atherosclerosis, a 
disease of the arterial wall. Atherosclerosis is an inflammatory disease characterised by 
lipid deposition in the arterial wall and can be initiated when endothelial cells experience 
disturbed or low flow patterns (Ku et al., 1985, Helderman et al., 2007). This activates 
endothelial cells which up-regulate expression of adhesion molecules and recruit 
inflammatory cells (Libby et al., 1996). In turn, the inflammatory response stimulates 
proliferation and migration of smooth muscle cells (van der Wal et al., 1994). 
Consequently, the arterial wall thickens. Compensatory outward remodelling occurs in an 
attempt to maintain lumen diameter and constant flow. This was first observed by Glagov 
and colleagues in 1987 and referred to as ‘Glagov’s phenomenon’ (Glagov et al., 1987). As 
invasion of monocytes into the lesion occurs and plaque expansion continues, the lesion 
can ultimately reduce the vessel lumen. The mature plaque consists of a lipid core, 
surrounding necrotic tissue and a fibrous cap (Fuster et al., 1990). When the plaque 
protrudes into the lumen and exceeds 40% of the vessel lumen area, Glagov’s phenomenon 
ceases and stenosis of the vessel occurs. This remodelling is termed ‘pathophysiological’ 
remodelling and causes narrowing of the vessel lumen and restriction of blood flow (Glagov 
et al., 1987).  Stenosis of a vessel may also occur if a plaque becomes unstable due to 
reduced fibrous cap thickness, increased necrotic core and inflammation. Unstable plaque 
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rupture induces a thrombus to form due to mixing of lipid and blood, causing a thrombus 
to occlude the vessel (Fuster et al., 1990). Vessel occlusion prevents downstream perfusion 
and results in tissue necrosis due to ischaemia.  
Strategies to alleviate symptoms such as percutaneous coronary intervention (PCI) or 
bypass surgery are invasive (Kugler and Rudofsky., 2003). Statins are used to lower low-
density lipoprotein (LDL) cholesterol which contributes to atherosclerosis progression 
(Vaughan et al., 2000). There is increasing evidence from clinical trials to suggest that 
statins reduce ischaemic events, as well as regulating thrombotic tendency (Pourati et al., 
2003). High doses of statins reduce plaque volume by a small amount but there is currently 
no therapy that can significantly reverse atherosclerosis to reduce vessel obstruction 
(Nissen et al., 2006). 
 There is a pressing need for novel therapies that could reduce the consequences of arterial 
diseases. One line of investigation is to encourage remodelling of small connecting blood 
vessels which exist between large conducting arteries that could naturally bypass the 
blockage and rescue/alleviate the symptoms and consequences of vessel occlusion. This 
process is known as arteriogenesis. 
1.2 Arteriogenesis and the process of collateral vessel remodelling 
Flow-induced remodelling of collateral vessels has been studied for centuries. The term 
arteriogenesis was coined by Schaper and colleagues in 1976, to describe the adaptive 
response of pre-existing arterioles to remodel into collateral arteries (Schaper and Ito., 
1996). Small vessel anastomoses (connecting arterioles which pre-exist between larger 
conducting arteries) divert blood flow around a blockage in a main conducting artery by 
remodelling into “collateral vessels” (Deindl and Schaper., 2005). These communications 
bridge the area proximal to the blockage with distal connections downstream (Schaper and 
Scholz., 2003). Following occlusion, a pressure gradient occurs which lowers pressure in 
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distal vessels, favouring an increase in flow in vessels proximal to the occlusion (Buschmann 
and Schaper., 2000). This increased flow and change in haemodynamics activates cells 
lining the blood vessels. This causes a cascade of events leading to expansion and 
enlargement of collateral vessels to accommodate the increase in blood flow. Although 
collateral vessels seldom if ever completely return flow levels to baseline, a sub-maximal 
amount of flow can compensate for the occlusion (Heil and Schaper., 2004), particularly at 
rest when basal blood flow requirements are low. 
1.2.1 Collateral vessel architecture 
Collateral vessel remodelling has generally been examined in large vessels in mammalian 
systems. In these models, collateral vessels, like all vessels, consist of an inner endothelial 
cell layer (tunica intima) and an outer smooth muscle cell layer (tunica media) with a 
middle elastic layer (internal elastic lamina). An external elastic lamina lies between the 
tunica media and the tunica external (Schaper et al., 1971). 
1.2.2 The timecourse of collateral vessel remodelling 
Studies of collateral vessel development following arterial occlusion often observe that the 
process occurs in two distinct phases: an initial increase in collateral vessel number; 
followed by a “pruning” selection process, whereby the most efficient collateral vessels are 
selected for persistence (Duvall et al., 2004). Vessels which do not carry enough blood flow 
do not remodel. Only 10% of initially expanding arterioles go on to become conducting 
collateral vessels (Scholz et al., 2001). This reflects Poiseuille’s law, which states that it is 
more energy efficient to have fewer large conducting vessels than many small, high 
resistance vessels (Hoefer et al., 2001). 
Generally for all species arteriogenesis occurs in phases. Differences occur between species 
in the timecourse of arteriogenesis (reviewed by Heilmann et al., 2002). Scholz et al., 
(2000) described four main phases of arteriogenesis in rabbits following hind limb arterial 
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ligation. These were: initial changes in endothelial cell transcription; proliferation of 
endothelial and smooth muscle cells; a synthetic phase which involves other cell types such 
as monocytes and macrophages; and a maturation phase (Scholz et al., 2000). This is 
summarised in Figure 1.1 and will be discussed in section 1.7.  
 
 
  Figure 1.1 A proposed timecourse of events during arteriogenesis in mammalian 
models  
The timecourse begins at occlusion of the femoral artery. The initial phase lasts from 
ligation to day 1. During this time transcription factors are thought to be expressed. 
Other early events start to occur such as proliferation of endothelial (EC) and smooth 
muscle cells (SMC) and expression of adhesion molecules. Monocyte activation and 
growth factor expression are also initiated at this early event. From day 1 the first new 
capillaries start to appear. Day 1-3 is referred to as the ‘proliferation phase’ as it is the 
peak of EC and SMC proliferation. By day 3, adhesion molecule expression ends but 
monocyte activity reaches a peak. From day 3-7 the process reaches a ‘synthetic 
phase’. Although monocyte activity and EC/SMC proliferation continue, growth factors 
stop being expressed. Collateral vessels have begun to appear at day 7 and thus the 
first recovery of blood flow starts to occur. From day 7-14 collateral vessels become 
established, known as the ‘maturation phase’. This phase still requires proliferation and 
monocyte activity. By day 14 collateral vessels have restored flow and the process of 
arteriogenesis ceases. 
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1.3 Arteriogenesis vs angiogenesis 
Following hind-limb arterial occlusion in mammalian models, two types of vessel growth 
are stimulated; angiogenesis and arteriogenesis (Hershey et al., 2001, Hoefer et al., 2001). 
By occluding the femoral artery, the foot becomes ischemic thus creating a hypoxic 
environment that stimulates angiogenesis (Ito et al., 1997). However, the small angiogenic 
vessels cannot facilitate re-perfusion of the foot as they do not carry substantial amounts 
of flow in the face of the occluded main artery. Proximal to the occlusion, in the upper leg, 
there is no hypoxia and pre-existing vessels are remodelled by arteriogenesis into collateral 
vessels to divert blood flow around the occlusion (Hoefer et al., 2001). Therefore, there is 
thought to be no direct correlation between ischaemia and collateral vessel development 
following arterial occlusion (Ito et al., 1997). Arteriogenesis is instead thought to be driven 
by haemodynamic factors, including pressure, stretch, vasoactive chemicals in the blood 
and the frictional drag of blood over the endothelial cells, known as shear stress (Schaper 
and Ito., 1996). Arteriogenesis occurs in less time than formation of capillaries, due to the 
structural expansion of pre-existing vessels via proliferation of vascular cells instead of de 
novo vessel growth (Hershey et al., 2001, Hoefer et al., 2001) . 
The role of angiogenic stimuli in collateral vessel formation has previously been 
investigated. A study by Schierling et al., (2009) created an arterio-venous (A-V) shunt 
between the distal femoral artery and vein following occlusion of a proximal femoral artery 
in a rabbit model (Schierling et al., 2009). The reduction of distal pressure induced by the 
shunt created higher fluid shear stress in collateral vessels. Although the A/V shunt is used 
to investigate the relationship between shear stress and collateral vessels (as discussed in 
section 1.5; Pipp et al., 2004), it has also been used to investigate if  maximal levels of 
collateral conductance that  occurred from increased shear stress, were in part due to 
angiogenic growth factors. Infusion of growth factors, vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor  (PDGF) and 
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monocyte chemoattractant protein 1 (MCP1), separately or in combination, did not match 
the improved collateral conductance of increased shear stress from the shunt. The most 
effective stimuli at increasing collateral vessel conductance was MCP1, followed by bFGF, 
however, the authors suggested that increasing shear stress in the developing collaterals 
was the strongest stimulus to collateral vessel growth (Schierling et al., 2009). 
The processes of arteriogenesis and angiogenesis are different in terms of mechanism, 
stimuli and resulting remodelled blood vessels (Heil et al., 2006) and these are summarised 
in Figure 1.2. 
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Figure 1.2 Angiogenesis and arteriogenesis are separate processes stimulated by different 
stimuli with different outcomes in vessel remodelling 
The two circles describe, in brief, the processes of angiogenesis and arteriogenesis, 
highlighting the major differences between the two. The overlap at the centre demonstrates 
some shared factors exist in these two distinct processes. The circle in the left represents 
angiogenesis. Ischemia induces angiogenesis which causes pre-existing capillaries to sprout 
de novo endothelial cell connections to increase the number and density of capillaries. This 
process takes days to complete. Arteriogenesis is represented by the circle on the right. 
Shear stress is thought to induce arteriogenesis which causes remodelling of pre-existing 
connections into conducting collateral vessels. This process takes days to weeks. Both 
angiogenesis and arteriogenesis require some stimulation from growth factors such as 
VEGF, FGFs and PDGF.  
Adapted from (Buschmann, Schaper et al., 1999) 
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Angiogenic sprouting is induced by hypoxia in ischaemic tissue and involves de novo vessel 
formation from capillaries (Risau., 1997). De novo capillary tubes form by endothelial cell 
proliferation, coalescence, differentiation and directed growth, without any contribution 
from smooth muscle cells (Carmeliet., 2000). Directed angiogenic growth depends on 
endothelial cell fate controlled by Notch signalling (Lawson., 2001). Endothelial cells of 
angiogenic vessels can become tip cells at the leading edge or supporting stalk cells 
depending on the signals they receive (Hellstrom et al., 2007).  
Sprouting angiogenic vessels respond to gradients of signals in their environment. VEGF is a 
powerful mitogen and chemoattractant which stimulates directed growth. Tip cells respond 
to the ligand, VEGF-A, and further sprouting and branching is controlled by the interaction 
between the Notch receptor, delta-like-4 (Dll4), and Notch-1 signalling (Hellstrom et al., 
2007). Stalk cells receive the signal to proliferate and thus the vessel elongates in a manner 
that is also dependent on VEGF-A (Gerhardt et al., 2003). Tip cells follow gradients of VEGF 
and other growth factors such as FGFs, or guidance cues such as ephrins, semaphorins, slits 
and netrins (Eichmann et al., 2005).  
The angiogenic response to occlusion usually happens within days. Hershey et al. (2001) 
used a rabbit model of ischaemia to show that angiogenesis and arteriogenesis were 
separate mechanisms of restoring blood flow (Hershey et al., 2001). Angiogenesis was 
monitored in the foot of the animal. Collateral conductance in the hind-limb was measured 
at specific timepoints following femoral artery removal. Capillary density was measured as 
a marker of angiogenesis and an angiographic score was used to quantify arteriogenesis. 
Following removal of the femoral artery, capillaries that formed in the foot were counted 
histologically to determine an angiogenic score over 5, 10, 20 and 40 days. VEGF was also 
measured and corresponded to peaks in angiogenic growth which occurred at 5 days. 
Collateral vessel growth was detectable by angiography at 10 days and was not associated 
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with ischaemia, or VEGF levels, but did result in improvement of the functional blood flow 
capacity of the limb. The group concluded that although initial angiogenic sprouting 
following artery removal was induced by ischaemia, this response did not account for 
improved collateral flow, which was a result of increased collateral vessel growth (Hershey 
et al., 2001). 
Sprouting angiogenesis is not the only method of de novo capillary formation. 
Intussusceptive angiogenesis is a process of microvascular growth which requires less 
proliferation than sprouting angiogenesis and instead involves rearrangement of 
endothelial cell plates (Djonov et al., 2000). Intussusceptive angiogenesis has been studied 
in the developing extra-embryonic vasculature of the chick embryo (Patan et al., 1993) and 
will be discussed in subsequent chapters of this thesis. 
In the developing extra-embryonic vasculature of the chick embryo, intussusceptive 
angiogenesis develops a mature vascular tree from a primitive vascular plexus (Nguyen., 
2006) (section 1.12). It is hypothesised to occur in four stages: inter-endothelial bridges 
appear between capillary zones in the direction of flow; these ‘bridges’ become ‘pillars’ 
which fuse and create a narrow tissue septa; segregation, growth and maturation of the 
structure produces feed vessels which separate up from the capillary plexus mesh. The 
small, surplus connections between these structures are then pruned and septa dissociate 
the vessels from the underlying mesh network (Djonov et al., 2000). The different 
mechanisms of sprouting angiogenesis and intussusceptive angiogenesis are summarised in 
Figure 1.3. In conclusion, experimental evidence from animal models suggests that 
therapeutic strategies for alleviating the consequences of arterial occlusive disease should 
be targeted to improving arteriogenesis rather than angiogenesis. Although an important 
feature of the response to vessel occlusion, angiogenesis alone is insufficient to reperfuse 
ischaemic tissue, whereas arteriogenesis has this capacity. 
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1.4 Cellular remodelling in arteriogenesis 
In contrast to the hypoxic stimulus in angiogenesis, collateral vessel formation is initiated 
when the endothelial cells lining connecting vessels experience changes in haemodynamic 
forces (Deindl and Schaper., 2005). The law of Histiomechanics proposed in 1893 suggests 
there is a relationship between the size of an artery and the blood velocity within it 
(Thoma., 1893). Fluid forces have therefore been studied in the context of collateral vessel 
formation for many years. In the cardiovascular system blood flow induces a range of 
physical forces on the vessel, including shear stress on the endothelial cells of the vessel 
lumen. The drag of blood flow over the cell surface creates shearing forces (Cunningham., 
2005). Mechanotransducers on the cell surface detect shear stress and propagate this 
signal to the nucleus. These signals modulate the physiological changes exhibited by 
Figure 1.3 Sprouting and intussusceptive angiogenesis form de novo vessels via different 
mechanisms 
A depicts the process of sprouting angiogenesis. A sprouting angiogenic vessel can be seen 
protruding from the main vessel. The sprouting vessel is made up of stalk cells and a 
leading tip cell. The vessel sprouts navigate and respond to VEGF through tip cell 
behaviours whilst stalk cells proliferate to elongate the vessel. B shows the process of 
intussusceptive angiogenesis. Intussusceptive angiogenesis occurs when intra-vascular 
pillars within a vascular mesh, fuse to produce larger feed vessels. These feed vessels 
protrude upwards and dissociate from the primitive mesh network to become 
independent lumenised capillaries.  
Adapted from (Djonov et al., 2000) 
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endothelial cells exposed to changes in flow (Peters et al., 2002). Genes involved in 
monocyte attraction, recruitment of inflammatory cells and cell proliferation, are 
upregulated to drive collateral vessel formation (Cai., 2008). 
Endothelial cell activation is thought to lead to monocyte invasion into the vessel wall (Heil 
and Schaper., 2004). Monocyte recruitment involves the chemokine MCP1, released from 
activated endothelial cells (Hoefer et al., 2001). Monocytes transmigrate through the 
vascular wall where upregulated adhesion molecules, Intercellular Adhesion Molecule 1 
(ICAM1) and Vascular Cell Adhesion Molecule 1 (VCAM1), are thought to mediate 
attachment of monocytes to the endothelial surface (Schaper and Scholz., 2003).  
Monocytes differentiate into macrophages and produce cytokines which create an 
inflammatory environment for collateral vessel formation, and growth factors which 
stimulate proliferation (van Royen et al., 2001). Endothelial and smooth muscle cell 
proliferation is required for outward remodelling which radially expands the vessel to 
accommodate the increased blood flow load (Scholz et al., 2001).  Monocytes also release 
proteases such as matrix metalloproteases (MMPs) to digest the surrounding matrix to 
increase the space available for collateral vessel expansion (Cai and Schaper., 2008). 
1.5 Haemodynamic forces as a stimuli for collateral vessel formation 
Arterial occlusion induces a wide range of effects on the vasculature and the tissue 
deprived of perfusion, such as hypoxia and ischaemia/necrosis (Helisch and Schaper., 
2003). It has been generally accepted that the driving force for collateral development is 
the alteration of local haemodynamic forces exerted on the nascent collateral vessel 
(Schaper., 1996). One theory is that occlusion of the main vessel leads to a pressure 
gradient and increased fluid shear stress in the developing collateral vessel, which 
remodels in response (Schaper., 1988). Schaper’s group have attempted to define the 
relative contribution of fluid shear in collateral remodelling, although technically this is very 
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challenging to address. Another group created an A-V shunt between the distal femoral 
artery and vein following occlusion of a porcine proximal femoral artery (Pipp et al., 2004). 
The collateral vessels remodelled due to the reduction of distal pressure, induced by the 
shunt, which exposed the developing collaterals to higher fluid shear stress. This change in 
blood flow was able to increase collateral vessel growth to a far greater size and improve 
the ability of collaterals to carry near baseline levels of blood flow.  The authors concluded 
that this experiment confirmed the central role of fluid shear stress, as a driver of 
arteriogenesis (Pipp et al., 2004). Although it remains difficult to exclude influences exerted 
by pressure, or even remote factors such as tissue ischaemia. Since distal ischaemia and 
angiogenesis may influence distal pressure, this could indirectly influence haemodynamics 
in the developing collateral vessels. The exact contribution of each influence initiated by 
arterial occlusion on arteriogenesis remains difficult to completely assess. 
1.6 How do endothelial cells detect haemodynamic changes? 
The manner in which endothelial cells detect and respond to haemodynamic force is 
increasingly well understood. Davies (1995) suggested that transduction of mechanical 
stimuli occurred via specific mechanotransduction sites, by a local reorganisation of cell 
surface receptors and by transmission of the mechanical signal into the cell by cytoskeletal 
elements (Davies., 1995). A tensegrity model was proposed which further implied that, via 
integrins and cytoskeletal connections, mechanical stimuli could influence regulatory cell 
signalling, leading to changes in gene expression (Ingber., 2003). Other mechanosensors 
thought to detect changes in flow have been identified in endothelial cells, including: 
caveolae, ion channels, cilia, junctional proteins and signal cascades, G protein activation of 
mitogen-activated pathway kinase (MAPK) pathway to the cell nucleus (Davies., 1995, 
Noria et al., 1999, Helmke and Davies, 2002, Osawa et al., 2002, Helmke and Davies., 2002, 
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Weinbaum et al., 2007). A summary of these flow-sensors can be seen in the cartoon in 
Figure 1.4.  
If haemodynamic forces induce endothelial activation and initiate remodelling, these forces 
must be sensed by the endothelial cells. A primary flow sensor, responsible for 
mechanotransduction of a shear stress-related stimulus, has yet to be elucidated. Work in 
this field has been comprehensively reviewed and possible mechanisms advanced (Davies., 
1995). However, there is no evidence to show that these mechanisms drive collateral vessel 
formation. Some of the pathways which have been suggested to be involved in 
mechanotransduction of changes in haemodynamic flow are summarised in Figure 1.4. 
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Figure 1.4 Endothelial cell mechanosensors sense changes in flow and transduce the 
signal to the nucleus via various signalling pathways 
Changes in flow can be detected by primary cilia on the cell surface. Flow can also be 
detected by integrins which are involved in ECM-cell interactions. Junctional proteins and 
complexes between endothelial cells act as mechanotransducers which stimulate signalling 
pathways to the nucleus. Membrane structures at the cell surface such as the glycocalyx, 
ion channels, receptor tyrosine kinases and G protein receptors mediate shear stress 
signals to the nucleus by activating signalling cascades. The cytoskeleton not only senses 
flow-induced changes in cell shape, but ties together the mechanosensors to generate a 
shear stress response. Mechanotransducers stimulate signalling pathways by activating 
small GTPases such as Ras and Rho. Signalling pathways which propagate the signal to the 
nucleus include NfκB, MAPK and ERK. Shear stress signals cause a change in gene 
transcription in the nucleus to induce a remodelling response (Section 1.6.2). 
Adapted from (Ngai, 2010) 
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1.6.1 Signal transduction of fluid forces 
Eitenmuller et al., (2006) identified three main pathways activated in endothelial cells 
exposed to changes in haemodynamic flow following arterial occlusion (Eitenmuller et al., 
2006). Rabbits were subjected to femoral artery occlusion and A/V shunts. Collateral 
arteries were identified and tissue was prepared for microarray and Western blot analysis, 
to assess gene and protein expression. The collateral vessels extracted from shunted legs 
showed increased protein expression of activated extracellular signal-regulated kinase 
(ERK) and the Ras-Erk pathway. This is a pathway known to be involved in growth factor-
initiated cell proliferation. The Rho pathway was also upregulated in collateral vessels 
exposed to high shear stress. The Rho pathway is proposed to mediate cell motility by 
regulating the actin cytoskeleton. Nitric oxide (NO) pathways were also upregulated, 
however this pathway is extremely complex and no mechanism for upregulated NO was 
identified. The group deduced that changes in haemodynamic flow might cause 
deformation of endothelial cells and alter the cytoskeleton. This may initiate signals to the 
nucleus to up-regulate chemokines and adhesion molecules and Rho pathways. Attracted 
monocytes were hypothesised to release growth factors which induce cell proliferation via 
the RAS-ERK pathway.  
Signalling pathways, RAS-ERK and Rho, were said to enable ‘concerts of events’ which 
contributed to the sustained growth of collateral vessels in shunt models with sustained 
shear stress. It has been proposed that development of collateral vessels, induced by 
changes in flow, may also be mediated by these same pathways (Eitenmuller et al., 2006). 
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1.6.2 How does stimulation of mechanotransduction pathways result in changes 
in gene expression?   
Many endothelial genes possess a shear stress response element (SSRE) in their promoter 
region. Shear stress signals transduced to the nucleus, result in activation of the SSRE in 
shear responsive genes, leading to alteration in gene transcription (Resnick and Gimbrone., 
1995). The shear stress response element has been identified as a GAGACC sequence 
(GGTCTC complementary sequence) and has been found in the promoter region of shear 
responsive genes such as platelet derived growth factor (PDGF-B), Transforming growth 
factor β1 (TGFβ1), MCP1, endothelin1 (ET-1), ICAM1 (Resnick et al., 1993, Miyakawa et al., 
2004).  The SSRE binds transcription factors which both positively and negatively regulate 
gene expression. For example, transcription factor nuclear factor κappa-β (NFκ-β) has been 
shown to modulate expression of MCP1 (Resnick et al., 1993). VCAM1 and ICAM1 have a 
repressive and active SSRE. In low shear stress VCAM1 is upregulated and ICAM1, 
downregulated, however, with increasing shear stress both molecules are upregulated 
(Walpola., 1995). Transcription factors such as early growth response protein-1  (Egr-1), 
sp1, NFκ-β, activator protein-1 (AP-1), c-myc, c-jun are induced early following exposure to 
shear stress and interact with the SSRE to mediate gene expression in the first few hours 
(Lan et al., 1994, Khachigian et al., 1997, Garcia-Cardena and Gimbrone., 2006). In cultured 
bovine aortic endothelial cells exposed to physiologic levels of laminar shear stress, this 
early expression of Egr-1 was investigated (Khachigian., 1997). Gel shift studies showed Egr-
1 to bind the SSRE of PDGF-A, which was induced by shear stress. This was found to be 
specific and time-dependent. Egr-1 was upregulated 30 minutes-1 hour following increases 
in shear stress and is referred to as a ‘master switch’, controlling expression of other 
endothelial genes including PDGF-A, FGF2, VEGF and MCP1 and adhesion molecule ICAM1 
(Khachigian., 1997).  
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1.7 Transcriptional changes induced by altered shear stress 
There is increasing evidence that a number of genes are activated by shear stress following 
arterial occlusion, and modulated by different signalling pathways. Shear stress activated 
endothelial cells may modulate certain genes to regulate processes which contribute to 
vessel remodelling (Resnick and Gimbrone., 1995, Gimbrone et al., 1997, Topper and 
Gimbrone., 1999)  .   Flow-induced changes in gene expression have been investigated in 
both in vivo and in vitro models, in a variety of species (as discussed below and in section 
1.10). Different gene expression profiles are reported in these models, despite the 
detection of similar responses such as inflammation. This suggests that the transcriptional 
profile of the endothelial cell response to fluid mechanical forces is temporal, spatial and 
species-dependent. In vivo and in vitro experiments to investigate this shall next be 
described below. 
In vitro experiments are often performed in cultured endothelial cells exposed to flow 
which can be exposed to physiologically similar levels of shear stress. DNA microarray 
analysis sheds light on the transcriptional changes which occur in shear stress activated 
endothelial cells. One such study found expression of 52 genes to be altered in response to 
changes in shear stress in cultured human umbilical cord endothelial cells (HUVECs) after 6 
or 24 hours exposure to shear stress (25 dynes/cm2) (McCormick et al., 2001). Genes, 
including MCP1, that were upregulated were involved in proliferation, vascular tone, 
cytoskeleton and inflammation. This study also documented up-regulation of genes with 
vasodilatory properties endothelial nitric oxide (eNOS) and down-regulation of 
vasoconstrictor genes (ET-1) (McCormick et al., 2001). Expression of these genes was 
speculated to modulate vascular tone to normalise shear stress (Peters et al., 2002, Hierck 
et al., 2008).  
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Genes found to be upregulated in arteriogenesis in vivo have also been observed in in vitro 
studies.  MCP1, which has been studied in a number of animal models of arteriogenesis (Ito 
et al., 1997b, Scholz et al., 2000, Pipp et al., 2004), has been shown to be induced in 
response to increased shear stress in cultured HUVECs. Levels of MCP1 RNA increased 2-3 
fold under shear stress, compared to static conditions. This was found to be an early, 
immediate gene activation response to increased shear stress (Shyy et al., 1994). Further, 
Scholz et al., (2000) conducted molecular histology on collateral vessels after femoral 
artery occlusion in rabbits, over a timecourse from 2 hours to 240 days after occlusion. The 
group first observed endothelial upregulation of ICAM1 and VCAM1 genes at early 
timepoints (12 hours) following occlusion. Infusion of MCP1 increased monocyte adhesion 
which improved collateral vessel formation.  The authors then were able to reproduce the 
findings in vitro in cultured HUVECs following the onset of shear stress, where induction of 
ICAM1 and VCAM1 occurred early on following the onset of shear stress (Scholz et al., 
2000). Expression of ICAM1 and VCAM1 have been reported to not only be genes regulated 
by shear stress but also modulated by the presence of smooth muscle cells, in vitro (Chiu et 
al., 2003). One investigation found that co-culturing endothelial cells with smooth muscle 
cells influenced the endothelial response to shear stress. In a parallel plate, flow system 
cells were separated by a porous membrane. Static co-cultured endothelial cells expressed 
upregulated genes ICAM1, VCAM1 and E selectin, however in the presence of shear stress, 
smooth muscle cells were inhibited from inducing adhesion molecule expression in 
endothelial cells. When endothelial cells were removed from co-culture or cultured next to 
fibroblasts, these genes were no longer expressed (Chiu et al., 2003).  
Low and high shear stress have been show to modulate gene expression in cultured human 
coronary endothelial cells. Peters et al., (2002) investigated cultured endothelial cells which 
were exposed to 0, 15 or 45 dynes/cm2 of laminar shear stress for 1 hour and then the 
transcriptional profile was assessed by cDNA microarray (Peters et al., 2002). Results 
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showed early upregulation of transcription factors, factors involved in signal transduction, 
antioxidants, vaso-reactivity, cell-cycle genes and genes regulating the cytoskeleton (Peters 
et al., 2002). This data suggested that shear stress induced expression of transcription 
factors extensively re-programme the genes that coordinate an endothelial response to 
changes in flow. Another group investigated the genes expressed during oscillatory and 
laminar flow patterns of endothelial cells in vitro (White et al., 2011). Kruppel-like factor 2 
(KLF2) was found to be one gene that was upregulated under high shear conditions and 
said to play a role in the amplification of shear responsive signalling (White et al., 2011).  
KLF2 is a shear responsive transcription factor which regulates expression of many genes 
and has been shown to be upregulated in response to prolonged shear stress in vivo and in 
vitro (Dekker et al., 2002).  
In vivo, low and high shear stress can also be investigated by analysing gene expression at 
different regions of the artery, such as bifurcations where shear stress is high and flow is 
disturbed. Egorova et al., (2011), studied shear stress in a model observing embryonic 
endothelial cells of the chick heart and found KLF2 to be essential in coordinating the 
response of the endothelial cell to changes in flow (Egorova et al., 2011). KLF2 is 
differentially activated in high shear and low shear environments and is athero-protective 
(Dekker et al., 2002, Groenendijk et al., 2004) . This gene may therefore also play a role in 
regulating changes in gene expression in endothelial cells of collateral vessels.  
Temporal patterns of gene expression have been reported in vivo and in vitro. ‘Typical 
response patterns’ to continuous shear stress of a number of representative genes have 
been described in endothelial cells exposed to continuous laminar flow (Resnick, Gimbrone, 
1995). Diamond et al., (1990), were the first to show that fluid mechanical forces could 
directly alter gene expression (Diamond et al., 1990).  
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In a comprehensive review of the subject by Resnick and Gimbrone (1995), mRNA encoding 
c-fos, a DNA binding protein, shows a rapid and immediate response to shear stress; PDGF-
B mRNA shows a rapid upregulation and transcript levels remain high for a few hours after 
the onset of shear stress. MCP1, ICM1 and TGF-B genes also show this pattern. VCAM1 
gene is downregulated in response to laminar flow (Resnick, Gimbrone, 1995). 
 Lee et al., (2004), investigated temporal expression of flow-responsive genes using a DNA 
microarray in mice following tied-ligation or sham-ligation after 6 hours and 1,3,7 and 14 
days. This group also found early upregulation of transcription factors and DNA binding 
proteins. This was followed by a mid-phase of upregulated inflammatory genes, along with 
cell cycle genes and cytoskeletal genes (Lee et al., 2004a). Although a similar pattern of 
temporal gene expression was observed as the in vitro study by Diamond et al.,(1990) in 
the study by Lee et al., (2004), the transcriptional profile of genes was not replicated 
between models: for example, adhesion molecules were not expressed, however, MCP1 
was upregulated (Lee et al., 2004a). This highlights the fact that some mechanisms may be 
universal to shear exposed endothelial cells, but that expression of key genes may differ 
due to differences in species, windows of expression, environment and flow patterns. 
Understanding and characterising the expression patterns of ‘shear-responsive’ genes will 
provide a clearer overview of the transcriptional responses of endothelial cells to changes 
in haemodynamic flow. This information could then be used to further elucidate the 
pathology of vascular disease and endothelial dysfunction and suggest new therapeutic 
strategies. 
1.8 Therapeutic promotion of arteriogenesis 
The above studies suggest potential mechanisms whereby haemodynamic alterations may 
influence arteriogenesis. Other studies provide more direct evidence of the mediators of 
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arteriogenesis. Transcription factors which control gene expression in response to changes 
in shear stress (discussed in section 1.6.3) have been shown to regulate expression of 
growth factors. In vivo experiments have gone on to explore whether exogenous infusion 
of growth factors, or manipulation of growth factor signalling, can affect arteriogenesis. A 
description of some of the investigations into the factors which might therapeutically 
promote collateral vessel growth are summarised below. 
MCP1 has been shown to improve collateral vessels in rabbit and porcine models of arterial 
occlusion (Hoefer et al., 2001, Voskuil et al., 2003). Infused MCP1, was given locally via a 
mini-pump for a 1 week period, either 3 weeks or immediately following ligation of the 
femoral artery in rabbits. MCP1 treatment caused a significant increase in collateral vessel 
density proximal to the ligation in the upper leg within the first week, compared to controls 
receiving saline only (Hoefer et al., 2001).  A similar study showed the same results in rabbit 
models (Ito et al., 1997). Femoral artery occlusion was performed in 12 rabbits which then 
received infusion of either MCP1 or saline via osmotic mini-pump for 7 days. Angiograms 
showed that rabbits that had received MCP1 had improved collateral vessel formation in 
the thigh (Ito et al,. 1997). These experiments suggest that stimulation of macrophages and 
monocytes could be a therapeutic tool to induce collateral vessel formation in mammals. 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a cytokine that functions 
as a growth factor to stimulate production of macrophages. GM-CSF has been found to 
improve arteriogenesis in animal models such as the pig. Continuous infusion of GM-CSF by 
intra-arterial delivery for 1 week following femoral artery ligation increased collateral 
conductance in pigs when compared to saline infused controls (Grundmann et al., 2006). 
However, clinical studies in patients with peripheral arterial disease (not eligible for bypass 
surgery) were not as successful. The patient study focussed on the effect of short term, 
local and systemic infusion of GM-CSF. Although some patients benefitted from the 
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treatment and showed improved collateral conductance, the study cohort was small and 
the results were variable and thus inconclusive (Seiler et al., 2001).   
In the 1990s experiments were performed to investigate the therapeutic potential of 
growth factors such as Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth 
Factor (FGF1 and FGF2) in stimulating collateral vessel growth (reviewed by Epstein et al., 
2001).  Some of these shall next be described. 
The effect of VEGF treatment on collateral vessel development was first observed in in vivo 
studies in which the coronary vessels of dogs were obstructed to cause ischaemia to the 
ventricle of the heart (Banai et al., 1994, Unger et al., 1994). Ten days after creating the 
vessel obstruction, intracoronary infusion of VEGF or saline were given daily for 28 days. 
Collateral blood flow was measured and quantified using microspheres, at regular intervals 
during treatment. VEGF administration significantly increased collateral vessel flow, 
showing a 40% increase in collateral flow. The treatment also increased the number of 
small vessels supplying the ischaemic tissue (Banai et al., 1994, Unger et al., 1994).  
Another group observed the effects of VEGF on endothelial and smooth muscle cell 
proliferation in collateral vessels (Takeshita et al., 1995). Rabbits received femoral artery 
ligation and 10 days later a bolus injection of either VEGF or saline. Proliferation of 
endothelial and smooth muscle cells was assessed by Bromodeoxyuridine labelling at days 
3, 5 and 7. VEGF did increase cell proliferation (maximal at 5 days) compared to untreated 
controls, but this response was returned to baseline by day 7. Further, collateral vessels in 
different areas of the upper leg were assessed and proliferation was confined to only mid-
zone collateral vessels and was not observed at the stem or re-entry collaterals. However, 
the authors concluded that VEGF stimulated endothelial and smooth muscle cell 
proliferation was enough to improve collateral vessels and haemodynamic flow (Takeshita 
et al., 1995).  
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One other mechanism for how weak arteriogenic effects of infused VEGFA might improve 
collateral vessel development was proposed by Breier et al., (2002). The group investigated 
the monocyte attractant effect of VEGF A binding to VEGF receptor 1 on the surface of 
monocytes. Mice heterozygous for VEGFR1 were found to have impaired collateral vessels 
21 days after femoral artery ligation leading the authors to conclude that VEGF and VEGFR1 
are determinants of arteriogenesis (Breier et al., 2002).  
A role for up-regulation of endogenous FGFs in arteriogenesis remains unclear. In one 
study, FGF receptor 1 (FGFR1) mRNA, protein and kinase activity were upregulated briefly 
during femoral artery occlusion in rabbits (Deindl et al., 2003). Increases in FGFR1 
expression was thought to occur in response to monocyte release of FGF ligands, and not 
to FGFs produced by the endothelial cells of the collateral vessels. To investigate further, 
rabbits were treated with MCP1 to stimulate arteriogenesis and also received an FGF 
inhibitor. These animals showed reduced arteriogenesis, despite the increase in MCP1. This 
result suggested that FGFR1 is upregulated in vessels during arteriogenesis and FGF ligand 
is supplied by monocytes which produce and deliver growth factors to developing collateral 
vessels (Deindl et al., 2003).  
FGF2 has been shown to improve collateral vessels when delivered to mice by an osmotic 
mini-pump for seven days after hind-limb arterial occlusion  (Scholz et al., 2002). The mice 
receiving FGF2 showed enhanced speed of arteriogenesis. Morphometry analysis showed 
increases in collateral vessel diameter which was shown to be a result of increased 
endothelial and smooth muscle cell proliferation. Due to this improved collateral vessel 
conductance, less angiogenesis was observed distally as the limb was more efficiently re-
perfused and therefore ischaemia was reduced (Scholz et al., 2002). 
PDGF has been found to act as a smooth muscle cell chemoattractant which induces 
smooth muscle cells to migrate (Dardik et al., 2005b). RNA levels of PDGF do not appear to 
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change in the early stages of collateral vessel growth (reviewed by Schaper, 2003). The 
transmission of this growth factor from endothelial to smooth muscle cell is not thought to 
be important due to the presence of monocytes which fulfil this role (reviewed by Schaper 
and Scholz 2008). Protein levels of PDGF have also been assessed following insertion of an 
ameroid constrictor around the left circumflex artery of canine hearts, and in the femoral 
arteries of rabbits which had undergone hind limb artery ligation and arterial/venous shunt 
(Wu et al., 2010). Immunohistochemistry revealed significant upregulation of PDGF in 
collateral vessels compared to control vessels which had not experienced changes in 
haemodynamic forces (Wu et al., 2010). 
Clinical evidence for the arteriogenic potential of growth factors remains contentious. 
However, one Phase 1 clinical trial in humans supported a case for VEGF in arteriogenesis 
but this trial did not progress to Phase II suggesting that more carefully monitored clinical 
investigations are needed (Epstein et al., 2001). Naked DNA plasmids containing 
endothelial cells and an isoform of human VEGF were injected into the limbs of patients 
with peripheral arterial disease (Baumgartner et al., 1998). Three patients, not suitable for 
invasive bypass surgery, received this treatment. Angiography and ability to exercise were 
measured. Two months after therapy, significantly more collateral vessels were observed 
by angiography which resulted in increased flow and limb salvage. Tissue samples from 
these patients showed increased endothelial proliferation. However, the study cohort was 
too small to draw conclusions from the data (Baumgartner et al., 1998).  
In conclusion, therapeutic factors can promote collateral vessel formation in animals which 
is promising for clinical application; however, more study into this field is required before 
an optimal approach to using growth factors as therapies for vascular diseases is identified.  
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1.9 Changes in haemodynamic flow can alter endothelial cell arterial/venous 
identity 
Changes in blood flow can directly alter molecular markers that specifically identify arterial 
or venous vessels (Othman-Hassan et al., 2001, le Noble et al., 2004). The studies described 
below provide an indication of the signalling pathways that govern arterial and venous 
identities. Research in this area could have implications in the clinic, for example, 
manipulating arterial/venous identity of endothelial cells in vessel biopsy surgery, to 
encourage graft patency, For my research however, an understanding of endothelial cell 
plasticity (i.e. regulation of arterial/venous marker expression) was important to 
understanding mechanisms involved in collateral vessel remodelling. 
Identifying reliable endothelial arterial and venous markers allows investigation into how 
and when these markers are up or downregulated in response to haemodynamic forces. 
Two transmembrane receptors known to play a role in vascular development have been 
investigated in chimera studies (Moyon et al., 2001). Arterially expressed neuropilin-1 
(nrp1) and venous tie-2 genes were analysed in sections of aorta, carotid artery and 
cardinal and jugular veins of quail embryo donors that were grafted onto the coelom of 
chick embryo hosts at different stages during development. From Embryonic day (E) 2-7 
cells from arteries and veins did not maintain their original arterio-venous identities and 
were able to migrate from the donor graft to colonise the host vasculature. Tie-2 
expression did not persist when such cells colonised the chick host's artery. Grafted cells 
originally expressing nrp1 did not maintain expression of the arterial marker when grafted 
into a vein. Eventually at later stages of development (E11) this plasticity was lost (Moyon 
et al., 2001).  The authors concluded that endothelial cell fate was plastic and 
arterial/venous marker expression was regulated by flow, until later stages of 
development. 
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le Noble et al., (2004) investigated plasticity of endothelial cell arterial-venous fate by 
removing flow from the extra-embryonic vasculature of chick embryos (le Noble et al., 
2004). The group first observed flow-dependent development of the right vitelline artery 
by excising all 3 germ layers at HH st 10. Removing perfusion at this early stage of 
development resulted in the absence of the right vitelline artery which was replaced by a 
single vein. Flow in the vitelline vessels was further investigated in HH st 18 embryos by 
inducing a temporary arterial occlusion by elevating the right vitelline artery with tungsten 
wire for 24 hours. When arterial flow was obstructed to one side of the vitelline circulation, 
the arterial markers, ephrin B2 and nrp1, were downregulated after 10 minutes and 
undetectable after 4 hours. The venous markers, neuropilin-2 (nrp2) and tie-2, were 
upregulated, although expression was not strong until 12 hours post-ligation, suggesting 
that flow-regulation of arterial markers was more rapid than upregulation of venous 
markers. Aside from the expression of the molecular markers, vessel morphology showed 
the arterial bed on the tied-ligated side became venularised. Restoration of flow, by 
releasing the elevated wire, downregulated the venous markers and arterial markers were 
again expressed after 4 hours of re-perfusion (le Noble et al., 2004) . These findings provide 
evidence to suggest that endothelial cells remain plastic during early stages of 
development and can adapt their arterial/venous identity depending on the environment. 
Furthermore, the findings suggest that arterial identity is driven by flow. 
Conversely, there is evidence that endothelial cell fate is pre-determined (Lawson et al., 
2001). In zebrafish a loss of Notch signalling results in a loss of arterial ephrinB2; over-
expression of Notch inhibits venous fate. These changes in endothelial cell fate disrupted 
vessel patterning in developing embryos. This data suggested that Notch expression is 
required for determining arterial/venous fate and that a main role of Notch is to drive 
arterial expression and repress venous differentiation of endothelial cells (Lawson et al., 
2001). Evidence for arterial Notch signalling in arterial cells has also been investigated in 
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chick embryos where the Notch ligand, dll4, was identified, using in situ hybridisation, in 
the arterioles but not the venules of the yolk sac and could also be strongly detected in the 
proximal vitelline arteries of HH st 16 embryos (Nimmagadda et al., 2007).  
In conclusion it is likely that a balance of genetics and blood flow patterns vessel 
architecture. Although pre-determined cell fate is evident in endothelial cells of various 
model systems there is strong evidence for flow and mechanical forces altering gene 
expression and arteriovenous identity.  
1.10 Model systems of collateral vessel formation 
Studying collateral vessel formation in humans is technically very difficult. It is not possible 
to induce this experimentally since this would require sustained arterial occlusion, which 
would be damaging. Although many patients present with occluded arteries, the timing of 
the occlusion is often unknown, the occlusion may be immediately or subsequently fatal, 
and the ability to visualise and quantify collateral vessels clinically is limited and often 
highly invasive. To understand the mechanisms of collateral vessel formation, researchers 
must therefore rely on animal models. Sir John Hunter first described collateral vessels in 
1785 (reviewed in (Murley., 1984)). He ligated the external carotid artery in a stag 
preventing circulation to one antler. After ligation the antler became cool and the arterial 
pulse was impalpable. However, two weeks later, the antler was once again warm and a 
pulse could be felt. Dissection revealed small collateral vessel anastomoses which bypassed 
the ligation to restore blood flow. Since this experiment, many other animal models have 
been developed, both mammalian and non-mammalian: some of these are summarised 
below. 
Mouse, rat and rabbit models have been widely used to investigate collateral formation 
(Scholz et al., 2000, Herzog et al., 2002, Stabile et al., 2003, Terry et al., 2011). The hind-
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limb model involves invasive surgery under general anaesthesia to access the femoral 
artery, which is ligated, greatly reducing blood flow to the foot (Ito et al., 1997a, Herzog et 
al., 2002) . Laser Doppler or angiography is used to then quantify foot blood flow or to 
visualise collateral vessels (Limbourg et al., 2009). These imaging methods do not allow for 
real-time observation of collateral development and are expensive and time-consuming. 
Nevertheless, many important discoveries concerning pro-arteriogenic factors have been 
identified using these models as described in section 1.8. A particular advantage of the 
mouse is the ability to study genetic knockouts. Athero-prone mice or those with other 
gene defects can be used to uncover more about the disease process and progression. 
The canine and porcine models allow focus on the coronary vessels due to the larger 
cardiac size. These two models differ: Arteriogenesis in the canine heart depends on pre-
existent vessels (Schaper et al., 1990). The canine model facilitated much of Schaper’s early 
work on arteriogenesis in the 1970s (Borgers et al., 1971, Schaper et al., 1971, Schaper and 
Pasyk, 1976) .  
The pig can be used as a model for arteriogenesis research if using the hind limb model. It is 
not an ideal model as large inter-species differences exist (Voskuil et al., 2003, Pipp et al., 
2004). Further, there are few pre-existing coronary collateral vessels which do not remodel 
in response to increased fluid shear stress. Instead large vessels devoid of smooth muscle 
resembling capillaries form to recompense for the lack of perfusion in the coronary arteries 
(van den Wijngaard et al., 2011).  
The zebrafish is a novel model of cardiovascular disease and has several advantages over 
mammalian models (Packham et al., 2009). The optical clarity of the embryos allows for 
visualisation of the circulating blood within the vessels; further, transgenic fish can be 
created to enhance this visualisation. Endothelial-specific promoters can be used to drive 
expression of reporters such as green fluorescent protein (GFP) in blood vessels (Lawson 
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and Weinstein, 2002, Lyssenko et al., 2007). Further to the use of fluorescent reporter lines 
to enhance vessel visualisation, mutants can be produced to model cardiovascular 
abnormalities. The gridlock mutant is a model of aortic occlusion and was characterised by 
Gray et al., (2007) as a model of arteriogenesis (Gray et al., 2007). Collateral vessels were 
observed to develop from pre-existing endothelial connections to restore aortic flow. 
However, the small size of these vessels, and absence of investing smooth muscle, mean 
that it cannot replace the use of mammalian models to understand human arteriogenesis. 
In March 2004 the first draft of the chicken genome was completed (2004, Wallis et al., 
2004). This confirmed that many coding genes were homologous to human genes. We can 
thus use the chicken for comparative genomics and as a model of human disease and 
development. The chick embryo lends itself particularly to vascular biology and the study of 
haemodynamics (Hughes., 1935, Lee and Lee., 2010). Thoma discovered the effect of blood 
flow on vessel configuration and observed that in this system blood flow regulated vessel 
growth (Thoma., 1893). Before onset of blood flow there was a uniform pattern of vessels 
which became defined into arteries once circulation had begun (Hughes., 1937). Hughes 
continued Thoma’s observations in the chick embryo; in an era predating advanced imaging 
techniques, he was able to document aspects of vascular development by simply drawing 
vascular structures injected with ink. Hughes also experimented with analysis of the extra-
embryonic vasculature in ovo and in vitro (Hughes., 1937). This early work highlights the 
robustness of the chick embryo model system. The ability to observe vessel development 
over time without invasive or expensive procedures demonstrates attributes that the chick 
embryo can offer cardiovascular research.  
In vitro analysis of endothelial cell responses can provide information on angiogenesis, 
wound healing, tumour biology, gene expression, cell proliferation and migration and 
endothelial dysfunction (Jaye et al., 1985, Coomber and Gotlieb, 1990). Flow chambers can 
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model the effects of shear stress, and allow for external regulation of laminar and/or 
disturbed flow (Dewey et al., 1981, Davies et al., 1986). This technique allows for the 
monitoring of an exclusively endothelial cell response to a specified environment, but is 
less often applied to multi-cellular models. Although this is advantageous to an 
uncontrolled in vivo environment it is important to acknowledge that an in vitro cell 
response is limited; complex factors which may be present in vivo are eliminated in a 
controlled system. No significant in vitro models of collateral development have been so far 
developed, justifying the continued use of animal models. 
1.11 The chicken embryo as a model system to study flow-induced remodelling 
There are many advantages in using the chick embryo over other model systems. Ethically 
it is preferable to use a non-mammalian model for clinical research; the chick embryo is 
cheap, husbandry is low maintenance and the embryo is robust. The vasculature is visible in 
vivo by light microscopy and real-time observation of vessel growth is neither invasive, nor 
time-consuming. The extra-embryonic vessels of the chick embryo are easily accessible in 
ovo after 66-68 hours of incubation, by making a small window in the shell. Manipulations 
of the extra-embryonic vasculature can be performed and then the chick can be covered 
and returned to the incubator to monitor flow-induced changes to the vasculature over 
time. 
1.12 The development of the chicken embryo extra-embryonic vasculature 
In the chick embryo, as with other vertebrates, the majority of cells forming the 
cardiovascular system derive from ventral mesoderm or extra-embryonic endoderm. An 
early process, termed vasculogenesis, drives the earliest stages of development of the 
extra-embryonic vasculature. In this process, small blood islands in the extra-embryonic 
tissue begin to form (Gonzalez-Crussi., 1971). Haematopoietic cells form inside the blood 
islands, surrounded by angioblasts – endothelial precursors. As blood islands fuse, 
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endothelial cells differentiate and a primitive network of vessels form (Risau and Flamme, 
1995). This is depicted in the schematic in Figure 1.5. 
The orientation of this vessel network is thought to be genetically pre-determined; further 
remodelling of the vasculature is then under the influence of blood flow following the 
onset of perfusion (Jones et al., 2006). Once vasculogenesis has completed and vascular 
precursor cells have formed lumenised tubes, angiogenesis continues to develop the 
vascular tree (as described in section 1.3). 
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Figure 1.5  The process of vasculogenesis in the extra-embryonic vasculature of the 
chicken embryo involves formation of blood islands from mesodermal cells which develop 
into capillaries with the onset of flow. 
 A Mesodermal cells committed to differentiate into endothelial cells initially give rise to 
angioblasts. Migrating mesodermal cells are bordered by ectoderm and endodermal cells in 
the primitive vascular primordial of the embryo. B Angioblasts fuse to create blood islands 
which are populated with haemopoietic cells derived from the yolk sac  C Blood islands fuse 
to form primitive capillaries and angioblasts differentiate into endothelial cells. Lumenised, 
functional capillaries mature and develop with the onset of circulation.  
Adapted from (Risau and Flamme, 1995) 
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The development of the extra-embryonic vessels in the chick embryo has been studied in 
detail for many years (Hughes., 1935). In 1992, Viktor Hamburger and Howard Hamilton 
recorded a series of normal stages of chick embryo development, which has become the 
gold-standard for determining the age of chick embryos in research (Hamburger and 
Hamilton., 1992). The arteries are the first vessels to develop around HH st 15 (see section 
2.1.4 for an explanation of Hamilton and Hamburger staging). The vitelline network is 
surrounded by a circular vein known as the sinus terminalis. This structure collects blood 
from peripheral capillaries and drains blood back to the heart via the posterior and anterior 
vitelline veins, which lie at the midline of the embryo. Before HH st 20, proximal vitelline 
vessels (lateral to the embryo body) are arterial (carry afferent flow out to the sinus vein). 
Proximal vitelline veins then develop to more efficiently return blood to the embryo as the 
extra-embryonic vasculature/tissue expands with the growing embryo (Hughes., 1935). 
These proximal vitelline vessels overlap one another, with the veins lying above the arteries 
in a cis-trans configuration carrying anti-parallel flow (Nguyen et al., 2006). The veins in the 
extra-embryonic vascular network are said to develop from pre-existing arterial 
connections which dis-connect from the arterial tree and re-connect as veins (le Noble et 
al., 2004). Figure 1.6 shows a diagrammatic figure of the extra-embryonic vasculature of a 
HH17 chick embryo and a later stage HH20 embryo to demonstrate the changes to the 
vascular tree as the embryo develops.  
Figure 1.7 shows representative micrographs of the embryo and vasculature at different 
stages (HH st13-17) to show the change in extra-embryonic vascular morphology over time 
in ovo.   
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Figure 1.6 Normal blood flow patterns  through the extra-embryonic vitelline vessel 
network of a chick embryo at HH st 17 and HH st 20 
A  shows a cartoon of the flow profiles in the vitelline vessel network of a HH st 17 chick 
embryo. Blue shading represents the area of small venules which drain blood back to the 
embryo via the main vein, known as the sinus terminalis which borders the vascular 
network. Red arrows represent arterial flow which enters the extra-embryonic network via 
vessels lateral to the body. Vessels become increasingly branched and smaller in size until 
capillaries reach the sinus terminalis and blood can be drained into the venous network 
and returned to the embryo. B shows the embryo at a later stage. The flow profile at HH st 
20 is more complex. Anti-parallel blood flow now exists as veins proximal to the embryo 
have developed to overlie the proximal lateral arteries. This allows more efficient venous 
return to the embryo as the entire network has expanded in size to grow with the embryo.   
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Figure 1.7 The development of the extra-embryonic vasculature of the chicken embryo, 
from HH st 13-17 
A shows the labelled vasculature of a representative HH st17 embryo. Proximal vitelline 
arteries lateral to the chick embryo carry arterial flow at this stage. Posterior and anterior 
vitelline veins lie at the midline of the embryo/yolk sac and return blood to the embryo. 
The sinus terminalis vein creates a border around the extra-embryonic tissue and collects 
blood to be returned by the venous system. B At HH st 13 it is difficult to see the defined 
outline of the embryo by light microscopy (embryo indicated by star). Perfusion has not 
begun at this stage therefore the vasculature cannot be seen as it is not yet perfused and 
still primitive. The developing primitive vitelline network can be seen in C. C shows HH st 
15 embryo, small capillary blood islands appear as spots of red at the posterior of the 
embryo and are indicated by the red arrow. Blood islands develop into the vitelline vein 
shown in A. These vascular orientations in these representative images were observed in 
all chicks at these stages (n=>100 embryos over the course of the project). Scale bar 
indicates 1000 m. 
49 | E m i l y  C l a r e  H o g g a r  
 
1.13 Chick embryo models to investigate the effects of changes in haemodynamic 
flow 
Due to the accessibility of the vitelline vasculature, previous groups have been able to 
manipulate blood flow to observe morphological patterning and molecular changes which 
occur following induced vessel occlusion.  
The previously mentioned study of flow regulation of endothelial identity by le Noble et al., 
(2004) utilised tungsten wires, to elevate the vitelline vessel and prevent flow (le Noble et 
al., 2004). This had the advantage of being easily removed to re-perfuse the vitelline vessel 
but le Noble also cauterised the vitelline artery prior to the onset of flow which prevented 
any further development of the right vitelline vessel. When ‘ligation’ of the right vitelline 
vessel was observed for 24 hours the group recorded ‘venularisation’ of the right vitelline 
vessel and ‘large arteries branching off the left vitelline artery were observed to project to 
the right side of the yolk sac, and crossed the midline’ (le Noble et al., 2004). This was never 
observed in unligated control embryos. Although we identified these vessels as collateral 
vessels, the group did not further acknowledge or study the collateral vessels which 
developed after ligation. The group instead, used this flow manipulating technique to 
observe flow regulated endothelial markers and document the haemodynamically driven 
expression of arterial markers in reperfused vessels (discussed in section 1.9).  
Groenendijk et al., (2005) used HH st 17 embryos to investigate transcriptional changes in 
shear related genes after alterations of flow which is ‘positively correlated with shear 
stress’  (Groenendijk et al., 2005). Flow and shear stress were altered by venous clipping of 
the right lateral vitelline vein which effected venous return to the heart. After 3 hours, 
analysis of mRNA levels from different areas of the cardiovascular system were analysed. 
This revealed that changes in blood flow through the heart and alterations in shear stress 
resulted in changes in gene expression. Following venous ligation, the aorta experienced 
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decreased shear stress, reduced expression of KLF2 and nitric oxide synthase 3 (NOS3) 
mRNA and up-regulation of ET1 mRNA. The opposite expression pattern was observed in 
the heart which experienced increased shear stress following ligation (Groenendijk et al., 
2005).  This is one example of how the extra-embryonic vasculature of the chick embryo 
can be manipulated to alter flow and can be used to assess consequent transcriptional 
changes. 
Flow manipulation of the vitelline network of HH st 17 chick embryos was also used by 
Buschmann et al., (2010) during the course of my studies. Tungsten wire elevated the right 
vitelline vessel in order to occlude flow and induce morphological changes in vessel 
patterning, and the group then studies arterial expression of the connexin gene (Gja5) 
(Buschmann et al., 2010). The group identified collateral vessels stemming from the left 
proximal vitelline vessel and crossing the midline to supply the tied-ligated territory with 
arterial flow. The group recorded the number of collateral vessels at a single 24 hour 
timepoint and used in situ hybridisation to detect Gja5 expression. The group used vascular 
casts of the remodelled vessels post-ligation at the midline of the embryo and reported 
that ‘splitting angiogenesis’ or intussusceptive angiogenesis (as described in section 1.3) 
was involved in the process of remodelling. Small capillaries which fed into the main 
posterior vitelline vein pre-ligation were seen to disconnect from the venous network and 
contribute to the arterial territory which the collateral vessel extended into. This work is 
discussed further in chapter 3 in the context of my own work – our results taken together 
strongly suggest that the chick embryo is a good model to study collateral vessel formation 
at the endothelial level. Buschmann et al., identified Gja5 expression in the collateral 
vessels of the chick embryo at 24 hours and subsequently found that Gja5 was involved in 
collateral vessel formation in mouse (Buschmann et al., 2010).  
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In summary, the chicken extra-embryonic vasculature has been used to observe 
morphological patterning and molecular changes which occur following induced vessel 
occlusion. This model has enabled studies to investigate the effect of flow on expression of 
arterial and venous endothelial markers, shear stress regulated genes and alterations in 
morphology of the vascular network. These studies are examples of how the chick model 
can be used to investigate blood flow remodelling and facilitate discovery of mechanisms 
of arteriogenesis. 
1.14 The advantages of using the extra-embryonic vasculature of the chicken 
embryo to study blood vessels in vivo 
As the chick embryo develops more oxygen is required, therefore from HH st 18 the 
allantois circulation develops and the chick depends on this, rather than the vitelline 
circulation (Deryugina and Quigley., 2008). The allantois is the embryo’s connection to 
chorion which lines the egg shell and provides gas exchange. These structures fuse at 
around HH st 23, forming the chorio-allantois. The highly vascularised chorio-allantoic 
membrane (CAM) has been used for many decades to study angiogenesis (Ribatti et al., 
1997, Brooks et al., 1999). The chick embryo has therefore been realised in recent years as 
an extremely good model for investigating the vasculature in terms of tumour growth 
(Deryugina and Quigley., 2008). This highly vascularised 3-D structure develops from the 2-
D flat vitelline membrane, during embryo development to later stages. The vessels at this 
stage are fragile and not appropriate for ligation techniques or vessel clamping as they 
easily tear. I therefore used embryos at an earlier stage for my experiments and 
concentrated on the vitelline vessels. However, previous studies using the CAM have 
shown that pharmacological agents can be applied to the extra-embryonic tissue to 
investigate effects on the vasculature (Ribatti et al., 1997, Deryugina and Quigley., 2008).  
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Pharmacological agents can be applied to the vitelline vessel on filter paper discs, matrigel 
plugs or gelatin sponges (Ribatti et al., 1997). The advantage to these techniques as 
opposed to simply dropping the drug in solution into the egg is that a specific area of the 
vasculature can be targeted, although some diffusion is likely. A stimulator or inhibitor of 
vascular growth can be applied to filter paper and positioned over the area of interest on 
the surface of the CAM/vitelline membrane. The embryo can then be re-sealed and 
returned to the incubator to continue development. At intervals during development the 
effect of the substance can be monitored by simply removing the vehicle of drug delivery 
and observing the vessels beneath. The speed of vascular development and the 
accessibility of the treated vessels, not to mention the ease of the assay, highlight the 
advantages that the chick embryo model has over drug screens using mammalian 
counterparts (Brooks et al., 1999). 
1.15 Cyclic nucleotide phosphodiesterases  
During the course of my studies I found phosphodiesterase 10A (PDE10A) to be 
upregulated during collateral vessel formation in the chick embryo. In order to introduce 
findings in chapters 4 and 5 I will therefore now discuss some general background to 
phosphodiesterases and PDE10A in particular.  
Phosphodiesterases (PDEs) are enzymes which perform phosphoric-diester hydrolytic 
cleavage of cAMP and cGMP. This cleavage inactivates the 5’ monophosphate of the 
second messenger preventing any further signalling (Essayan., 2001). PDEs regulate a 
variety of cell functions, including cell proliferation, inflammation and gene transcription 
(Lugnier., 2006). PDEs have been documented to control physiological functions such as 
smooth muscle relaxation, fluid homeostasis, platelet aggregation, cardiac contractility and 
immune responses (Matsumoto et al., 2003). PDEs themselves are regulated by 
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phosphorylation, sub-cellular localisation, protein interactions and small molecule 
association (Francis et al., 2001).  
1.15.1 Cyclic nucleotides 
Nucleotides have an aromatic base containing nitrogen, sugar (ribose/deoxyribose) and a 
phosphate group. Cyclic nucleotides have two phosphate groups linked to a ribose group in 
two different places making them ‘cyclic’ and allowing them to bind differently to proteins. 
Cyclic nucleotides act as intracellular second messengers to convey and amplify complex 
signals from outside to inside the cell (Essayan., 2001, Francis et al., 2001). Their level must 
be strictly regulated in order for them to orchestrate complex signalling events and 
crosstalk between pathways (Beavo., 1995, Soderling and Beavo., 2000). Cyclic nucleotides 
regulate important mediators of cell signalling such as protein kinase A (PKA) and protein 
kinase G (PKG), exchange protein directly activated by cAMP (EPAC), gated ion channels 
and PDEs (Lugnie.r, 2006). 
1.15.2 Protein kinases 
Protein kinases (PK) are cyclic nucleotide binding proteins consisting of two regulatory and 
two catalytic subunits (Seino and Shibasaki., 2005). Cyclic nucleotides stimulate their own 
degradation by binding to Protein kinases. For example, Protein kinase A (PKA) binds two 
cAMPs to its regulatory subunits which cause a conformational change to release two 
catalytic subunits. These catalytic subunits catalyse the phosphorylation of proteins such as 
PDEs (Christina., 2010). Protein kinases activate PDEs by transferring a terminal phosphate 
group from an ATP molecule to a hydroxyl group on the PDE (Christina., 2010).  PDEs in 
turn inactivate cyclic nucleotides to reduce the cAMP/cGMP signal (Beavo., 1995). 
In the vasculature, cAMP/PKA signalling has been shown to regulate endothelial cell 
differentiation by up-regulating VEGF-A receptors and nrp1. cAMP can also activate arterial 
fate and arterial gene expression by activating phosphatidylinositol-3 kinase (PIK3) which 
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activates Notch signalling (Chiu and Chien., 2011). cAMP/PKA activation has also been 
investigated in the context of vascular barrier integrity. cAMP/PKA signalling was found to 
regulate endothelial cell cytoskeletal reorganisation in cultured bovine endothelial artery 
cells. When the cells were treated with PKA antagonists, including RP-Br-cAMPs, Western 
blotting revealed increased ERK1/2 and MAPK signalling, and immunofluorescent studies 
showed that this lead to actin cytoskeleton rearrangement (Liu et al., 2001).  
Endothelial cell proliferation is mediated by complex interactions of multiple signalling 
pathways. In one study, cultured bovine brain endothelial cells were used to investigate 
cAMP/PKA signalling mitogen-activated proliferation (D'Angelo et al., 1997). Mitogens, 
VEGF and bFGF stimulate cell proliferation and activate MAPK signalling pathways. 
Increased levels of cAMP/PKA signalling prevented activation of VEGF and bFGF-induced 
MAPK signalling and cell division (D'Angelo et al., 1997). This finding suggested that 
cAMP/PKA signalling in endothelial cells could play a role in inhibiting mitogen-activated 
cell proliferation.  
1.15.3 The phosphodiesterase family   
Eleven different PDEs have so far been described, categorised according to regulation, 
pharmacokinetics and sequence (Beavo., 1995). The different PDE isoforms also have 
different splice variants (Buschmann et al., 2003, Bender and Beavo, 2006). The main 
classifying factor of the subgroups of PDEs depends upon the PDE substrate: cAMP, cGMP 
or both. All PDEs share a similar protein structure, with targeting and regulatory domains in 
the NH2 terminal region and a conserved catalytic domain towards the COOH terminal end 
(Seino and Shibasaki., 2005). 
Although PDEs are ubiquitously expressed in the cells of the body, PDE family members are 
distributed differently with higher expression in specific tissues (Lugnier., 2006). 
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In vascular smooth muscle PDEs 1-5 have been well characterised (summarised by Polson 
and Strada., 1996). Due to PDEs acting on cyclic nucleotides most investigations of PDEs in 
the vasculature have been related to control of vessel tone and therefore PDE function in 
vascular smooth muscle cells (Matsumoto et al., 2003). For example, in the clinical setting, 
the PDE5 inhibitor, Seldenafil, has been widely used in vascular surgery as a tool to induce 
vasodilation. PDE5 degrades cGMP, therefore inhibition enables manipulation of vascular 
tone (Rybalkin et al., 2003). 
Table 1 shows the functions of some of the vascular located PDEs. 
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Table 1. Annotations of some of the observed functions of vascular located PDEs 
reported in the literature. The table lists the PDE, the observed location in the 
particular study and the observed effect of inhibition. This gives some clues as to the 
functional role of the PDE. PDEs 1-5 have been observed to play functional roles in 
endothelial and smooth muscle cells. Function is determined by cellular location.  
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1.16 Phosphodiesterase 10A  
Phosphodiesterase 10A (PDE10A) is cyclic nucleotide PDE which hydrolytically degrades 
dual substrates, both cAMP and cGMP (Lugnier., 2006). PDE10A protein expression has 
previously been investigated using immunohistochemistry in a variety of tissues taken from 
mouse, rat, dog, cynomolgus and human using an antibody against rat PDE10A (Coskran et 
al., 2006). Coskran et al., (2006) observed PDE10A to be strongly expressed in the brain in 
all of these mammals, in particular the striatum and substantia nigra. PDE10A expression 
was also found peripherally, including the heart and aorta but not in smooth muscle. 
Depending on the tissue, PDE10A protein could be detected in the cytoplasm or the 
nucleus of cells (Coskran et al., 2006.  
1.16.1 PDE10A function 
PDE10A has been widely studied in the brain and has been shown to contribute to neuronal 
function (Hebb et al., 2004, Rodefer et al., 2005, Nishi et al., 2008). Anxiety, Huntington’s 
disease and schizophrenia have all been related to PDE10A function (Hebb et al., 2004, 
Rodefer et al., 2005, Siuciak et al., 2006a). In mice with Huntington’s disease, treatment 
with the PDE10A inhibitor papaverine hydrochloride has suggested that PDE10A is a 
possible therapeutic target for improving the symptoms of schizophrenia, and to improve 
cognitive, motor and psychological function (Hebb et al., 2004, Rodefer et al., 2005). 
However, the role of PDE10A in brain function remains unclear.  
During the course of my work, PDE10A was shown to play a role in pulmonary vascular 
remodelling in rats (Tian et al., 2011).  Pulmonary vessels that remodel due to proliferation 
of vascular smooth muscle cells, endothelial cells and fibroblasts, cause increased vascular 
resistance leading to pulmonary hypertension. Pulmonary hypertension can be induced in 
rats by injection of monocrotaline. PDE10A mRNA and protein levels were found to be 
upregulated in the nuclei of remodelling pulmonary vascular smooth muscle cells in 
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monocrotaline injected rats. When these rats were infused with the PDE10A inhibitor, 
papaverine hydrochloride for 14 days, this reduced proliferation and remodeling of 
vascular smooth muscle cells. Increased cAMP levels were measured in cultured pulmonary 
arterial smooth muscle cells and cAMP response binding protein (CREB transcription factor) 
phosphorylation levels were also found to be increased in these cells, in the presence of 
papaverine. Similarly to PDE10A inhibition with papaverine, siRNA knock down of PDE10A 
RNA reduced pulmonary artery proliferation and remodelling (Tian et al., 2011). 
1.16.2 PDE10A mechanism of action 
The anti-proliferative effect of PDE10A inhibition has been suggested to be due to PDEs 
counteracting pathways involved in smooth muscle cell proliferation by blocking cyclins and 
increasing anti-proliferative molecules (Hayashi et al., 2000). Further evidence suggests 
that cAMP/PKA binding may block cell cycle progression by phosphorylating transcription 
factor CREB (Klemm et al., 2001). One hypothesis is that as PDE10A can be found in 
different subcellular compartments (nucleus or cytoplasm) the effect of cAMP hydrolysis in 
different cellular locations will cause different effects (Zippin et al., 2003). For example, 
PDE10A expression/inhibition in the nucleus may regulate cell proliferation by controlling 
cAMP/PKA levels and therefore CREB phosphorylation. It is likely that PDE10A 
expression/inhibition could induce a different effect if expressed elsewhere in the cell. 
PDE10A mechanism of action remains largely unknown and more work is required to 
further characterise the function of this enzyme in different cellular processes. The role of 
PDE10A in the endothelium has not previously been investigated. 
1.17 Thesis aims 
Considering the clinical implications, research to understand arteriogenesis is extremely 
important. The chicken embryo appears to provide a good model system in which to 
investigate collateral vessel formation (discussed in section 1.14). I therefore set out to 
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characterise collateral vessel development in the chick embryos and identify genes 
involved in this process. Below I list the objectives for each of the three results chapters 
that follow. 
Chapter 3 
Perform a longitudinal quantification of developing collateral/collateral number  following 
unilateral vitelline artery ligation 
Perform a longitudinal quantification of developing collateral/collateral diameter following 
unilateral vitelline artery ligation 
Establish a system to assess blood flow in the vitelline vessels after unilateral vitelline 
artery ligation 
Examine expression of various markers in developing collateral vessels 
histologically/histochemically 
Examine proliferation in developing collateral vessels after unilateral vitelline artery ligation 
Chapter 4 
Characterise transcriptional changes during different phases of flow-induced vessel 
remodelling  
Identify candidate genes which may contribute to collateral development 
Chapter 5 
To determine the temporal and spatial expression of PDE10A protein in the extra-
embryonic vitelline vasculature during flow-induced remodelling 
To establish the effect of pharmacological inhibition of PDE10A on flow-induced 
remodelling 
To examine mechanisms whereby PDE10A may influence flow-induced remodelling 
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Chapter 2 
Materials and methods 
Materials 
Equipment 
Materials used Purchased from 
Forceps (#4, #5) World Precision Instruments 
25G/18G needle Microlance 
Plastic syringes (various sizes) Plastipak, Sigma Aldrich 
Suture 8/0 Prolene, Ethicon, Johnson & 
Johnson 
Glass coverslip Fisher scientific 
Superfrost slides Fisher Scientific 
Spatula (5x7mm) World Precision Instruments 
Iris scissors World Precision Instruments 
Eppendorfs Eppendorf UK 
Filter 0.2um Filtopur 
Filtertips/pipette tips StarLabs 
Pipettes StarLabs 
Pasteur pipettes StarLabs 
Filter paper Whatman #1, Sigma Aldrich 
Parafilm Sigma Aldrich 
Nitrocellulose membrane Amersham, hyperbondC, Fisher 
Scientific 
6-well plate (34mm diameter) Sigma Aldrich 
384-well plate Anachem 
Incubator Sanyo 
Waterbath  
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Upright epi-fluorescent combi-
microscope 
Leica M216FA 
Sensi-cam QE camera PCO 
Light emitting  diode LA GmBH 
LaVision Davis 8.0 DaVis 
Nanodrop ND-1000, Labtech 
Vortex Cifton cyclone, MSE Sanyo 
Microarray  Affymetrix chicken gene chip 
QRTPCR Rotor 6000, Corbett life science 
Aspirator  Vacusafe, Integra 
Orbital shaker PSU 100, Grant instruments 
Gel doc Geni 2, Fisher Scientific 
Ulltra Centrifuge Avanti J-25 Beckman Coulter Inc 
Microtome Leica RM2155, Leica 819 blade 
Cryostat Bright OFT  
Spectrophotomer Jenway 
Apotome Zeiss Imager Z1, Axiocam MRM 1.0X 
Camera Nikon Coolpix 5400 
Stereomicroscope Nikon SM21500 
Spot cam SPOT insight Colour 1.0X 
Image J National institute of health 
Lightsource Schott KL2500 
Kits/reagents 
Reagent used Purchased from 
cDNA synthesis Verso, Thermo scientific 
ExoSAP IT Affymetrix 
Maxi prep Quiagen 
Ethanol/Methanol Fisher Scientific 
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NaCl/KCL/CaCl2 SigmaAldrich 
Isopropanol Fisher Scientific 
Super Optimal Broth (SOC) Invitrogen 
Luria Bertani (LB) broth Sigma Aldrich 
Luria Bertani (LB) agar Sigma Aldirhch 
Ampicillin Sigma Aldrich 
Xylene Fisher Scientific 
Corazzi’s Haemotoxylin Gills #1, Sigma Aldrich 
Eosin Y Sigma Aldrich 
Formamide Fisher Scientific 
NuPAGE 10X running/transefer buffer NuPAGE, Novex 
NuPAGE bis-tris pre-cast 
polyacrylamide gel 
NuPAGE, Novex 
NuPAGE antioxidant NuPAGE, Novex 
NuPAGE Reducing agent NuPAGE, Novex 
Tween Sigma Aldrich 
Triton X-100 Sigma Aldrich 
Chaps Sigma Aldrich 
Papaverine hydrochloride Sigma Aldrich 
Dispase Boehringer Mannheim 
Sodium bicarbonate Sigma Aldrich 
DMEM Sigma Aldrich 
Paraformaldehyde Sigma Aldrich 
Sucrose Sigma Aldrich 
Chemiluminescence Amersham, Fisher Scientific  
 Enzyme endonucleases New England Biolabs 
RNA polymerases Promega 
DNA buffer Promega 
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DNAse Invitrogen 
Nitro blue tetrazolium (NBT) Roche 
BCIP Roche 
Protease inhibitor Roche 
Lysis buffer Qiagen 
4',6-diamidino-2-phenylindole (DAPI) 
stain 
Invitrogen 
Heat Inactivated Goat Serum (HINGS) Sigma Aldrich 
Agarose Invitrogen 
SYBR green sensimix plus Quantace 
Primers Sigma Aldrich 
Phosphate buffered saline (PBS) 1X Roche 
Ethidium bromide Life technologies 
Hyperladder Bioline 
Loading buffer Bioline 
TRI reagent Sigma Aldrich 
Chloroform Sigma Aldrich 
Collagen (rat) Sigma Aldrich 
Vectorshield (with DAPI stain) Vectorlabs 
Glycergel mounting medium Dako 
OCT mounting media VWR 
Leibovitz-L15 media Sigma Aldrich 
BioRad protein assay BioRad 
Alpha competent cells Invitrogen 
 
Antibodies 
Antibody used Concentration used Purchased from 
Rabbit polyclonal antibody to 
PDE10A 
1:250 GeneTex 
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Rabbit polyclonal antibody to 
VE-cadherin 
1:100 Abcam 
Alexa Fluor 488/594 goat 
anti-rabbit IgG 
1:500 Abcam 
Rat monoclonal antibody to 
Bromodeoxyuridine 
1:1000 Abcam 
Alexa Fluor 488 donkey anti-
rat IgG 
1:500 Abcam 
 
2.1 General chick embryo methods 
2.1.1 Storage and incubation 
Fertile White Leghorn (Gallus gallus) chicken eggs were purchased fresh from Henry Stuart 
& Co. Ltd, Louth, Lincolnshire. On delivery, eggs were stored blunt-end-up, in a controlled 
environment room at 18°C for up to five days before incubation. Eggs were incubated at 
37°C in a humidified environment, for 60 to 68 hours prior to experimentation. For post-
operative survival, opened eggs were sealed to avoid dehydration. Experiments extended 
no further than 48 hours following experimental manipulation. 
2.1.2 Developmental stages of the chicken embryo 
In 1951 Viktor Hamburger and Howard Hamilton developed a staging guide for 
embryologists using the chicken embryo as a model of development (Hamburger and 
Hamilton., 1951). The age of the chick is thus described in terms of Hamburger and 
Hamilton (HH) which describes the length of incubation and identifies the stage (st) of the 
embryo; at the stages used here, somite number and limb bud development provide highly 
accurate reference points. The guide itself provides a rigorously documented description of 
the embryo at each stage, followed by a series of images corresponding to each stage. I 
used embryos at HH st 17. At this stage the chick embryo has developed extra-embryonic 
blood vessels which connect the embryo proper to the yolk sac. The heart begins beating at 
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HH st 9 but circulation is not fully functional until HH st 15. Therefore at HH st 17 the extra-
embryonic vessels are sufficiently mature and perfused.  
2.1.3 Windowing the egg 
Eggs were positioned in a holder made of Styrofoam plastic to prevent movement. The 
blunt end was wiped with 70% ethanol to avoid infection. Instruments were sterilised with 
70% ethanol. Blunt forceps (#4) were used to create a crack in the shell, into the air cell 
above the embryo. A small window was created by removing shell and first opaque 
membrane, with the forceps. Insertion of an 18G needle fitted with a 10ml syringe three-
quarters of a way down the egg, removed 3-5ml albumin. This allowed the embryo to drop 
away from the window to avoid any harm or shearing of the embryo or extra-embryonic 
vessels. Further dissection of the overlying vitelline membrane with forceps (#5) revealed 
the embryo positioned on the yolk sac. To re-seal eggs after opening, sellotape or parafilm 
were used. 
2.1.4 Embryo staging and inclusion criteria 
Incubation duration of 66-68 hours developed the chick embryo to HH st 17 (Hamburger 
and Hamilton, 1951). Morphological inclusion criteria were implemented to standardise the 
experimental model due to variation between embryos in a batch. Embryos were required 
to have circulation in the yolk sac vasculature (blood flow through right and left vitelline 
arteries, with venous return through single anterior and posterior veins). The vitelline veins 
were used as markers of the midline (the boundary between the left and right vitelline 
artery perfusion territories). The vitelline arteries needed to be of an adequate size 
(diameter of approximately 200-250m) to allow successful ligation.  
2.2 Arterial ligation 
Microsurgical ligation was performed on the right vitelline artery using straight-tipped 
forceps, surgical spring scissor and a length of suture (8-0 sized prolene suture). Ligations 
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were created before the first bifurcation of the artery, most proximal to the embryo. A 
windowed egg was placed under a stereo-microscope with an overhead light source. A 
magnified view of the embryo allowed the suture needle to be guided under the artery and 
tied. The knot was pulled tight, taking care not to tear the blood vessel. Excess suture 
length was cut off (example shown in Figure 2.1). Control (sham-ligated) embryos 
underwent the same procedure as tied-ligated embryos however the suture was left un-
tied beneath the right vitelline artery in a manner that did not interrupt blood flow. In the 
results chapters for clarity I refer to embryos where the suture was tied off to induce vessel 
occlusion as “tied-ligation” and embryos where the suture was left untied as “sham-
ligation”. 
 
  
Figure 2.1. Micrograph images of a sham ligation and a tied ligation 
Low power and high power views of examples of chicks after sham (A) or tied (B) 
ligation. The black box around the right vitelline vessel indicates the location of the 
suture, shown at higher magnification. A shows the suture beneath the vessel. The 
suture is left un-tied to leave blood flow un-disturbed. Sham ligations do not occlude 
flow. B shows a knot around the vessel. Blood appears darker in image B due to 
stagnant blood distal to the occlusion. 
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2.3 Particle Image Velocimetry 
Particle Image Velocimetry (PIV) was performed in the lab of Dr Christian Poelma 
(University of Technology, Delft). Protocols for imaging were carried out in line with the 
protocol of the Poelma lab (described in 2.3.2). PIV measurements were performed at the 
anterior and posterior poles of the embryo, to record flow within developing collateral 
vessels. I acquired data from collateral vessels at 4 hours post tied-ligation and followed 
these collaterals to a later stage (7 hours post tied-ligation). I had hoped to obtain data up 
to 24 hours, but embryos died before reaching this stage (discussed in Chapter 3). 
Unfortunately due to the limited length of time that I was visiting the Poelma lab I was 
unable to optimise this to improve survival. I therefore recorded a separate group of 
embryos which had been ligated for 24 hours to assess the velocity of blood flow in mature 
collateral vessels. 
2.3.1 Preparation of the embryo for imaging 
To elevate the embryo within the egg, and prevent dehydration during imaging, drops of 
Locke’s solution (0.94% NaCl, 0.0045% KCl, 0.004% CaCl2) were added. A small circular 
glass coverslip was then placed over the surface of the vitelline membrane, creating a seal 
around the edge of the windowed shell. This kept the embryo hydrated and prevented 
movement but also ensured completely flat 2D imaging – important for data acquisition. 
The eggs were then placed in a water bath (38°C) which allowed constant and prolonged 
recordings of up to 20 minutes without observing a reduction in chick heart rate. After 
imaging eggs were removed from the water bath, 1-2ml albumin extracted using a 18G 
needle and 1ml syringe, in order to reseal the window, and then returned to the incubator. 
2.3.2 PIV Recordings 
Eggs were placed under an upright epifluorescent combi-microscope with zoom (Leica MZ 
16 FA). Magnifications of 5x and 10x were achieved with a Leica FluoCombi III objective. A 
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PCO Sensicam QEcamera (1376 x 1040 pixels) was used for recordings with binning to 
improve signal-noise ratio. A high-powered pulsed light emitting diode (LED) was used to 
illuminate and capture images (pulse-rate=200us). Pulsed light is used in order to acquire 
consecutive images milliseconds after each other. This is necessary because the interval 
between light pulses needs to be sufficient to capture the largest displacements in the 
selected area of measurement. For all measurements 1000 images were recorded for each 
vessel at 5x and 10x magnifications, 5000s time delay between frames. When embryos 
required a ligation during the recording process this was done whilst the embryo remained 
in the water bath. Figure 2.2 shows the equipment set-up used for PIV experiments. 
 
  
Figure 2.2 Particle Image Velocimetry apparatus 
Embryos were imaged in ovo. Eggs were kept warm in a water bath maintained at 38°C . 
Recordings were made using a pulsing light source and high speed camera. From one 
frame to the next the particle (red blood cell) is tracked and recorded and the particle 
displacement is then calculated  to measure the velocity of blood flow. 
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2.3.3 Time-averaged velocity fields 
PIV quantifies blood flow within blood vessels by using red blood cells as tracers (Poelma, 
2012). Individual red blood cells can be followed by taking a series of images with a high-
speed camera. From this, the distance individual red blood cells travel between two frames 
can be calculated - this is known as the particle displacement (Lee et al., 2007, Poelma et 
al., 2012). The area of measurement in an image can be sub-divided into smaller windows 
of view, known as interrogation windows. The displacement of a red blood cell from one 
window to the next, over these consecutive measurements, can then be statistically 
analysed using a cross-correlation algorithm. The local velocity of the blood flow can be 
calculated by dividing the displacement of the red blood cell by the time difference 
between the two frames (interrogation windows) (Vennemann et al., 2006).  
For large collateral vessels the velocity of the flow was slow enough to record with a single 
frame. However in most cases the blood velocity (and therefore pixel displacement) was 
slightly faster than anticipated and required a double frame recording. Images were 
therefore recorded in pairs. The time difference (∆t) between frames was specified to 
ensure pixel displacement did not exceed 10-15 pixels during a cardiac cycle. For double 
frame recordings we used 500s ∆t. Displacement is calculated from one frame to the next 
by cross-correlation. Each correlation of a single pair of interrogation windows leads to a 
single displacement vector. Overlap of interrogation windows can be specified which then 
determines the size of the grid of computed velocity vectors. Multi-pass PIV evaluation 
uses vectors in the first image as a reference for the vector field of the second image. This 
shifts the interrogation window accordingly to determine the particle image shift and 
correlate the correct particles. Finally, vectors are combined to get a complete 2D vector 
field of the vessel of interest. 
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LaVision DaVis 8.0 software was used to correlate images and further processed the 
recordings to acquire time averaged blood velocity field profiles for each vessel. PIV 
analysis was performed using version 7.2. 
The processing of each image involved: shift correcting for any movement of the embryo 
during recording; calculating an average for this shift corrected image; subtracting the 
averaged image from shift corrected image; calibrating the image to display velocity as 
m/s; calculating the vector field of the calculated ‘difference’; cross correlating this result 
(constant multi-pass; 50% overlap of consecutive images (interrogation windows);32x32 
pixels, interrogation window size). 
Image J was used to measure the diameters of the vessels in Figure 3.7 by calibrating the 
scale of the image and using the line tool to measure the length of the line drawn across 
the diameter of the vessel (section 2.24). 
For vessels recorded at 24 hours LaVision processing software also produced parabolic 
curves from the data which showed blood velocity was highest at the centre of the vessel 
and these can be found in the Appendix (Figure A3). 
2.4 Microarray methods 
I performed all surgical procedures, tissue sampling and RNA extraction. Sample labelling, 
array hybridisation and scanning of the array was performed by Dr Paul Heath of the 
University of Sheffield Microarray Core Facility. The raw .CEL data files were analysed by my 
bioinformatician colleague Dr Marta Milo to generate fold-change data and the probability 
of a positive log ratio (PPLR) for each gene (section 2.6.1). I performed all further analysis. 
2.4.1 Tissue excision   
Embryos were prepared with either a sham or tied-ligation (Figure 2.1). For microarray 
analysis of gene expression, tissue was excised from the area of collateral vessel growth at 
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T0, 4 hours and 12 hours post tied-ligation. Control samples were collected at the same 
timepoints after sham-ligation. A sterilised spatula with angled tip (5x7mm) and Iris scissors 
(~2cm straight blade) were used. A vertical incision was made from the sinus terminalis up 
to the tail of the embryo, along the midline. The spatula tip was slid under the yolk sac 
membrane, to the left of the first incision. Scissors were then used to cut around the tip of 
the spatula, leaving a rectangular area of the membrane. Figure 2.3 shows the area 
dissected for microarray.  
2.4.2 RNA extraction 
For microarray analysis, three replicates were used per timepoint and each replicate 
contained pooled RNA from three embryos. RNA was pooled to provide sufficient RNA and 
to reduce variability while three replicates were performed to assess array variability and 
to allow statistical comparison. 
Dissected tissue was placed in a 1.5ml Eppendorf containing 200l TRI reagent for 
immediate RNA extraction. The tissue was homogenised through a 25G needle and 1ml 
syringe five times. Excised tissue was pooled from three embryos for each time point. This 
was because 1 individual embryo did not provide enough tissue for analysis but also, use of 
pooled embryos reduces the influence of variability between individual embryos. When all 
tissue samples had been collected and homogenised the Trizol method of RNA extraction 
was used as it provides a greater and more accurate RNA yield than commercially available 
column assays (Nolan et al., 2006). All pipette tips were single use sterile filter pipette tips 
and sterile conditions were maintained during the experiment. 300l of TRI reagent was 
first added to the tissue sample. The solution was mixed, and 100l of chloroform added. 
The solution was mixed using a vortex and centrifuged at 13,000rpm for 15 minutes at 4°C. 
Centrifugation and aqueous solutions separated out RNA and removed protein. The 
colourless upper aqueous phase was transferred to a new RNase-free Eppendorf and 250l 
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isopropanol was added. The solution was mixed and centrifuged at 13,000rpm for 20 
minutes at 4°C. A pellet was identified at the bottom of the solution. The solution was 
removed without disturbing the pellet. 0.5ml 75% ethanol was added and the Eppendorf 
vortexed to free the pellet from the side. The Eppendorf was centrifuged at 8,000rpm for 
15 minutes at 4°C. All ethanol was removed and the pellet re-suspended in 15l RNase-free 
water. Volumes were measured and dispensed using laboratory pipettes. 
2.5 Spectrophotometry 
The quality and quantity of RNA samples was quantified using a NanoDrop 
spectrophotometer (ND-1000, Labtech). Spectrophotometers measure absorbance of light 
through a sample to calculate the concentration of RNA based on the optical density. 2l of 
each RNA sample was tested. Purity of RNA was assessed by the ratio of absorbance at 
260nm and 280nm. 
2.6 Affymetrix microarray  
An Affymetrix chicken gene chip was used which assessed expression of 32,773 transcripts. 
Affymetrix chips are a synthesised oligonucleotide array which claim high sensitivity, 
specificity, standardisation and reproducibility (Jayapal and Melendez, 2006). Affymetrix 
microarray protocols involve RNA extraction and single labelling and hybridisation of each 
sample to a different chip. Hybridisation occurs between sequence-specific binding of 
target sequences and probe sequences. Fluorescent labelling enables detection of probe 
bound transcripts. The intensity of the fluorescence relates to the amount of bound probe 
and in turn acts as a measure of the target RNA sequence (Liu et al., 2005). Affymetrix 
system uses a ‘perfect match/mismatch’ hybridisation (Liu et al., 2005). A perfect match 
probe is complimentary to the target sequence. The mismatch probe acts as a control for 
hybridisation specificity: 1 base is mismatched in an otherwise complimentary sequence 
(Lee., 2004). Standardised methods of reporting microarray studies are available for the 
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scientific community on databases such as MIAME (The Minimum Information About a 
Microarray Experiment) (Jayapal and Melendez, 2006). 
Microarrays were performed on the 3 best quality RNA samples (determined by purity and 
concentration from spectrophotometry) for each timepoint; pre-ligation, 4 hours post tied-
ligation, 12 hours post tied-ligation, 4 hours and 12 hours after sham-ligation (Figure 2.3) 
and selected from a total of 5 samples at each timepoint. Microarrays were performed 
using Affymetrix GeneChip arrays (Affymetrix) by Paul Heath (University of Sheffield 
Microarray Core Facility) at the Royal Hallamshire Hospital, Sheffield. 
 
 
 
 
 
 
2.6.1 Microarray data analysis  
Raw microarray data files (.CEL files) were analysed to generate levels of gene expression. 
This is based on an algorithm which compares the difference in signal between perfect 
Figure 2.3. Microarray RNA extraction was performed at 3 timepoints in sham and tied-
ligated embryos 
Tissue was excised from the posterior midline area in sham and ligated embryos 
(indicated by the blue box; midline indicted by dashed line). Dissections of uniform sizes 
of tissue were performed at T0, 4h and 12h post-ligation or post-sham in HH st 17 
embryos. 
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match and mismatch hybridised probes (Milo et al., 2003). The signal intensity and quality 
of the average difference is then also calculated by an algorithm. For data analysis, 
hypothetical genes and non-annotated genes were excluded. These refer to genes which 
have not yet been experimentally characterised and whose function cannot be elucidated 
on sequence comparisons alone (Kolker et al., 2004). Cut-offs for the Probability of Positive 
Log Ratio (PPLR) and fold-change were used to identify the most significantly differentially 
expressed genes. The PPLR takes into account variations between samples and variations 
between chips by working out uncertainty measurements from replicate experiments to 
calculate standard errors and estimations of expression levels. This makes it more stringent 
than a P value when assigning significance to an observation (i.e. the likelihood of that 
observation occurring by chance) (Pearson et al., 2009). A PPLR close to 1 indicates a high 
probability of upregulation and a PPLR close to 0 implies a high probability of down 
regulation. For this study transcripts were selected for further analysis based on a PPLR of 
>0.8  or <0.2. 
The microarray data was normalised to give the signal of each array the same distribution 
and arrays were scaled to have the same mean values. Normalisation takes into account 
the variation from each microarray chip to make the numbers from one chip mean the 
same as the numbers from another chip. Variation between signal from different arrays 
may come from experimental conditions or slight differences in RNA concentration for 
example. Reducing the variability of the signal for each individual probe set increases the 
likelihood of detecting true differences in differential gene expression between groups. The 
signal of the array was normalised over all 15 chips. Normalisation of the microarray data 
was performed by Dr Marta Milo, a bioinformatician. Dr Milo also performed statistical 
analysis on normalised microarray data for this project using open source software 
Propagating Uncertainty in Microarray Analysis (PUMA)  (Pearson et al., 2009). This method 
of probe level analysis extracts a level of uncertainty associated with each probe set to 
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estimate gene expression with a credibility interval  (similar to a confidence interval) (Milo 
et al., 2003). This model has been shown to be more effective than traditional statistical 
models as it increases reproducibility of fold-change observed, by more accurately 
identifying differential gene expression (Milo et al., 2003).  
To calculate the significance of changes in expression ratios the following formula was 
used:  Eg = Tg/Cg, where g represents gene, T is the test sample and C is the control 
sample. When the level of g is the same in both the test and control samples the ratio 
equals 1. If g is upregulated in the test sample the ratio will be greater than 1. If g is 
downregulated the ratio will be between 1 and 0. Fold change is then calculated by 
multiplying the reciprocal of the downregulated gene by -1. In order to identify 
differentially expressed genes in my microarray data I decided to use a cut off of a fold 
change of greater than 1.5 or -1.5. 
The key comparison was between the sham and tied-ligated groups at each timepoint. For 
comparisons between 4 hours sham and tied-ligated, and 12 hours sham-ligated and tied-
ligated, I clustered expression of these genes by their relative change from baseline. 
Normalisation for baseline expression allowed assessment of changes over time in each 
group as well as assessment of differential expression between sham and tied-ligated 
tissue. 
TreeView analysis was by software designed by Michael Eisen (Stanford University). Data 
was uploaded into the programme and was automatically clustered hierarchically. Cluster 
currently performs three types of binary, agglomerative, hierarchical clustering. The basic 
principle of TreeView is to assemble a set of items (genes or arrays) into a tree, where 
items are joined by very short branches if they are very similar to each other, and by 
increasingly longer branches as their similarity decreases (Eisen et al., 1998).  
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2.7 Gene ontology tools  
Gene ontology Protein ANalysis THrough Evolutionary Relationships (PANTHER) can be 
used as a tool to predict the pathways and processes of genes in microarray data. 
Differentially expressed genes were compared to a reference list and sorted into biological 
processes. The results give an estimation of the number of genes observed in the process 
(from the microarray data) and the number of genes expected to be in the process (from 
the reference list). A fold change representation was calculated by dividing the number of 
genes observed by the number of genes expected in the reference list (fractional 
difference). A positive fractional difference implies an overrepresentation of a gene in the 
process. PANTHER analysis also assigns a P value to the genes in the list. A p value <0.05 
was considered statistically significant. PANTHER analysis of biological pathways and 
cellular components can be found in the Appendix (Figure A6, A7). 
2.8 Quantitative real-time PCR 
2.8.1 Primer stocks 
Ensembl was used to detect cDNA sequences for the candidate genes 
(http://www.ensembl.org/). Primers were then selected from sequences ~250 base pairs 
long using Primer3Plus  (http://www.bioinformatics.nl). The primer size parameters were 
based on the optimum number of base pairs for successful DNA binding. The melting 
temperature (TM) was based on the optimum range of temperature for annealing. This is 
important as GC bases share triple hydrogen bonds instead of normal double hydrogen 
bonds, therefore more heat is required to break the bonds (Nolan et al., 2006). The primer 
GC% relates to the number of GC base repeats in the primer sequence; more GC bases in a 
sequence results in less successful DNA amplification (Nolan et al., 2006). 
The parameters used were as follows;  
Primer Size = minimum 18 base pairs long ; maximum 24 base pairs long  
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Primer TM =  minimum annealing temperature 58°C ; maximum temperature 60°C  
Primer GC% = minimum GC content 50% ; maximum GC content 60% 
 
Candidate genes to validate by QRTPCR were selected based on fold change, and a list of 
specifics as described in Chapter 4. Housekeeping genes were essential to use as a 
reference gene to compare expression fold changes. Housekeeping genes were selected 
from the microarray data and were picked based on a constant expression level across all 
timepoints and experimental conditions. 
 
 
 
 
Gene name Primer Sequence 
Prostate stem cell antigen PSCA (forward) CTTCAGCATCATCAGCAAGG 
PSCA (reverse) GGTCATGGGAGCTCTGTTTC 
Stanniocalcin 2 STC2 (forward) AGCTGCATCAGCCGTAAGT 
STC2 (reverse) CATCTCCACAATGACCTGGA 
A Disintegrin And 
Metalloproteinase with 
Thrombospondin 
Motif(ADAMTS)-like 1 
ADAMTSL1 (forward) CATCTGTGGTGTGCACTGG 
ADAMTSL1 (reverse) AGGCTTGTTGGTACGGATGT 
Phosphodiesterase 10A PDE10A (forward) AGCCATCCCATGTTACACC 
PDE10A (reverse) TTCCAGGAGCAACGGACT 
 
FAT tumour suppressor 
homolog 4 
FAT4 (forward) CCAAGCATTACGCCTGTATC 
FAT4 (reverse) TTGGGTTGACACCTGTTCTG 
 
Matrix metalloproteinase MMP9(forward) CGTGATAGATGATGCCTTCC 
MMP9 (reverse) CTAAGCCGGTTCCCAGAGT 
 
Iroquois homeobox 4 IRX4 (forward) CTGAAGACGTGGCTGTACGA 
Table 2.1 Primers used for QRTPCR. Primer pairs selected for use are described for 
each gene in the table above.  
Forward and reverse sequences are shown. Those in red highlight the primer sets that 
had to be designed numerous times (MMP9 re-designed on 3 occasions, CC2D1B re-
deigned on 3 occasions, IRX4 re-designed on 4 occasions). 
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IRX4 (reverse) TTGGGAGACCAGGTCATCTT 
Coil-coilC2domain 
containing 1B 
CC2D1B (forward) GCGGTACAGGGAGCAATCT 
CC2D1B (reverse) CTCTTCTGGAAGGCAGCATC 
RPL4(housekeeping gene) RPL4 (forward) TGAACAAGCTGAACCTGCTG 
RPL4 (reverse) TGGATCTCCTGGCTTCTCAG 
U1 (housekeeping gene) U1 (forward) GTGTGACTGGTGGCATGAAG 
U1 (reverse) CCCGGAGTCTTGGTCCTATT 
 
 
Filtered lab water (MilliQ) was used to dissolve primers to a concentration of 100M. From 
this a working stock of 10M was made for heat gradient PCR tests. For all other QRTPCR 
runs, 5M concentrations were used. Table 2.1 shows a list of the primers used, obtained 
from Primer 3 Plus based on the parameters above. Primers were tested with cDNA 
synthesised from chick embryo RNA collected as described above (Section 2.4) using the 
Thermo scientific verso cDNA synthesis kit. A justification of the primers selected for 
analysis can be found in Chapter 4. 
2.8.2 Heat Gradient PCR 
A gradient PCR of varying temperatures was performed on each primer pair using chick 
embryo cDNA.  This was to test for an optimum temperature at which the primer binds to 
the product without primer dimers or extra product.  Each row of the machine 
corresponded to a set temperature along the gradient. A master-mix was calculated for the 
required number of tubes using the following measurements: 
Gradient PCR master-mix solution 
2x Biomix 10l 
reverse  primer 2l OF 10M 
forward primer 2l OF 10M 
cDNA  1l 
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Nuclease free Water 5l 
 
20l was pipetted into small PCR tubes and run on a gradient PCR machine with heated lid 
on the following program: 96 well plate; [gradient] HS5 grad with heated lid: 3 minutes at 
95°C , 40 cycles at 75°C for 30 seconds (primer binding), range of temperatures (50-65°C ) 
30 seconds (to find optimal annealing temperature), 72°C extension step for 1min 
(amplification of DNA product), 40 cycles at 72°C for 5 minutes. 
The lowest temperature tested was 50°C , highest 65°C . At the end of the programme, 1-
2l of product was run on an Agarose gel as described (section 2.12) and run at 150v for 
15mins. Optimal temperatures for further QRTPCR were selected based on bright bands 
with no primer dimers and no extra product.  
2.8.3 Primer Concentration Optimisation for QRTPCR 
A range of forward and reverse primer concentration (nM) combinations were tested with 
standardised cDNA:  50/50, 100/100, 150/150, 150/300, 300/150, 300/300, 300/600, 
600/300, 600/600, 900/600, 600/900, 900/900 (i.e. 50nM forward primer/50nM reverse 
primer)  
Master-mixes were made up to the required  primer concentration for the combination 
tested. Each volume was calculated for 3 replicates (x3.5) strip tubes. Sensimix plus SYBR 
kit was purchased from Quantace. SYBR green allows detection of PCR products as it 
fluoresces when it binds to double stranded DNA. During the PCR reaction, the dye binds to 
each new copy of double stranded DNA (generated at the annealing/extension stage 
following primer binding) (http://www.lifetechnologies.com/uk/en/home/life-
science/pcr/real-time-pcr/qpcr-education/taqman-assays-vs-sybr-green-dye-for-
qpcr.html). For all QRTPCR work sterile conditions were maintained and filter tips (Starlab) 
used.  
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An example of a master-mix for testing primers at 50/50nM concentrations 
 Per tube(l master-mix(l 
SYBR (sensimix)  10 35 
Forward primer 0.2 0.7 
Reverse primer   0.2 0.7 
MiliQ water   7.6 30.1 
cDNA  1 3.5 
 
2.8.4 cDNA dilution assay for standard curve analysis 
A NanoDrop was used to test cDNA yield and purity (260/280). cDNA was then serially 
diluted to obtain a range of concentrations as follows: dilution factors: 1, ½, 1/5, 1/10, 
1/20, 1/50, 1/100, 1/200, 1/500, 1/1000. cDNA was run with the selected primer 
concentration as decided from the primer test. 19l of master-mix was run with 1l cDNA 
(2-3 replicates) at each concentration.  
2.8.5 ROTOR6000 Analysis 
cDNA was prepared using a Thermo Scientific kit and extracted RNA (section2.4). 1l was 
pipetted with 9l of master-mix into strip tubes with caps on ice in triplicate. Tubes were 
labelled and loaded into the Rotor 6000 machine. For ROTOR6000 a 3-step program with 
melt was used for a total of 45 cycles; the temperature was altered to be primer specific.  
To assess specific binding melt curve analysis was performed by slowly raising the 
temperature of the reaction and monitoring fluorescence. From a melt curve graph the 
melting temperature of the created product can be identified. The peak that this related to 
allowed me to observe if there was a clean amplification of a single product. Melt curve 
analysis was used to check for primer dimers (left of curve) and extra product (right of 
curve), one peak was deemed optimal and indicated an optimal primer concentration. If 
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melt curves showed extra peaks and concentration alteration did not improve the result, 
primer sets were re-designed to a more specific sequence. 
2.8.6 Creating standard curves  
To measure the efficiency of my assay I ran template dilution curves in real time and from 
the resulting slope of the curve I was able to calculate the efficiency. A slope value of -3.3 
suggested that primers were amplifying at close to 100% efficiency. If the value was more 
negative this suggested that primers were not amplifying efficiently at this concentration. 
The efficiency calculation (E) was as followed: 
E= Gradient of the line (R2)/-3.3 x 100  
If primers are  >110% = hyper efficient      <100%= under efficient.  
Serial dilutions were prepared using 1l template cDNA and run in triplicate with a 
minimum of 5 dilution points. Data was extracted from cycle threshold (Ct) values. Log of 
concentration was plotted against ct value. Fewer Ct values indicate high gene expression 
as each Ct value relates to a doubling of the target product (Nolan et al., 2006). 
Hyper/hypo efficient primers (i.e. those that were not in the accepted range between 
100%-110% efficiency) were not used, to avoid false positive/false negative results. Primers 
that could not be optimised were re-designed. If re-designed primers could not be 
optimised it was assumed the level of gene expression was too low to identify. These genes 
were therefore not studied further. Figure 2.4 shows a typical melt curve. Figure 2.4 also 
shows how the gradient is calculated form the plotted standard curves. 
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Figure 2.4 Successful primer binding was indicated by a lack of primer dimers, 
appropriate cycle threshold (ct value) and primer efficiency, calculated from a 
standard curve 
 
A shows a representative plot from a QRTPCR run. Each curve represents an individual 
sample. Samples run at a variety of concentrations/temperatures and each was run with 
a technical repeat. Primer dimers indicated non-specific binding and can be seen as 
small bumps prior to the large curve which indicates the cycle threshold at which the 
gene could be amplified successfully. B shows the plot of log of concentration against ct 
value for a representative sample. From the gradient of the line the efficiency of the 
primer can be calculated. 
 
A 
B 
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Primer set Optimal concentration 
l) 
Optimal 
temperature (°C) 
Primer efficiency 
ADAMTSL1 150/150 60 105% 
PDE10A 150/300 60 107% 
PSCA 300/300 59 110% 
STC2 150/300 58 105% 
RPL4 300/150 60 101% 
U1 150/300 60 107% 
 
2.8.7 Running QRTPCR samples  
Samples were diluted with purified (milliQ) water to a constant concentration of ~200ng/l. 
For each run, 3 biological samples at 3 different time-points were pipetted with 2 technical 
repeats for the gene of interest and the housekeeping gene. Housekeeping genes, U1 (RNA 
splicing) and RL4 (ribosomal protein) were selected based on their consistent expression 
levels to maintain cell function. These genes were not affected by experimental conditions 
(as observed in the microarray in sham and tied-ligated embryos at T0, 4 hours, 12 hours) 
and therefore could be used as reference genes.  
2.8.8 Sample analysis  
Cycle threshold (Ct) values (as a mean of the 2 technical reps) were recorded for each 
timepoint. A low Ct value indicated high gene expression.  From this data, the relative fold 
change could be calculated using the delta Ct formula (2^-∆∆ct) (Nolan et al., 2006). mRNA 
fold change greater than 1 indicated an increase in gene expression compared to the 
experimental control, values less than 1 were indicative of a decrease in expression. 
 
Table 2.2 A table to show the optimal concentration at which to use the primer sets in 
order for the primers to work most efficiently.  
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The delta delta ct formula: 
 
 
2.9 PDE10A response to changes in flow in cultured endothelial cells  
Human Umbilical cord Vein Endothelial Cells (HUVECs) were collected from post-natal 
mothers who gave consent to donate this tissue. Ethical approval was obtained from the 
Multicentre Research Ethics Committee (MREC 05/Q2308/17) and the study is on the 
National Institute for Health Research Portfolio (ID3635). HUVEC RNA samples were 
prepared by Marwa Mahmoud, a colleague at the University of Sheffield (Evans 
laboratory). 
 HUVEC were isolated from 7 umbilical cord veins. The cords were cleaned with Azowipe™ 
tissue (70% v/v Isopropyl Alcohol) to remove blood. Using a 20ml syringe 10ml-15ml of 
serum-free M199 media was flushed through the veins. 10-15ml per cord of 1mg/ml 
collagenase from Clostridium histolyticum (sterile filtered using a 0.2μm Filtropur™ filter) 
was injected into the vein. The flow-through containing the extracted HUVECs in 
collagenase was flushed into a 50ml tube, and was centrifuged at 1200rpm (210g) for 5 
minutes. The cell pellet was resuspended in 5ml of complete M199 growth medium and 
was seeded onto a pre-gelatinised (1% gelatin from bovine skin); the media was made up 
to 12ml in each flask. The cells were maintained at 37:C in M199 growth medium for 24 
hrs, then rinsed in phosphate buffered saline (PBS) (warmed at 37 :C for 10 minutes), 
before adding fresh M199 media. The cells were then maintained in growth medium, 
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changed every 2-3 days. Once isolated HUVEC (passage 0) reached 80-90% confluence, they 
were passaged. The cells were washed with HBSS and detached by adding 1ml of pre 
warmed (in 37 :C incubator) TrpLe ™ Trypsin and incubation at 37 :C for 1-2 minutes then 
neutralised with serum and M199 media. Trypsinised cells were centrifuged at 1200rpm for 
5 minutes. The pellet was resuspended in growth medium and divided accordingly into pre-
gelatinised T75 flasks. For all experiments the cells were used at passage 2-4. 
The 6-well orbiting plate in vitro method was used to expose HUVECs to physiological levels 
of shear stress to attempt to simulate an in vivo environment (Warboys et al., 2010). 
HUVECs at 90% confluency growing in a T75 flask were seeded into 1% gelatin-coated 6-
well plates at a cell density of 400,000 cells, and maintained at 37 :C for 24 hours in order 
to allow cells to reach confluence. The media was removed by aspiration using a Vacusafe 
aspirator and the cells were washed with HBSS (pre-warmed at 37 :C). 3ml of growth 
media was added to each well. The cells plated on the 6-well plates were placed on a PSU-
10i orbital shaker for 72 hours at a speed of 210rpm (5g), which was kept in a 37 :C 
incubator.  HUVECs at the periphery of the orbiting well of a six-well plate are subjected to 
non-disturbed flow, while those at the centre of the well experience disturbed flow 
patterns (De Luca, Warboys and Evans,unpublished). Static cells were placed in the 
incubator for 72 hours and experienced no changes in flow or shear forces. 
Following orbiting, media was aspirated using the Vacusafe aspirator and cells washed 
twice with ice cold PBS. Cells were isolated from the periphery and centre of the well in PBS 
using the rubber end of a 1ml syringe. The cells were then added to a 15ml tube. Cell 
scrapes were centrifuged to a pellet at 1200rpm for 5 minutes. The pellet was resuspended 
in lysis buffer and homogenised by passing through a 21G needle and a 1ml syringe 5-7 
times.  70% ethanol was added to the cell lysate to precipitate the nucleic acid. Total RNA 
was extracted using the RNeasy kit. RNA concentration and purity was assessed by 
nanodrop. 
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2.9.1 HUVEC QRTPCR 
PDE10A expression in flow treated HUVECs was assessed by QRTPCR. 200ng RNA was 
converted to cDNA using the iScript cDNA synthesis kit™.  
An example of a master-mix solution for cDNA synthesis 
 Volume (l) 
5X iScript reaction mix 5 
iScript reverse 
transcriptaser 
1 
Nuclease free Water variable 
Template RNA(200ng) variable 
Total volume 25 
Thermal profile used: 5minutes at 25°C , 42°C for 30 minutes, 85°C for 5 minutes, 4°C for 10 
minutes. 
For the QRTPCR 5l of cDNA (2ng) and 15l of QRTPCR mastermix was aliquoted in 
triplicate into a 384 well plate. KAPA SYBR green detection system was used. 
Gradient PCR master-mix solution 
1x KAPA SYBR FAST 
qPCR kit master mix 
10l 
reverse  primer 0.4l of 200nM 
forward primer 0.4l of 200nM 
cDNA(2ng) 5l  
Nuclease free Water 4.2l 
 
Thermal profile used: 3 minutes at 95°C , 95°C for 5 seconds, 60°C for 45 seconds (x40 
cycles), 95°C for 5 minutes with gradual temperature increase by 0.5°C increments. Melting 
curves were used to assess primer specificity as before. 
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QRTPCR analysis was carried out using Bio-Rad CFX manager 3.0 software. Samples were 
run alongside a housekeeping gene, Hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) involved in nucleotide synthesis and PDE10A primers (sequences shown below) 
were used at a concentration of 5M. The data was analysed using the previously 
described delta delta Ct formula (2^-∆∆ct) (Nolan et al., 2006). The Ct value of each sample 
was normalised to the ct value of a non-flow responsive housekeeper gene (delta Ct) and 
the relative mRNA fold change between samples was calculated using the delta 
comparative Ct (2-∆∆ct) equation. The ∆∆Ct was calculated by subtracting the average ∆Ct 
value of sample 1 (e.g. disturbed flow/static flow sample) from sample 2 (e.g. non-
disturbed flow sample) and then subtracting the average ∆Ct value of sample 2 from itself. 
As before, an mRNA fold change greater than 1 indicated an increase in gene expression 
compared to the experimental control, values less than 1 were indicative of a decrease in 
expression. An un-paired t-test was used to look for statistical differences in the data. This 
was more stringent than a paired t-test, which could have been performed as 
disturbed/non-disturbed flow treated cells were from the same cord, it also accounted for 
the fact that HUVECs experienced different experimental conditions. 
PDE10A Primer sequences for QRTPCR on HUVECs: 
Primer Set 1: Amplicon Size = 127                     length         TM 
L1 AGCAATGCTGTCCTCACTTG 20 59.04 
 
 
R1 CCCTGTGTGCCATTGATTAG 20 59.00 
 
P1 ACGGCTTTGCAAGCCCTGCT   20 68.59 
 
 
Primer Set 2: Amplicon Size = 97 
L1 TCTCTGCTTATGTGGCCAAG 20 59.02 
 
R1 GTCCCTGATTCCAGTCCAGT 20 58.95 
 
P1 CATCCTTGGAGATGAACGATTTCCAA 26 68.06 
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2.10 cDNA synthesis 
cDNA was synthesised using a Thermo Scientific kit. 
An example of a master-mix solution for cDNA synthesis 
 Volume 
(l) 
5X cDNA buffer 4 
DNTP mix 2 
Random hexamer Primer 
(Bioline) 
1 
Verso enzyme mix 1 
Water variable 
Template RNA(g/l)* 1-5 
Total volume 20 
 
*RNA volume based on NanoDrop reading (ng/l) 
A reverse transcription cycling program was used: 30 minutes at 42°C for 1 cycle; 2 minutes 
at 95°C for 1 cycle.  
Exonuclease 1 and Shrimp Alkaline Phosphatase (ExoSAP) in buffer reduced unconsumed 
dNTPs and primers in PCR product prior to DNA sequencing. ExoSAP-IT kit and ExoSAP PCR 
program (45minutes at 37°C, 10 minutes at 98°C) were used to recover as much PCR 
product as possible and to clean-up the product for sequencing. The brightness of the 
product band on the Agarose gel corresponded to the amount of product (ng). For 
sequencing, PCR products were diluted to 10l of 50ng concentration. Primers were made 
to 1M concentration.  
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2.11 DNA Sequencing  
Sequencing of purified PCR products was performed by the Core Genomic Facility 
(University of Sheffield), using Applied Biosystems 3730 DNA Analyser. I then analysed the 
chromatogram data. I then analysed the chromatogram ABI file data using FinchTV 
(http://www.geospiza.com/Products/finchtv.shtml.  Wherever possible, ambiguous sites 
along the sequence (‘N’ bases) were re-annotated using the software. Data was then 
exported and BLAST searches were performed using Ensembl, supported by the National 
Centre for Biotechnology information (NCBI). This gave a probability score that the 
sequence was correct for the gene of interest. It also allowed alignment of the sequence to 
other published sources. 
2.12 Agarose gel electrophoresis 
To determine the size of DNA product, agarose gel electrophoresis was performed. In this 
technique, an electric current causes the negatively-charged sugar phosphate backbone of 
the DNA to be attracted to the positively-charged anode. DNA products are separated by 
size and detected using a fluorescent DNA binding dye. 1g agarose was dissolved in 100ml 
TAE buffer (40mM Tris, 20mM acetic acid, 1mM EDTA) using a microwave. 50ml of the 
solution was left to cool before adding 2 drops of the DNA binding dye, ethidium bromide 
(~0.5glThe solution was poured into a gel mould and a comb inserted to form loading 
wells for samples. Once cool and solid, the comb was removed from the set gel. 2l 
hyperladder  IV (0.1-1kb) was used to run alongside samples as a marker of DNA molecular 
weight.  PCR product was added to DNA loading buffer. Gel electrophoresis was performed 
for 15 minutes at 150volts. Bands on the gel (corresponding to sample size) were visualised 
and photographed using a GENi2 gel documentation system with in-built trans-illuminator 
and camera. 
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2.13 Molecular biology  
2.13.1 Plasmid purification 
Neuropillin 1(nrp1) and neuropillin 2 (nrp2) probes were kindly sent from Ofra Kessler of 
Professor Neufeld's laboratory, Israel Institute of Technology. Gene sequences of interest 
were ligated in bacterial DNA plasmids. These were salvaged from blotting paper by 
immmersion and gentle mixing in TE buffer (TRIS, EDTA). To amplify the DNA plasmids and 
gene of interest, 2l DNA plasmid and TE solution were added to E.Coli DH5 alpha 
competent cells (InVitrogen), which had been thawed on ice. DNA was introduced into the 
cells by a process of first combining plasmids and cells in an Eppendorf tube and gently  
mixing (so as not to shear DNA), incubating tubes on ice (30 minutes) and then inducing an 
increased temperature heat shock reaction by placing tubes in a water bath at 42°C for 2 
minutes. Sudden increases in temperature create pores in the cell membrane of the 
bacteria to allow plasmids to enter the cell (www.Jove.com). Following heat shock reaction 
the cells were returned to ice for 2 minutes. 250l Super Optimal broth with Carbolite 
repression (SOC) was added to the tubes in a sterile manner. The tubes were incubated for 
1 hour at 37°C on a lab shaker (225 rpm). 50l and 150l of transformation mix were 
spread onto pre-warmed agar plates using a sterile protocol and sterile filter tips.  
2.13.2 Bacterial cell culture and DNA extraction  
Bacterial colonies  were grown on static Luria Bertani (LB) agar plates containing the 
appropriate antibiotic at 37°C. A single colony of cells was grown first in LB broth and 
antibiotic (ampicillin, 50g/ml) on a shaker at 225rpm for 8 hours at 37°C. 2 ml of the 
culture was then transferred to 200ml of LB broth containing ampicillin and cultured 
overnight on the shaker (37°C, 225rpm). The next day the culture was spun at 6000g for 15 
minutes at 4°C (Beckman centrifuge, Avanti J-25). DNA was extracted from the pellet and 
purified using HiSpeed Plasmid Maxi kit according to manufacturer’s instructions. 
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2.13.3 DNA linearisation 
To lineraise the bacterial plasmid, specific restriction enzyme endonucleases were used to 
obtain sense and anti-sense cDNA (see Table 2.3). Digests were left at 37°C for 4 hours in 
total to ensure the DNA was efficiently linearised. 1g of un-cut plasmid DNA was run 
alongside 1g of linearised DNA on a 1% Agarose gel to check for successful linearisation. 
DNA was purified by ethanol precipitation. Purified DNA was reconstituted in Milli Q water. 
2.13.4 Riboprobe synthesis 
To transcribe riboprobes from the linearised DNA, RNA polymerase enzymes (and supplied 
buffer) were added to a reaction with 1g of linearised DNA, Digoxygenin (DIG) RNA 
labelling mix (containing antigen labelled bases for immunohistochemical reaction) and 
RNASE inhibitor. Table 2.3 lists the restriction enzymes used to linearise the DNA and the 
polymerase enzymes used to transcribe from the linearised DNA to make anti-sense and 
sense riboprobes  for the nrp genes of interest. 
The reaction was left at 37°C for 2 hours. In this reaction, any remaining DNA was 
degraded by DNAse. RNA was purified by ethanol and lithium chloride precipitation. RNA 
was reconstituted in ice cold TE buffer. RNA probes were run on a 1% agarose gel and RNA 
concentration and quality was recorded using a NanoDrop spectrophotometer.  Probes 
were stored at minus 20°C. 
 
Plasmid Linearised  Transcribed  Source 
NRP1 Sense: Sal I  
Anti sense: SacII  
T7  
SP6 
Proemga 
NRP2 Sense: Hba I 
Antisense: Hind III 
SP6 
T7 
Promega 
 
Table 2.3 A list of enzymes used to extract the DNA from bacterial plasmids 
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2.14 Preparation of tissues for histology 
Tissues were fixed in 4% paraformaldehyde (PFA) at 4°C. For whole mount in situ 
hybridisation, embryos were fixed overnight. For whole mount immunofluorescence and 
cryo-sectioning of frozen tissue and paraffin wax embedded tissue, embryos were fixed for 
2 hours. For cryo-sectioning of extra-embryonic vessels, 30% sucrose solution (overnight) 
preceded mounting in mounting medium (OCT). 
For immunohistochemistry the area dissected was either the proximal vitelline vessel or 
the area of collateral vessel development in the extra-embryonic area vasculosa (see Figure 
3.14-3.15).For all histological protocols which required fine dissection, the embryo and 
surrounding extra-embryonic tissue was dissected out of the egg into ice-cold Leibovitz (L-
15) medium. The fine membrane covering the extra-embryonic vessels was removed using 
fine forceps (#5). Further dissection of the tissue was performed using sterile tungsten wire 
dissecting needles. Vitelline vessels were relatively easy to isolate from surrounding tissue, 
however collateral vessels were more challenging due to nature of their development 
(i.e.from pre-existing connections (section 3.4)) and could not be isolated. Collateral vessels 
were therefore sectioned within a dissected area of tissue.  
For paraffin embedded sections wholemount tissue was dehydrated through increasing 
concentrations of ethanol (70%, 90%, 100%, 30 minutes each), ethanol was then cleared 
with Xylene (mixed isomers) (immersing in solution twice for 10 minutes each). Paraffin 
wax was heated to 60°C. Tissue was placed in an embedding cage and placed into the 
molten paraffin wax in an oven over night. Once tissue and wax had hardened, the wax 
blocks were mounted onto a chuck for sectioning by microtome. 
2.15 Tissue sectioning 
Microtome sectioning, for immunohistochemistry, was performed using a Leica (Model 
RM2155) with Leica 819 brand blade. The water bath was warmed to 42°C and filled with 
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filtered Milli Q lab water. 7m thick sections were cut (as advised by colleague Janet 
Chamberlain’s protocol for tissue sectioning with microtome) and paraffin wax sections 
collected using a SuperFrost/Plus slide. Slides were stored in a rack to dry at 40°C 
overnight. 
Cryosectioning, for immunohistochemistry, was performed using a Bright OTF cryostat, in a 
temperature controlled environment (specimen -23°C). Tissue was mounted onto metal 
chucks on dry ice using OCT and sectioned at 12- 15μm thickness. Sections were thaw 
mounted on to slides and air-dried for 1 hour. 
2.16 Immunohistochemistry 
2.16.1 Haematoxylin and Eosin staining 
Haematoxylin and Eosin (H&E) staining allows a distinction within a sample of tissue 
structure and nuclei. As wholemount labelling was prone to high background, due to the 
overlying vitelline membranes and ectoderm obscuring the intricate vasculature, cross 
sections through tissue were acquired by sectioning paraffin-wax embedded tissue 
samples.  
For paraffin wax-embedded tissue, wax was removed from slides by placing the rack in a 
bath of xylene (twice for 10 minutes each) followed by graded reduced concentrations of 
ethanol (100%-50%) for 2 minutes each. For Haematoxylin and Eosin staining, the slides 
were immersed in Haematoxylin (Gills #1) for 2-3 minutes. Slides of sectioned tissue were 
immersed in 1% acid alcohol for 30 seconds then washed in tap water for 2 minutes. Slides 
were then dipped 10 times in 95% alcohol. This was followed by counter-labelling with 
Eosin Y solution for 20 seconds. Tissue was then dehydrated (95%, 5 minutes each), 
followed by two immersions in xylene for 5 minutes each. Tissue was mounted in xylene-
based mounting medium.  
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2.16.2 Antibody immunolabelling 
Slides were placed in a humid environment and washed with PBS before blocking for 1 hour 
with PBS supplemented with 1% heat inactivated goat serum, 1% Triton 10X in PBS. 
Sectioned tissue was incubated with primary antibody overnight at 4°C Tissue was then 
incubated in secondary antibodies (Invitrogen goat anti–rabbit IgG; Alexa 488 or Alexa 594, 
1:500) for 1 hour at room temperature. Tissue was washed in PBS and mounted for 
microscopy in Vectashield with DAPI.  
For whole-mount immunohistochemistry embryos were blocked using PBS supplemented 
with 1% Triton 10X, 1% heat inactivated goat serum overnight at 4°C. Tissue was incubated 
with primary antibody solution was incubated overnight at 4°C. PBS washes were 
performed throughout the following day on a gentle rocker at room temperature. Tissue 
was then incubated in secondary antibody solution was incubated overnight at 4°C and all 
samples were kept in the dark. Extensive washing was performed before staining with DAPI 
nucleic acid stain for 1 hour and mounting embryos in a depressed slide with Vectashield 
and coverslip. 
For negative controls, separate slides with adjacent sections were incubated with 
secondary antibody only. Positive tissue was difficult to acquire, although for PDE10A 
antibody optimisation, mouse cerebellum and chick cerebellum were used (Appendix A9). 
 
 
 
 
 
 
Antibody Source Species Optimal 
concentration 
PDE10A (polyclonal) Genetex Rabbit anti-human 1:250 
VE-cadherin 
(polyclonal) 
Abcam Rabbit anti-human 1:100 
Table 2.4 A list of antibodies used to detect proteins by immunofluorescence.  
 
The table lists the antibodies and where they were purchased as well as the species they 
were raised in and the optimal concentration which was used. 
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BrdU (monoclonal) Abcam Rat anti-BrdU 1:1000 
2.17 PDE10A immunohistochemistry optimisation 
To initially predict if the PDE10A antibody would react against chick PDE10A protein I used 
clustal alignment to check that the peptide sequence the antibody binds to in human was 
present in the chick PDE10A protein. Clustal alignment showed a good match between 
sequences (Appendix, Figure A8), however this was not sufficient to confirm specific 
binding I therefore sought to test the antibody in tissue positive for PDE10A (positive 
control). 
In the literature PDE10A is reported to be expressed in the mouse brain and testis tissue, 
further the manufacturers of the antibody reported reactivity in mouse tissue. I therefore 
attempted to find an optimum concentration to use the antibody at using embryonic 
mouse brain tissue by testing a range of concentrations (1:500, 1:1000, 1:1500) (Appendix, 
Figure A9) and by altering blocking steps (duration of time tissue was incubated with PBS 
supplemented with 10% heat inactivated goat serum). After acquiring preliminary results, I 
tested the antibody in embryonic chick brain tissue. I tested the same range of 
concentrations but found the optimal concentration to be 1:250 in the chick brain tissue 
(Appendix, Figure A10). I therefore performed subsequent analysis on extra-
embryonic/vascular tissue using a concentration of 1:250 (as shown in Chapter 5, Figures 
5.3, 5.4). Despite my efforts to find an optimal concentration at which to achieve specific 
binding, PDE10A antibody remained difficult to use. Due to lack of funds, a second antibody 
could not be purchased, I therefore had to settle on the concentration which appeared to 
give sufficient results (Table 2.4) (further discussed in chapter 5) and validate PDE10A 
expression with the same antibody but a secondary technique (Western blotting). 
Optimisation steps took many months and an estimated n=50 chicks. 
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2.18 Whole-mount in situ hybridisation 
To detect RNA/gene expression in whole mount tissue preparations , whole embryos were 
carefully dissected using a similar method as described in section 2.4.1. Iris scissors were 
used to cut around the sinus vein border to dissect the whole embryos along with all the 
extra-embryonic tissue/vessels and placed into ice cold Lebovitz (L-15). Any yolk was 
washed from the membrane. Embryos were transferred carefully with the aid of spatula 
and laid flat in separate wells of a 6-well plate in PBS. Following washes, embryos were 
fixed in ice cold 4% PFA overnight at 4°C to fix transcripts in place. Embryos were then 
dehydrated in a series of graded methanol/PBT concentrations (25%, 50%, 75%, 100%). 
Liquid was pipetted on and removed from the wells using a Pasteur pipette being careful 
not to contact the embryo. Embryos were stored in 100% methanol overnight at minus 
20°C. Embryos were rehydrated (100%, 75%, 50%, 25% methanol/PBT) and washed in PBT 
(PBS and 1% Tween) before incubating for 18 minutes on ice in Proteinase K solution 
(10μg/μl). Embryos were washed and fixed with ice cold 4% PFA on ice for 20 minutes. Pre-
warmed prehybridisation solution (50% formamide, 5X saline-sodium citrate (SSC) pH 7, 0.1% 
Triton x100, 0.5% CHAPS (Sigma) 1mg/ml YEAST RNA, 5mM EthyleneDiamineTetraAcetic acid, 50 
μg/ml heparin) was pipetted into each well, submerging each embryo adequately and incubated 
with embryos at 65 °C for 90 minutes. DIG-labelled RNA probes were added (1 μl in 10ml 
prehybridisation solution) overnight to allow hybridisation to occur between the probe to the 
target sequence. The following day embryos were washed in buffer 1 (50% Formamide, 5X SSC 
pH4.5, 1%Sodium Dodecyl Sulfate) and buffer 2 (50% Formamide, 2XSSC pH4.5, 1%Tween); 
each wash was performed twice for 30 minutes at 65°C. Embryos were washed in Tris-
buffered saline and Tween (TBST) and left at 4°C overnight. Embryos were washed in an 
alkaline phosphatase buffer (NTMT) solution (5M NaCl, 2M Tris pH9.5, 1M MgCl2, Tween 20, 
water) three times for 30 minutes in total; the salt and detergent concentrations were 
optimised to help specific binding and remove non-specific elements. Antibody 
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phosphatase binding was performed with nitro-blue-tetrazolium (NBT)and 5-bromo4-
chloro 3’indolyphosphate p-toluidine salt (BCIP) enzymes in NTMT solution. These were 
added to each embryo until a colour change was observed, indicating a complete reaction 
and gene expression. 
2.19 Protein extraction  
Tissue was collected, from the area of flow-induced vessel remodelling (as indicated in 
Figure 2.3), in sham and tied-ligated chick embryos at T0, 4 hours, 8 hours, 12 hours and 24 
hours post tied-ligation/sham-ligation (as described in Section 2.2).  Eight embryos were 
used, per group. Tissue was added to lysate buffer (150mM NaCl, 50mM Tris, 0.1%SDS, 
0.5% Sodium deoxycholate, 1%NP-40, PBS) and homogenised by passing it through an 18G 
needle and 1ml syringe 5-7 times. 1 tablet per 10ml of protease inhibitors were added to 
homogenised tissue samples to prevent protein degradation. Following centrifugation 
(13,000 rpm), lysate supernatant was kept for protein quantification by Bradford assay 
(Biorad assay). Bovine Serum Albumin (BSA) (1mg/ml) and tissue lysate was serially diluted 
to create a standard curve using a spectrophotometer. Optical density was measured at an 
absorbance of 595nm. This data was used to calculate the optimum concentration of each 
protein sample to use in the Western blot procedure.  
2.20 Western blotting 
Tissue lysates were first heated to denature the protein and allow SDS binding. Lysates 
were then added to loading buffer and reducing agent before loading  12μl into a  poly-
acrylamide NuPAGE, Bis-Tris gel (4-12%). A pre-stained protein ladder was loaded at either end 
of the gel and 500μl of anti-oxidant was added to the SDS NuPAGE running buffer. Protein was 
resolved by electrophoresis at 160v for 1 hour.  
Electro-blotting (90v, 1.5hours) transferred proteins to nitrocellulose membranes (Amersham 
Hybond C) in NuPAGE transfer buffer with 20% Methanol. To prevent non-specific binding, 
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membranes were blocked with 5% milk, 0.1% Tween, TBS for 1h at room temperature in a 
Falcon tube and experienced gentle rotation. Anti-rabbit PDE10A polyclonal antibody was added 
to 5% milk (1:3000) overnight at 4°C. Membranes were washed in a solution of tris-buffered 
saline and tween (TBST) 5 times and incubated for 1 hour at room temperature with secondary 
antibody and reporter enzyme (Jackson labs, anti-rabbit HRP 1:6000). Membranes were again 
washed 5 times in TBST and then wrapped in clingfilm. Blots were developed with Enhanced 
Chemi-luminescence which provided a substrate for the horseradish peroxidase (HRP) enzyme. 
Blots were exposed onto hyperfilm and labelled with protein sizes as was indicated by the 
protein ladder used initially to identify the correct band of interest. 
Unfortunately, extra bands on my blots did limit the results and therefore the conclusions. I 
therefore attempted to improve this by optimising blocking steps using both milk solutions 
and bovine serum albumen (BSA). Blocking steps were optimised by trialling different 
concentrations of blocking reagents and length of time of blocking. I also tested whether 
the blots could be improved by altering antibody concentration. In case the antibody was 
binding non-specifically I reduced the concentration from 1:250 to 1:500 and 1:1000 but 
this had no effect. 
2.21 Pharmacological assays 
I conducted pharmacological assays to attempt to elucidate a role for PDE10A in flow-
induced vessel remodelling.  
At HH st17, embryos were prepared as described in sections 2.1.3-2.2 (depending on the 
experiment). At T0 (post tied-ligation/sham-ligation) embryos received drug treatments or 
PBS by a drug delivery mechanism of Whatman #1 filter paper discs which had been 
previously prepared. Filter paper discs were cut uniformly with a 5mm diameter hole punch 
and put into a beaker which was covered and sterilised by autoclaving and drying.  The 
sterilised discs of filter paper were soaked in 5μl of drug or PBS and placed over the 
vitelline membrane (the thin layer of membrane) covering the extra-embryonic vasculature 
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area of interest (See Figure 2.5). Most filter paper assays were assessed after a single 
timepoint (24h), however, this is described as 24-28 hours as for practical reasons analysis 
at the exact time was not physically possible. I therefore describe results as 24-28 hours to 
include the time taken to conduct operate on and analyse each individual embryo during 
these experiments. 
For studies investigating an initial toxic effect of the drug, discs were placed lateral to the 
embryo body over the proximal vitelline vessels. For studies affecting the effect of the drug 
on collateral vessel formation discs were placed at the anterior and posterior poles of the 
embryo (Figure 2.5). Heart rate was measured by counting heart beats in ovo of each 
embryo for 15 seconds. 
Filter paper was the ideal method of drug delivery for this model as it was inexpensive, 
easy to use and remove from the membrane and preliminary experiments showed that it 
was able to deliver solvents such as food colouring to the extra-embryonic membrane 
(Appendix, Figure A11). When administered systemically to humans, papaverine is renally 
excreted with a half-life of 1.5-2 hours (Ritschel and Hammer., 1977). These are therefore 
effectively slow-release reservoirs of drug and the half-lives are therefore anticipated to be 
longer than those following single systemic administration.  
Although the discs were applied topically to the area of interest, since the drug is expected 
to diffuse from the filter paper, there is a likelihood of drug effects both outside the area of 
application of the drug, and also systemically. These potentially confounding effects are 
discussed in the relevant results chapter (Chapter 5 discussion).  
I first used a PDE10A inhibitor, papaverine hydrochloride. To investigate the effect of 
PDE10A inhibition on vessel remodelling I used the cAMP analogue (PKA inhibitor), Rp-8-Br-
cAMPS. 
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Papaverine hydrochloride is an opium alkaloid used clinically for its ability to induce 
relaxation of smooth muscle at high concentrations. Although its pharmacology is not 
entirely clear, papaverine has been shown to be an antagonist of PDEs. Papaverine has 
been shown to be most specific against PDE10A, with an IC50 of 0.036Μm, thirty six-fold 
lower than the IC50 for PDE3A and over 270 times lower than for PDE5 (the PDE present in 
smooth muscle) (Ritschel and Hammer., 1977).  In my studies papaverine hydrochloride 
was diluted to the specific concentrations specified in Chapter 5 (5m, 10m, 20m) using 
PBS, with gentle heat and constant stirring until the powder had dissolved. The vial was 
protected from light as the drug is light-sensitive. 
Rp-8-Br-cAMPS is a cAMP analogue which competitively binds to PKA. By occupying cAMP 
binding sites, Rp-8-Br-cAMPS prevents PKA from dissociation and therefore activation.  In 
this study, Rp-8-Br-cAMPS stock solution was a gift from Dr Stephen Renshaw’s laboratory 
(The University of Sheffield).  Rp-8-Br-cAMPS was diluted into PBS to achieve the required 
concentrations as described in Chapter 5 (30M, 50M, 100M, 200M, 500M). The assays 
were performed according to the same protocol as for papaverine assays. Control chicks 
were also treated in the same way as in the papaverine assays and received PBS alone.  
For assays which examined the effect of more than one drug, 5l of each (papaverine and 
Rp-8-Br-cAMPS) was pipetted onto the same disc but the concentration was doubled 
(200M Rp-8-Br-cAMPS; 40M papaverine). 
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2.22 Proliferation assays 
2.22.1 In vivo proliferation assays 
To assess proliferating cells in the area of flow-induced remodelling I assessed 
Bromodeoxyuridine (BrdU) incorporation into the DNA of cells in this area. The disadvantage to 
using BrdU is the antigen retrieval step, which requires damage of the nucleus to reveal the 
epitope in the DNA. Quantification of DNA positive labelling therefore had to be conducted by 
calculating DAPI area and positive BrdU area. 
Immediately following in ovo ligation, BrdU was pipetted onto the vitelline membrane in the 
area of flow-induced vessel remodelling (area indicated in Figure 2.3). Optimisation of this 
technique was required as it was questionable as to whether BrdU sufficiently reached the 
endothelial cells and was incorporated into the DNA (see Table 2.5) therefore a range of 
concentrations and volumes and were tested. I also tried injecting the BrdU underneath and 
over the top of the vitelline membrane to test whether this made a difference. I further 
validated positive labelling by sectioning tissue from the neural tube of the same developing 
 
Figure 2.5 Filter paper discs were used as a method of drug delivery 
Discs were placed over the vitelline vessels of early stage chicks (A) or later stages (A’) to 
assess the effect of the drug on normal vessel development. Discs were placed over the 
midlines of either sham (B) or tied-ligated chicks (B’) to assess the effect on remodeling. 
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embryos that vessels were taken from. The neural tube in a growing embryo contains 
proliferating cells, therefore acting as a positive control. I used 25l of 1mM BrdU injected over 
the vitelline membrane for my experiments as this was found to give optimal results. 
For each analysis of collateral vessel tissue, 6-8 sections were taken and mounted onto slides. 
Once each section on each slide was imaged using the Apotome fluorescent microscope, Image J 
was used to assess the positive BrdU labelling. Each section was divided into 4-6 fields of view 
and fluorescent micrograph images were taken. Using ImageJ the colour channels of each image 
was split to more specifically calculate positive DAPI or BrdU labelling. Blue and green channels 
were analysed separately for individual quantification which could then be used to calculate 
proliferation index. The extent of positive labelling, was measured automatically by ImageJ. To 
do this the threshold tool was used as adjusting the threshold intensity of an image which picked 
up the positive labelling. Once the threshold parameters were set, this remained the same for 
each image analysed. Image J then calculated the area of positive labelling. When all fields of 
view had been analysed the data was added together to give the result of BrdU staining over the 
whole section. The average was then calculated from the individual sections to give a single data 
reading for one piece of tissue. 
For proliferation assays investigating pharmacological effects, 5mm sterilised filter paper discs 
containing 20M papaverine were applied to the anterior and posterior poles of the embryo 
over the midline  (Figure 2.5) . Embryos were re-sealed and returned to the incubator for the 
required length of time.  After this time, if filter paper had been applied discs were removed 
using forceps, then using spring scissors and fine forceps the area of collateral vessel remodelling 
was excised and dissected (as described in Section 2.4). Tissue was fixed in 4% PFA for 2 hours 
and incubated in 30% sucrose overnight then mounted in OCT on dry ice for cryosectioning (as 
described Section 2.15). Sections were cut at 15m and processed for immunohistochemistry (as 
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described in Section 2.16) and assessed for anti-BrdU (1:200) and anti- VE Cadherin (1:100) 
labelling. 
 
 
 
 
 
 
 
 
 
 
For analysis of proliferating cells, Apotome images were split into red, green, blue channels. 
For DAPI analysis threshold was altered to optimise visualisation of labelled cells. This 
threshold was then set and was kept constant for all DAPI image analysis. This was 
repeated to assess the positive labelling of the proliferation marker and again, threshold, 
once set, remained consistent for each image. Threshold analysis (ImageJ) removed any 
bias and measured the density of the labelling in the image. To acquire a proliferation index 
the area of DAPI staining was divided by the area of positive proliferation marker labelling 
(+ve BrdU area/+ve DAPI area x100). All analysis was performed blinded from knowledge of 
which sample was from which condition. 
Concentration of 
BrdU (M/mM) 
Volume pipetted (l) Number of embryos 
(location of injection on/over 
vitelline membrane) 
100M 25 3 injected under 
3 injected over 
100M 100 3 injected under 
3 injected over 
1mM 25 3 injected over 
3 injected under 
1mM 100 3 injected over 
3 injected under 
 
Table 2.5   BrdU delivery to endothelial cells in the area of collateral vessel formation 
was optimised by testing  a range of concentrations and volumes. 
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2.23 Microscopy 
2.23.1 Fluorescence microscopy  
Slides were analysed and photographed using a Zeiss Apotome (Imager z1 + Apotome) with an 
AxioCam (MRM 1.0X). Data was collected using AxioVision version 4.6.3. For Alexa 488 
visualisation, a laser with an excitation wavelength of 488nm was used; Alexa 594 was observed 
at 594nm; DAPI was visualised at 405nm. For Apotome Z stack images, stacks were 
compounded to a flat, single picture using image J software (National Institutes of Health). 
Channels were split into red, green and blue using Image J, to visualise individual staining 
patterns before merging.  
2.23.2 In vivo microscopy  
For time-course experiments, a digital camera was mounted onto the camera mount of a 
stereomicroscope and an overhead light source positioned over the platform of the 
microscope. Photomicrographs for drug assay analysis were performed on a Leica 
microscope (M2125, 10x/21b) connected to a Spot camera and software (SpotCam). 
Photography was performed at room temperature (around 24°C). Eggs were prepared as 
described in Section 2.1.2-2.1.4 and positioned in the Styrofoam holder.  Photographs were 
taken of the midline superior and inferior to the embryo. The embryo was then re-sealed 
using parafilm and returned to the incubator (38°C). 
2.24 Image analysis 
Images of the yolk sac vasculature were used to assess collateral vessel growth across the 
midline (the original location of the vitelline veins). Micrographs were analysed using 
ImageJ software (version 1.35p)(National Institutes of Health). The image scale was 
calibrated to 0.213 pixels/m for time-course images and 0.310 pixels/m for drug assays. 
Image analysis was performed blinded; each of the image folders containing the different 
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groups to be analysed were temporarily re-named by a colleague so that the true identity 
of images were unknown until post-analysis. Images were viewed at high magnification 
(200-600% original image size). Using a line draw tool and automatic measurement 
(ImageJ), the diameter of all arteries crossing the midline was recorded. Collateral vessel 
number and diameter were noted for each image and was limited only by the resolution of 
the micrographs. Pixel intensity was not appropriate to use for analysis of these images as 
the albumen over the surface of the vitelline membrane blurred vessel boundaries which 
would have caused anomalies and given false results. The light source was also difficult to 
keep constant for all eggs analyse between different experiments and so would have also 
hampered this type of analysis. These limitations are discussed further in chapter 5.  
2.25 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software. For each graph 
presented, data is shown as mean ± standard error of the mean (SEM). For data with two 
groups, Student's t-test was used to examine whether statistically significant differences 
between groups were present. For data with more than two groups a one-way ANOVA was 
performed with an appropriate post-test. Post-tests were selected based on the 
comparisons performed; to compare a mean to every other mean a Tukey post test was 
used; to compare every mean to the control mean a Dunnett post test was used; To 
compare selected means a Bonferroni post test was used.  
For data which analysed two nominal variables and one measurable variable a 2-way 
ANOVA was performed.  In all these statistical comparisons, a p value <0.05 was considered 
statistically significant. A record of the n numbers used in each experiment is presented in 
the figure legends of each of the results. On average, experiments were repeated on a 
minimum of 2 separate occasions.  
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Figure 2.6 Micrograph images to show how collateral vessels were identified. 
The panel shows representative images of developing collateral vessels in one 
embryo over a 12h timecourse. Collateral vessels can be seen crossing from left to 
right across the midline. The midline is defined by a dashed line at T0. Blue lines in 
the images on the right trace examples of collateral vessels seen in the images on 
the left. The midline can be seen to retract as collateral vessels extend over 12h. 
(scale bar = 1000m) 
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Chapter 3 
Characterising the chick embryo as a model of flow-induced vessel 
remodelling 
Summary 
In this chapter I describe my studies that extend and further characterise the chicken 
embryonic model of flow-induced remodelling first described by le Noble et al. (2004). As 
outlined in section 1.13, Le Noble’s description of this model was in a study that attempted 
to define the contribution of blood flow to arterio-venous identity of the extra-embryonic 
vasculature. They induced unilateral vitelline artery occlusion and demonstrated that this 
downregulated arterial identity in the ligated circulation, an effect reversed with 
restoration of blood flow (le Noble et al., 2004). The focus of their study was the effect of 
removal of blood flow on the ligated/reperfused vitelline vessels, not the unligated 
vasculature. Although the authors described remodelled vessels extending from the 
unligated territory at the poles of the embryo, these were not quantified or characterised 
nor termed ‘collateral’ vessels. My intention therefore was to study the effects of unilateral 
vessel ligation upon the unligated territory in the expectation this might provide insight 
into flow-induced remodelling and collateral vessel formation. 
During the course of my studies, le Noble’s group published a second paper (Buschmann et 
al., 2010) that, in fact, confirmed that following obstruction of the right proximal vitelline 
vitelline artery, the unligated vessels of the left vitelline circulation remodelled. The 
authors termed such vessels that extended across the midline, carried arterial flow and 
connected to the left proximal vitelline vessel, “collateral vessels” and showed that these 
supplied the tied-ligated territory. The number of collateral vessels was quantified, but only 
at a single timepoint (24h after ligation). Finally, this study identified an arterial gene, 
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Gja5, which was upregulated in collateral vessels in the chick embryo and required for 
collateral development in a mouse model (Buschmann et al., 2010). 
Despite the fact that this second paper described the model that I had been working to 
establish, a number of outstanding questions remained. In particular, the group did not 
perform a detailed time-course of collateral vessel development, nor did they quantify 
collateral vessel number over time.  Further, they did not analyse collateral vessel 
diameter, nor the cellular/molecular profile of collateral vessels.  Finally, this study did not 
investigate mechanisms of collateral development in the chick.  I wished to address these 
issues in order to better characterise collateral vessel remodelling in the chick, and inform 
subsequent analyses (chapters 4 and 5).  
I therefore set out to: 
 Perform a longitudinal quantification of developing collateral/collateral number  
and diameter following unilateral vitelline artery ligation 
 Establish a system to assess blood flow after unilateral vitelline artery ligation 
 Examine expression of various markers in developing collateral vessels 
histologically/histochemically 
 Examine proliferation in developing collateral vessels after unilateral vitelline artery 
ligation 
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3.1 Occlusion of the right vitelline artery by surgical ligation  
I adapted the model of le Noble et al., (2004) but instead of using tungsten needles to 
elevate the artery and occlude flow (le Noble et al., 2004), I developed a surgical suture 
method (see Materials and Methods section 2.2).  
Microsurgical ligation of the right proximal vitelline artery was performed. Ligations were 
performed proximal to the first bifurcation of the artery, i.e. immediately distal to the 
embryo. Control embryos underwent the same surgical procedure leaving the suture un-
tied beneath artery (referred to as ‘sham-ligated’). Such sham-ligations left blood flow 
undisturbed (Figure 3.1A) as evidenced by moving red blood cells observed by light 
microscopy. By contrast, in a tied-ligated embryo, 30 seconds after occlusion, the vessel 
distal to the suture site darkened, as flow was abolished and blood stagnated (Figure 3.1B). 
In these vessels, I observed that red blood cells were not moving, indicating flow cessation. 
In all experiments, successful occlusion was judged by observation of cessation of blood 
flow and stagnation. 
Having induced right vitelline artery occlusion, I examined the effect on the architecture of 
the left vitelline circulation. Tied-ligated embryos were compared with sham-ligated 
embryos to control for any non-specific effects of the surgery. 
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3.2 The effect of right vitelline artery ligation on the left proximal vitelline 
circulation 
Since unilateral vitelline artery ligation abolishes blood flow to one side of the vitelline 
vasculature, it is highly likely this alters the haemodynamics in the unligated territory. The 
exact nature of this disturbance will be determined by a range of complex factors, including 
effects on cardiac output, alterations in pressure, vaso-regulation and passive vessel 
expansion. To examine evidence for such events I examined whether the diameter of the 
unligated proximal vitelline artery alters following ligation of the contralateral proximal 
vitelline artery.  
I measured the diameter of the left proximal vitelline artery immediately pre- and post-
tied-ligation of the right vitelline artery, and 10 minutes following tied-ligation. The change 
in vessel diameter from baseline (pre-ligation) is shown in Figure 3.2A, expressed as 
percentage change from baseline diameter, to account for variability in vessel diameter 
prior to ligation. 
Figure 3.1 Representative micrograph images of the right vitelline vessel of a HH st 17 
chick embryo showing a sham ligation and a tied ligation 
A shows a sham suture beneath the right vitelline vessel (arrow). Sham ligations do not 
occlude flow. The suture is left un-tied to leave blood flow un-disturbed B  shows a 
vitelline vessel which has been tied and ligated. The suture (arrow) was tied into a knot 
around the vessel. This image was taken 1-2 minutes after surgery.  n=~>100 embryos 
over the course of the project 
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In embryos undergoing sham-ligation of the right vitelline artery, there was a small 
reduction in the diameter of the left vitelline artery, particularly 10 minutes post-surgery 
(Figure 3.2A). By contrast, in embryos in which the right vitelline artery was ligated, there 
was a significant increase in the diameter of the left vitelline artery both immediately and 
10 minutes post tied-ligation (Figure 3.2A). Although this suggests a change in the 
haemodynamic forces exerted in the unligated territory, it is not possible to conclude what 
is driving the increase in diameter. Further measurements of pressure, cardiac output, 
vasoregulation, and shear stress would be necessary to elucidate the exact mechanism.  
Heart rate was not significantly different between sham and tied-ligated embryos (Figure 
3.2B). Analyses of embryonic development over the entire timecourse of the experiment 
showed that ligation does not adversely affect the embryo or the rate of embryonic 
development, relative to control. 
In the course of my studies, Buschmann et al., (2010) showed an increased diameter, mean 
velocity and mean shear in the unligated vitelline artery at a later, single (5 hour) timepoint 
(Buschmann et al., 2010). My findings are therefore consistent with theirs and taken 
together; suggest that blood flow is increased to the unligated territory in response to the 
tied-ligation. 
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Figure 3.2 Following right proximal vitelline artery ligation, the left vitelline 
artery increases in diameter significantly compared to sham controls 
A shows right proximal vitelline artery diameter (%) change from baseline (pre-
ligation). Measurements were taken post-ligation, and a further 10 minute 
follow-up. The left vitelline artery expands after ligation and this persists to 10 
minutes following the procedure. The difference in size is significant compared 
to the sham-ligated vessel, immediately after and 10minutes after ligation. 
(p<0.005, p<0.0005; n=20 embryos) B Neither ligation nor sham ligation affects 
heart rate (n= 20). Data was analysed with 2-way ANOVA and Bonferroni 
multiple comparison post-test.  
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3.3 The collateral vessel response following unilateral vitelline artery ligation. 
I next examined the effect of unilateral vitelline artery tied-ligation on development of the 
unligated posterior medial vitelline territory. As detailed above, Buschmann et al., (2010) 
identified collateral vessels in a chick embryo model of occlusion but only quantified 
collateral vessel number at 24 hours after tied-ligation (Buschmann et al., 2010). I wished 
to extend these studies to attempt to identify key phases of the remodelling process. I 
performed right proximal vitelline artery tied-ligation or sham-ligation as before and 
quantified number and diameter of “collateral vessels”. In keeping with the Buschmann 
study, collateral vessels were defined as those crossing the embryo/yolk sac midline from 
the unligated to the ligated territory, carrying blood flow (from left to right across the 
midline – termed ‘arterial flow’) and stemming from an identifiable source (left proximal 
vitelline vessel) (Buschmann et al., 2010). Following ligation, micrographs of each embryo 
were acquired every 4 hours until 48 hours. The number and diameter of collateral vessels 
extending from left to right towards or across the midline were quantified for each embryo.  
Immediately post tied-ligation, the vitelline vasculature in the posterior-medial extra 
embryonic tissue was identical in sham-ligated and tied-ligated embryo: no collateral 
vessels were apparent (Figure 3.3). As expected, the vitelline vasculature of sham-ligated 
embryos maintained a normal symmetrical orientation over the 48 hour timecourse, with 
no collateral vessels crossing the midline (Figure 3.4). No vessels crossing the midline were 
ever observed at any timepoint in sham-ligated embryos. 
In contrast, tied-ligated embryos showed evidence of collateral vessel remodelling at the 
earliest time-point examined (4 hours post tied-ligation). Even at this early time-point, I 
could detect vessels that carried blood across the midline (left to right), not seen in sham-
ligated embryos.  
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Over the next 4 hours, the posterior vein gradually regressed to be replaced by a collateral 
network delivering blood across the midline to supply the tied-ligated side of the chick 
(Figure 3.5). Although only the posterior of the embryo is depicted in Figure 3.5, a similar 
though less pronounced process occurred at the anterior pole with 1 or 2 collaterals 
extending from left to right (Figure 3.6 shows a representative image of the whole embryo 
at 24 hours post tied-ligation).  
 
 
 
 
 
Figure 3.3  The vascular morphology of the vitelline network of a HH st 17 chick 
embryo immediately (T0) post-tied-ligation (right panel) or sham ligation (left 
panel) 
A Shows a representative sham-ligated HH st 17 chick embryo. The embryo body is in 
the centre of the image. Vitelline arteries (indicated by arrows) protrude from the 
embryo body in branches. The suture (blue thread) can be seen to lie under the right 
vitelline artery. The box indicates the posterior medial region of the embryo. Small 
capillaries in this area can be seen to join to the posterior vitelline vein. B Shows a 
representative image of a tied-ligated embryo at T0. The suture in this image was 
tied in a knot around the right vitelline artery. The back boxed area highlights the 
area at the posterior of the embryo which also contains many small capillaries  (n=18 
but  ~>100 embryos over the course of the project showed this same morphology) 
(scale bar = 500m) 
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Figure 3.4  The vascular morphology over time following sham ligation of the 
vitelline network of a HH st 17 chick embryo 
As in Figure 3.3A, the suture is passed beneath the right vitelline artery and left 
untied (blue thread). At 4h post-ligation the orientation of the vitelline vascular 
network has not changed. Anterior and posterior midlines remain in a central 
position (arrows). Capillaries at the posterior of the embryo join to the posterior 
vitelline vein. The branched network of arteries remains symmetrical. At 12h 
although the network has increased in size over time it remains in the same 
orientation. At 24h the network has again expanded, the embryo has also grown in 
size, but the orientation of vessel morphology remains much as it was at earlier 
timepoints.  (n=18 but  ~>100 embryos over the course of the project showed this 
morphology) (scale bar = 500m) 
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Figure 3.5 Unilateral vitelline artery ligation induces a dynamic compensatory response 
to restore blood flow to the tied- ligated territory  
The time-course of collateral development after right vitelline artery tied-ligation in a 
single chicken embryo. The blue suture can be seen to be tied around the right proximal 
vitelline artery. The chick body is in upper middle of the image. The anterior vitelline 
vessels are not shown (see Figure 3.6). At 4 hours post tied-ligation developing collateral 
vessels extended from the distal branches of the left vitelline artery and cross the 
midline (indicated by the dashed line) by making small connections with pre-existing 
capillaries in the area. The arrows in the images indicate examples of collateral vessels.  
(n=18) 
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Figure 3.6 The sham and tied-ligated chick embryo model  at 24 hours post-ligation 
A Micrograph of a sham-ligated chick embryo 24h post-surgery. The suture can be seen 
untied underneath the proximal right vitelline artery (RVA) (indicated by star). The 
midline vitelline vein at the anterior (AVV) and posterior (PVV) remains in the same 
location as at T0, Figure 3.3). The right vitelline artery (RVA) and left vitelline artery (LVA) 
maintain a symmetrical orientation. B shows a tied-ligated embryo at 24h (ligated suture 
indicated by star).Collateral vessels (CV) indicated with arrows and can be seen at the 
anterior and posterior poles. The proximal right vitelline artery regressed and was 
replaced by small venules which extended from the distal branches of the collateral 
vessels crossing the midline. Compared to the embryo in A, the embryo in B clearly 
shows the remodelled vitelline vascular network which no longer maintains a 
symmetrical distribution either side of midline veins. (n=18) 
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I next quantified collateral vessel number and diameter in tied-ligated embryos over a 48 
hour timecourse at 4 hour intervals (Figure 3.7). Following ligation, number of collateral 
vessels crossing the midline rapidly increased, with a peak around 12 hours post-ligation 
(mean 8±2). After this, the number of collaterals gradually fell (mean: 4±1 at 48h post-
ligation, Figure 3.7A). Statistical analysis revealed a significant increase in collateral number 
from immediately post-tied ligation (T0) to 12 hours (p<0.0001). Between 12 hours and 36 
hours collateral vessel number decreased significantly (p<0.05).  
Collateral vessel diameter progressively increased over time until a plateau around 36 
hours post tied-ligation (Figure 3.7B). Over time the diameter of the collateral vessels 
significantly increased between T0 and 12 hours (p<0.0005), 12 hours and 32 hours 
(p<0.05) and 24 and 36 hours (p<0.005).  
I sought to infer the haemodynamic properties of the collateral vessels indirectly from the 
anatomical measurements acquired. If a circular lumen is assumed, the cross sectional area 
(CSA) of each collateral vessel is *radius2. The sum of the CSA of all collateral vessels is 
likely to reflect total conductance or capacity. I therefore calculated the sum total CSA of all 
collateral vessels at each timepoint. This showed that despite the reduction in collateral 
vessel number after 12 hours post tied-ligation, there was a steady increase in total CSA 
until at least 36 hours post tied-ligation (Figure 3.7C). CSA significantly increased between 
T0 and 32 hours (p<0.005), 12 to 36 hours (p<0.0005) and 24 to 36 hours (p<0.005). 
This data supports the premise that some collateral vessels are selected for persistence and 
increasing diameter, while others regress. This is haemodynamically more efficient 
according to Poiseuille’s law, and thus a favourable response. A similar response has been 
described in rabbits and other rodents (Scholz et al., 2002, Eitenmuller et al., 2006). 
Although the mechanisms behind these processes have not been elucidated, my studies 
suggest that the chick model of collateral vessel development parallels mammalian species. 
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Figure 3.7 Collateral vessels actively remodel to favour persistence of a small number 
of large vessels 
A The mean number of collateral vessels over time from T0 to 48h. There was a 
statistically significant increase in the number of collateral vessels between T0 and 12h 
(p<0.0001). Between 12h and 36h collateral vessel number decreased  significantly 
(p<0.05). B The mean diameter of these persisting collaterals at each timepoint. Mean 
diameter significantly increased between T0 and 12h (p<0.0005), 12h and 32h (p<0.05), 
24 and 36h (p<0.005) C The mean total cross sectional area of all persisting collaterals at 
each timepoint. CSA was significantly increased between T0 and 32h (p<0.005), 12 and 
36h (p<0.0005), 24 and 36h (p<0.005). 2 way ANOVA with multiple comparisons  (n=18 
embryos)  
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3.4 Flow-induced vessel remodelling requires pre-existing connections to form 
collateral vessels  
Although in mammalian systems collateral vessels form from a pre-existing source (Heil et 
al., 2006) it was important to establish that the collaterals in the chick model also 
developed from pre-existing vessels (i.e. mimicking the situation in mammals). I performed 
high-power analysis of the distal branches of the left vitelline vessels at hourly intervals 
over the first 8 hours following right proximal vitelline artery ligation (Figure 3.8). Vessels 
extended by recruiting previously apparent, but smaller, vessels. From numerous distal 
vitelline vessel branches, one or two became dominant. These vessels were termed 
‘developing collateral vessels’ as they eventually carried arterial flow across the midline but 
at this early timepoint did not extend across the midline. Figure 3.8 shows a panel of 
representative micrographs of distal vitelline branches. For example, at 2 hours following 
ligation vessels labelled c and d appeared of equal size. By 3 hours post-ligation, vessel c 
has a greater diameter. From 4 hours onwards branch d regresses whilst c persists.  
These studies suggest that in the chick, collateral vessels develop by recruitment of pre-
existing vessels and that some form of selection must take place, such that some collateral 
vessels continue to enlarge while others regress. Figure 3.8 gives a static picture of 
collateral vessel development at individual timepoints. To investigate a role for 
haemodynamic forces in the process of ‘selection’ in this model more research would be 
required.  
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Figure 3.8 Following right vitelline artery tied-ligation, the distal branches of the left 
vitelline artery remodelled in a flow-dependent manner 
Representative micrographs of the distal branches of the left vitelline artery over a time-
course from T0 post tied-ligation to 8h. At 2h post tied-ligation vessels labelled  c and d 
appeared of equal size. By 3h vessel c appears to have a wider diameter. From 4h 
onwards branch d regresses whilst vessel c persists to become a forming collateral 
vessel. Arrows point to developing collateral vessel c (n=12 embryos). The same process 
occurring in the same embryo can be seen at a lower magnification in the Appendix 
(Figure A1). 
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3.5 Using Particle Image Velocimetry to measure blood flow in collateral vessels 
A technique to measure blood flow, in real-time, in developing collateral vessels could 
determine if flow is involved in driving a  selection process. I therefore investigated one 
such technique to measure flow within developing collateral vessels, Particle Image 
Velocimetry (PIV). Previous studies have characterised flow profiles within chick extra-
embryonic vascular network (Lee and Lee, 2010, Poelma et al., 2010) or investigated the 
effects of venous clip obstruction and shear stress responsive genes (Groenendijk et al., 
2005). However, no previous work has measured blood flow or velocity in collateral vessels 
in chick embryos. These vessels are smaller than assessed in previous studies, and their 
peripheral site, and highly dynamic remodelling, presents significant technical challenges. I 
therefore attempted to establish whether it is possible to use PIV to quantify blood velocity 
in collateral vessels in the chick embryo. These studies were performed in the lab of Dr 
Christian Poelma, Delft, The Netherlands (section 2.3). 
I measured blood velocity in developing collateral vessels, 4 hours after tied-ligation - a 
point at which these are only just apparent on static micrographs (see Figure 3.5). Figures 
3.9-3.11 show PIV velocity maps, false coloured to indicate velocity, in an area of collateral 
vessel development. I annotated velocity on a single vessel for illustration; the dataset 
allows extraction of velocity at any point in the image acquired, which is a significant 
improvement over techniques such as Doppler which only allow single point assessment. 
Figure 3.9 shows the brightfield image of the embryo assessed at a low magnification to 
demonstrate the area of focus and developing collateral vessels. The velocity map shows 
the coloured vectors in the direction of flow. The fastest blood velocity detected in Figure 
3.9 was 428m/second. At a later timepoint (7 hours post-ligation) the highest velocity in a 
collateral vessel was 488m/second (Figure 3.10). 
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Figure 3.11 shows images acquired 4 hours and 7 hours post-ligation in an individual 
embryo, aligned to allows comparison of size and velocity of the same vessel (blue 
arrow)(i.e. not just focussing on the vessel carrying the fastest velocity). The image at 4 
hours (Figure 3.9) was rotated and cropped to orient to the appearance in the 7 hour 
velocity map. These images show that the collateral network in this individual chick 
increased both in diameter and velocity between 4 and 7 hours post-ligation. Figure 3.10 
shows that at 4 hours the vessel indicated by the arrow measures 69m in diameter and 
flow is 300m/second, but at 7 hours this same vessel had increased in size to measure 
100m and velocity has increased to 488m/second. 
I next attempted to determine whether it was possible to assess velocity serially in the 
same embryo at later timepoints. This was technically challenging, as many embryos died 
(discussed further in the conclusions at the end of this chapter), and identification of the 
same region of interest in an area undergoing both embryonic growth and collateral 
development was difficult. I was able to assess collaterals at 24 hours after ligation. At this 
timepoint collaterals are larger and somewhat easier to image. Figure 3.12 shows a single 
embryo where I have quantified blood velocity and diameter of 4 separate collateral 
vessels.  
These results are the first demonstration that PIV is able to characterise haemodynamics in 
developing collateral vessels in the chick embryo over time. I did not use these data to 
calculate shear stress as I felt that from the limited repeats (n numbers), the data was not 
sufficient to draw conclusions about shear stress in these collateral vessels. Although 
preliminary (as I was only able to spend a small amount of time in Delft performing these 
studies) these results show promise in allowing a more comprehensive assessment of the 
alterations occurring during vessel remodelling.  
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Figure 3.9 Particle Image Velocimetry recorded blood velocity in collateral vessels at 4 
hour post-tied-ligation  
A Brightfield image of a representative HH st 17 embryo, to show the area of the vitelline 
vasculature recorded at 4 hours post tied-ligation. Dotted line indicates midline. Box 
indicates area of B. Arrow indicates developing collateral vessel recorded with PIV at 4h 
B Brightfield image of boxed area in A at higher magnification to show the developing 
collateral vessel recorded (arrow). C PIV velocity map shows developing collateral vessel 
at 4 hours post tied-ligation. Arterial flow is indicated by direction of vectors (small 
coloured arrows) which pointed from left to right. The blood velocity in the main 
collateral vessel in the centre of the image (red vectors) was 428m/second. Flow was 
towards the midline of the embryo/yolk sac (representative image from n=3) 
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Figure 3.10 Particle Image Velocimetry recorded blood velocity in collateral vessels 
at 7 hour post tied-ligation  
A Brightfield image of same embryo as Fig 3.9, 7h post tied-ligation. Dotted line shows 
midline. Box indicates area containing collateral vessels that crossed the midline. 
Arrow indicates collateral vessel recorded with PIV at 4h and 7h B Brightfield image of 
boxed area in A at higher magnification to show the 7h collateral vessels recorded in C 
(arrow). C PIV velocity map shows 7h collateral vessel. The vessel with the highest 
blood velocity was recorded to be 488m/second (representative image from n=3) 
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Figure 3.11 Alignment of 4h and 7h images revealed an expansion of collateral 
network over time and increased velocity within collateral vessels 
A Individual velocity maps from vessels recorded at 4h and 7h post tied-ligation 
(Figures 3.9,3.10). Vessels can be aligned by identifying the large loop in the 
vasculature (indicated by blue box) and the smaller loop inside this (indicated by blue 
arrow). This allows the same vessel to be followed over time points to assess changes 
in size and blood velocity.  At 4 hours the vessel indicated by the arrow measures 
25m in diameter and flow is 300m/second. At 7 hours this vessel had increased in 
diameter to 55m and velocity to 488m/second (n=1) 
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Figure 3.12 Blood velocity in collateral vessels measured by PIV 24 hours post-tied-
ligation  
A Brightfield image of the area containing collateral vessels at 24h post tied-ligation. 
Labelled vessels (a-d) were assessed using PIV. B-E Collateral vessels (a-d) were 
recorded and are shown as a brightfield image (left panels) and as a velocity map 
(right panels). Vessel c had the fastest velocity (336m/s) High velocity is represented 
by red colour (vectors) and can be correlated to the colour map in B. (Representative 
recordings of collateral vessels from 3 embryos) 
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3.6 Histological examination of the area of collateral vessel formation  
I first established that I could identify vessels in the un-instrumented extra-embryonic 
tissue. Previous studies have shown that capillaries form from the mesoderm, and can first 
be detected shortly after HH st 13  (Flamme, 1989).  Figure 3.13 shows brightfield images 
which were taken over time in one representative embryo from HH st 13-st 17.  As 
depicted in Figure 3.13, my observations concurred with earlier reports (Flamme, 1989), 
showing that capillaries are readily detected in the extra-embryonic mesoderm by HH st 15. 
I next performed histological/histochemical analyses of the extra-embryonic vasculature, to 
determine the cellular composition of developing collateral vessels.  
3.6.1 Re-modelled collaterals express the endothelial cell marker, VE-cadherin 
To observe the structure of the extra-embryonic tissue to determine whether I could 
successfully visualise vascular structures in cross-sections, I first dissected easily accessible 
proximal vitelline vessels. These vessels could be isolated from surrounding tissue and 
cross-sectioned to show endothelial cells of the vessel wall, when labelled with an 
endothelial specific antibody. Anti-vascular endothelial-cadherin (VE-cadherin) was found 
to successfully label endothelial cells in the chick specifically (Section 2.16.2), I therefore 
chose to use this antibody to orientate vascular structures in my immunohistochemical 
studies. Figure 3.14 shows immunohistochemical labelling of HH st 17 proximal vitelline 
vessels with anti VE-cadherin.  
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Figure 3.13 Micrograph images to show the development of the extra-embryonic 
vascular network in the area of collateral vessel formation at the posterior of the 
chick embryo 
The panels show representative images of developing extra-embryonic vessels in one 
embryo from stage HH st 13-17.  A-C shows whole developing embryos from HH st13-
17 at a lower magnification. Black boxes indicate areas of focus of D-F. D At HH st13 
small connecting capillaries can be seen in the posterior-medial vitelline territory. E By 
HH st15 these small capillaries were more structured and resembled a primitive 
vascular network F By HH st17 the small capillary network remodelled into a vitelline 
vein at the centre line of the tail of the embryo. Venules either side of the vein can be 
seen to connect to a main vessel, delivering blood back to the embryo. 
(Representative embryos/images n>100 embryos over the course of the project) 
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Figure 3.14 The vessel architecture of the proximal vitelline vessel of a HH st17 chick 
embryo  
A Micrograph of a HH st 17 chick embryo. Blue arrow indicates the proximal vitelline 
vessel sectioned and stained histologically B a transverse section through cryo-
sectioned vitelline vessel. The vessel lumen can be seen surrounded by endothelial 
cells.  DAPI staining labelled cell nuclei, VE-cadherin can be seen to border the edges of 
endothelial cells. The merged image shows VE-cadherin labelling in green. 
Representative examples from 6 embryos. 
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I next sought to elucidate the structural architecture of the collateral vessels. I performed 
Haematoxylin and Eosin (H&E) staining on transverse sections through the extra-embryonic 
tissue in the area of collateral vessel formation in HH st 17 chick embryos. Figure 3.15B 
shows a representative section showing lumenised vessels with the appearance of a single-
layered capillary. As suggested in previous reports, there is no evidence of vascular smooth 
muscle investment of the vitelline vessels until at least HH st 27  (Lucitti et al., 2005) and 
even at this stage there is only a thin layer of smooth muscle which does not contain 
proteins such as elastin and therefore is unlikely to be capable of regulating vascular tone. 
H&E staining only showed cellular composition of the vessels and could not confirm that 
the collateral vessels were comprised of endothelial cells without a smooth muscle coat. I 
therefore next attempted to confirm their endothelial identity. VE-cadherin 
immunostaining labelled vessels in frozen cryosectioned extra-embryonic tissue, confirming 
their endothelial composition (Figure 3.15C). 
Having ascertained that collateral vessels express VE-cadherin, I asked whether VE-
cadherin could be detected on collateral vessels in whole mount preparations. Tied-ligated 
embryos were examined 24 hours post-surgery in wholemount preparations which showed 
VE-cadherin immunolabelling was readily detectable in collateral vessels (Figure 3.16). 
 The data did confirm my expectation that collateral vessels are composed of VE-cadherin 
expressing endothelial cells. However, this experiment highlighted the limitations of whole 
mount immunolabelling in the chick embryos in the area of collateral vessel formation and 
suggested that cross-sectioned tissue provided more valuable data. I therefore chose to 
use cross-sections of tissue for future immunohistochemical assays.   
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Figure 3.15 The vessel architecture of the extra-embryonic tissue of a HH st17 chick 
embryo  
A Micrograph of a HH st17 chick embryo. Black line indicates the area of extra-
embryonic tissue sectioned and stained histologically B H&E staining of a transverse 
section through the extra-embryonic tissue. Vessel lumen can be seen (VL) surrounded 
by a single layer of cells (EC). C shows a similar transverse section through cryo-
sectioned extra-embryonic tissue from the same area, from a different embryo. 
Immunofluorescent anti-VE-cadherin labelling shows positively labelled endothelial 
cells (EC) surrounding a vessel lumen (VL). Representative examples from 6 embryos. 
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Figure 3.16 Immunohistochemistry with anti-VE-cadherin labelling was used to 
identify collateral vessels in wholemount tissue dissected from the area of collateral 
vessel formation 24 hours post tied-ligation. 
A shows two collateral vessels in a brightfield image (black arrows). B shows collateral 
vessels (white arrows) labelled with VE-cadherin antibody. The borders of the 
endothelial cells could be seen. C shows the DAPI labelling of the endothelial nuclei in 
the blue channel. D shows the VE-cadherin labelling in the red channel. 
Representative image from 4 embryos. 
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3.7 Collateral vessels change expression of arteriovenous markers during flow-
induced remodelling   
Previous research has found that endothelial cells of the vitelline network are plastic in 
their vascular identity and endothelial cells express arterial/venous markers depending on 
their haemodynamic environment (le Noble et al., 2004). They investigated arterial/venous 
plasticity in the chick model using in situ hybridisation to assess mRNA expression of 
endothelial cell markers neuropilin 1 (nrp1), ephrin B2, EphB4 and neuropilin 2 (nrp2) after 
occlusion of the right proximal vitelline vessel. The focus of the le Noble study (2004) was 
on the proximal vitelline vessels, in particular the occluded artery which became 
venularised after 24 hours of vessel occlusion. The group observed expression of these 
arterial/venous markers in the proximal vitelline vessels at different timepoints following 
vessel occlusion. Flow was found to up-regulate arterial markers and in the occluded 
vessels without flow, venous markers were expressed (le Noble et al., 2004).  
Buschmann and colleagues (2010) also observed that gene expression could be altered by 
changes in flow. The group used in situ hybridisation in ligated embryos, to study 
expression of the connexin gene Gja5. This was upregulated in collateral vessels at 20 hour 
after ligation. The group concluded Gja5 expression was therefore driven by arterial flow 
(Buschmann et al., 2010).   
As yet, no study has studied different timepoints following ligation to address if collateral 
vessels alter their arterial/venous identity over time, in a manner that correlates with 
altered haemodynamic environment. I therefore wanted to characterise the 
arterial/venous identity of collateral vessels in the chick model and test the hypotheses 
that collateral vessels acquire arterial identity over time. I did this by observing nrp1 and 
nrp2 expression in collateral vessels. 
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I performed in situ hybridisation following ligation to track the changes in endothelial 
vascular markers during collateral vessel development. The timepoints I selected reflected 
two key phases of collateral vessel formation observed in the timecourse experiment 
(Figures 3.5, 3.7): at 4 hours post-ligation collateral vessels were developing and beginning 
to extend across the midline; at 12 hours post-ligation the number of collateral vessels has 
ceased to increase and vessels subsequently either persisted or regressed (Figure 3.7).  
I first sought to optimise riboprobes directed against an arterial marker, nrp1 (Moyon, 
2001) and a venous marker, nrp2 (le Noble, 2004) in unligated embryos. I used HH st 20 
embryos as at this stage the venous network has developed and overlies the arterial 
vitelline vessels giving me an opportunity to compare expression patterns. Figure 3.17A 
shows a representative schematic of the blood flow direction and arterial/venous 
patterning in a HH st 17 chick embryo. Figure 3.17B and C show wholemount in situ 
hybridisation preparations of the proximal vitelline vessel branches. Arteries expressed 
nrp1. Veins overlying the arteries appear clear as they do not express nrp1. Figure 3.17C in 
contrast showed expression of nrp2. Cells in the venous network expressed nrp2 whereas 
the vitelline artery beneath the vein showed no expression.  
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Figure 3.17 Neuropilin 1 expression can be seen in wholemount vitelline arteries of 
HH st 20 chick embryos. Neuropilin 2 venous marker labels the veins overlying the 
arteries. 
A At HH st20 veins overlie arteries in the vitelline vasculature. This schematic shows 
direction of blood flow in this cis-trans network. Red arrows indicate arterial flow 
away from the embryo body. Blue arrows represent venous blood flow returning to 
the embryo B and C wholemount views of in situ hybridisation for nrp1 and nrp2. B 
shows dark blue staining in the arterial branches of the right proximal vitelline artery 
indicating neuropilin1 (nrp1) expression. Veins are clear in comparison and show no 
nrp1 expression B shows the opposite staining pattern. Venous branches were 
superimposed over the arterial branches of the left vitelline artery and stained dark 
blue indicating nrp2 expression. (n=6 ) 
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I next examined expression of these genes during collateral vessel formation. Figure 3.18 
shows nrp1 and nrp2 in situ hybridisation after ligation. Four hours after tied-ligation the 
unligated side of the chick showed increased nrp1 expression, compared to the ligated 
side.  The area of collateral development (indicated by the box, Figure 3.18 A-B) showed 
high nrp1 expression (Panels A and C). At the same time, expression of nrp2 was 
downregulated in this region (Panels B and D). This suggests that venous capillaries become 
arterial as they are recruited into the expanding arterial collateral network. By 12 hours 
post-ligation, collateral vessels expressed nrp1 but not nrp2, suggesting that they adopt an 
arterial identity over time.  
Together these experiments suggest that increasing flow, i.e.altering haemodynamics, 
within the remodelling collateral vessels provokes a down-regulation of venous markers on 
endothelial cells and an up-regulation of arterial markers. Nrp1 expression increases over 
time, was in keeping with the observation that as collateral vessels develop and become 
established, they carry arterial flow (direction of flow from left to right) across the midline 
to the unperfused tissue (Figure 3.5). 
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Figure 3.18  Arterial neuropilin 1 is upregulated in collateral vessels 
A Shows up-regulation of nrp1 expression in the area of collateral vessel development 
(boxed area) 4h after tied-ligation. The right side of the embryo shows less expression. 
B Shows down-regulation of nrp2 expression in the area of collateral vessel 
development indicated by less staining C Higher magnification images of A showing 
nrp1 positive collateral vessels at 4h post tied-ligation(red arrow) D shows that there 
no nrp2 staining was detected in the collateral vessels at the same time-point (blue 
arrow points to clear vessel). E By 12 h post tied-ligation nrp1 is expressed by 
endothelial cells of collateral vessels (red arrow). Collateral vessels appear dark blue. F 
No expression of nrp2 was detected in collateral vessels at this time-point (blue arrow 
points to comparatively clear vessel). (n=6 embryos per group) 
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3.8 Is proliferation increased in areas undergoing collateral vessel remodelling? 
Collateral vessels are already apparent 4 hours post-ligation and their number increases 
rapidly (Figures 3.5, 3.7). As outlined in Chapter 1, little is understood of the mechanisms 
that govern collateral vessel formation. However, a number of studies suggest that in 
mammals, collateral vessel formation is accompanied by proliferation of endothelial and 
smooth muscle cells (Schaper et al., 1971, Hoefer et al., 2001). I therefore wanted to assess 
whether I could detect an increase in proliferation during collateral vessel remodelling in 
the chick, in a system in which vessels appear composed only of endothelial cells. 
I applied BrdU, topically to sham or tied-ligated embryos immediately after ligation to 
assess proliferating cells. Embryos were sacrificed after 4 hours, sectioned, and 
immunolabelled with anti-BrdU antibodies in the area of collateral vessel formation 
(section 2.22.1). Each embryo produced around 6 sections. For each section, BrdU positive 
cells were analysed (section 2.22.1) and the average proliferation index calculated for each 
embryo (Figure 3.19). Proliferation index was calculated by dividing the total area of BrdU 
positive nuclei by the total area of DAPI positive nuclei. These percentage area 
measurements were necessary as antigen retrieval damaged nuclei making it less accurate 
to count these individually. I found that the proliferation index was not significantly 
increased in tied-ligated embryos compared to sham-ligated controls (sham-ligated 
embryos 10±3%; tied-ligated embryos 15±3%) although there was a trend towards 
increased proliferation in tied-ligated embryos. I cannot conclude that proliferation does 
not play a role in the remodelling process, but no significant differences in proliferation 
were detected between sham and tied-ligated embryos. 
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3.9 Discussion 
In this chapter I set out to characterise collateral vessels that form in the extra-embryonic 
vasculature of the chick embryo following unilateral vitelline vessel occlusion. My data 
showed that following unilateral proximal vitelline vessel ligation, downstream distal 
branches in the unligated territory developed into collateral vessels. These collateral 
vessels increased in number until a plateau around 12 hours after ligation, before declining 
in number, with continued expansion of the persisting collateral vessels. This appears to 
involve selection of more efficient collateral vessels which persist over time but it was not 
possible to confirm what drives this selection. Collateral vessels were shown however to 
remodel from pre-existing vessels to carry arterial (afferent) blood across a previously 
venous territory. Histological examination showed that collateral vessels are predominantly 
endothelial and that this process involves a change in endothelial cell arterio/venous 
Figure 3.19 BrdU proliferation index in sham and tied-ligated embryos 4 hours post-
ligation 
Proliferation index was calculated based on area of positive staining for DAPI and 
BrdU.  There was no statistically significant difference in proliferation index between 
sham and tied-ligated groups at 4 hours post-ligation (n=6. Student’s t-test = n.s) 
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identity (small venules become arterial as they are incorporated into the collateral vessel 
network).  
I first set out to address whether I could successfully manipulate flow in this system 
without harming the embryo, and secondly, whether I could measure any changes in 
diameter of the left, (unligated) proximal vitelline artery, following occlusion of the right 
proximal vitelline artery. The unligated artery did indeed increase in vessel diameter, 
immediately post tied-ligation, and 10 minutes after ligation. This data suggested that the 
ligation neither caused the embryo harm nor lead to a marked reduction in cardiac output. 
My findings were also consistent with those of Buschmann et al., (2010) published during 
the course of my work who showed similar effects on the unligated artery diameter 5 hours 
after ligation (Buschmann et al., 2010). Early observations to monitor immediate effect of 
ligation on the size of the unligated vessel had not previously been investigated. 
The response to arterial occlusion in mammalian models is well documented and it is 
widely accepted that, following vessel occlusion, local changes in haemodynamics are the 
main driving force to remodelling. It also widely accepted that arteriogenesis is not due to 
contributions form angiogenic or ischaemic factors (section 1.3). A large proportion of this 
work derives from Wolfgang Schaper who refers to shear stress as the driving force of 
collateral vessel formation (Schaper, Scholz 2003). Following extensive conversations with 
experts in the field of biomechanics (Professor Rod Hose, Professor Pat Lawford, Medical 
Physics, University of Sheffield) I conclude that my data reflected a complex system 
whereby it is likely that a combination of factors, including pressure, flow, shear stress, 
vaso-regulation and cardiac output influence the remodelling response observed in my 
model. From my data alone, I cannot conclude which of these individual or combination of 
factors are driving collateral vessel formation in my model, although the literature suggests 
local shear stress may play a driving role.  
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Heart rate measurement following ligation showed no adverse effect of the arterial 
occlusion compared to sham-ligated controls (Figure 3.2B). Heart rate was around 120 
beats/min. This rate is  slightly lower than chick embryos at the same stage in other studies, 
such as Lee et al., (2007) who described a mean heart rate of 146±2 beats/min (Lee et al., 
2007). This slight reduction in heart rate could be due to a cooling of the egg during 
experimental periods. The speed of my ligations was initially slow (4-5 minutes) but it is 
worth noting that this was not the case with later experiments as the speed of my ligations 
improved over the course of my project (1min-30 seconds). Temperature can induce 
vasoconstriction (Nakazawa et al., 1985), although this was also unlikely to have affected 
results in my model due to the lack of smooth muscle in the vitelline vessels of the embryo 
at this stage and therefore a lack of vascular tone (Lucitti et al., 2005). I therefore do not 
consider it likely that this adversely influenced my findings. However, to remove any 
concerns a heated lamp could be used to keep a constant temperature during experimental 
procedure. 
I acknowledged that in this study, measurements of collateral vessels from the micrograph 
images were subjective (section 2.24). I therefore attempted to reduce error/bias in the 
following ways. I made repeated observations and measuring vessels with the same tools 
and protocol each time. This was controlled for with repeated experiments and biological 
replicates which made the data more reliable. I was blinded in my analysis and when 
measuring proximal vitelline vessels at high magnifications I was not aware if these were 
from tied-ligated or sham-ligated embryos. Future studies could explore automation of 
vessel analysis, such as by pixel intensity of photomicrograph images. Comparing red pixels 
(blood vessels) to background pixels might have allowed for automated and objective 
measurements of vessel size.  However, the albumin over the surface of the vitelline 
membrane blurs the defined vessel boundaries and makes even illumination of 
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micrographs challenging. This would make it difficult to automate detection of blood 
vessels accurately against the background. 
Further findings from my initial ligation experiments showed that unilateral vitelline vessel 
ligation of the right proximal vitelline artery resulted in distal remodelling of the vitelline 
network. ‘Collateral vessels’ were observed to cross the posterior and anterior medial 
territories to re-perfuse tissue with arterial blood (Section 3.3). I investigated this 
remodelling process further by serially quantifying collateral vessel remodelling by vessel 
number and size. I used the same definition of collateral vessels as Buschmann et al., 
(2010) (i.e. vessels which cross venous territories from left to right across the midline, 
carrying arterial flow) (Buschmann et al., 2010). 
My analysis of collateral vessel development following unilateral arterial ligation revealed a 
feature not previously described in this model; an initial “expansion” phase, which began 
around 4 hours post tied-ligation with a rapid increase in collateral number to a peak 
around 12 hours, followed by a “remodelling” phase, during which some collaterals 
regressed to favour persistence and continued expansion of a remaining smaller number 
(Figure 3.5, 3.7). Despite the reduction in vessel number after 12 hours, the mean diameter 
of the persisting vessels (and hence the likely flow carrying capacity) of the collateral 
vessels continued to increase over 48 hours. This process of selection of persistent 
collaterals allows development of a more haemodynamically favourable configuration. The 
mechanism behind such selection remains unclear, but it seems likely to be driven by local 
haemodynamic forces within the vessels based on mammalian studies (Pipp et al., 2004, 
Eitenmuller et al., 2006). 
My data showed a biphasic remodelling response similar to that observed in mammals 
(Hoefer et al., 2001, Herzog et al., 2002); both systems exhibit an initial rapid rise in 
collateral vessel number that then is refined to achieve a more haemodynamically efficient 
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configuration. This is described in a rabbit model of femoral artery occlusion where a 
timecourse identified an initial peak in collateral vessels (Hoefer et al., 2001). This 
‘expansion’ phase was then followed by selective growth of large vessels and ‘pruning’ of 
less efficient vessels. The chick embryo thus appears to display parallels to mammalian 
arteriogenesis.  
As discussed, it is widely accepted that arteriogenesis involves pre-existing vessels (as 
reviewed by Schaper, Scholz., 2003). However, there was a possibility that as I was studying 
collateral vessel formation in a developmental, embryonic model, the process may have 
involved de novo vessel formation. I therefore set out to show that collateral vessels in the 
chick stemmed from pre-existing vessels. My data showed that in the chick embryo (as in 
mammals) collateral vessels do not form from de novo sprouting of capillaries. Section 3.4 
describes 8 hour timecourse observations post-ligation and confirmed that pre-existing 
connections form collateral vessels. Collateral vessels were shown to extend from branches 
of the left, unligated vitelline artery. Further, small vascular connections downstream of 
‘developing’ collaterals could be seen to contribute to the remodelling vessel (Figure 3.8).  
The molecular mechanisms required to sense changes in haemodynamic forces, and then 
induce such selective remodelling, are unknown (although my later work sheds some light 
on this). However, in the literature, there is strong evidence to suggest that selection of 
persisting vessels is driven by haemodynamic force (Hoefer et al., 2001). Measurements of 
blood flow (and other parameters) are capable of examining this in detail in the context of 
fluid forces, but the micrographs appeared to suggest that bigger vessels were favoured 
over smaller vessels (Figure 3.8). 
To support the argument that collateral vessel formation in my model is not an angiogenic 
response, other characteristics of angiogenesis, not present in arteriogenesis could be 
investigated as described below: 
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Tests for hypoxia, the driving force of angiogenesis, could be investigated using embryos 
incubated in a hypoxic environment (~15% oxygen levels) (Ruijtenbeek et al., 2000) to see if 
this increased the number/diameter of remodelled vessels post-ligation. Previous literature 
however, has shown that this area of the extra-embryonic vasculature in the chick embryo 
is normoxic (Buschmann et al., 2010) supporting the idea that angiogenesis is not forming 
collateral vessels and is not required for this process. It is likely also that hypoxic conditions 
would reduce cardiac output and confound any results. 
VEGF levels could have been analysed by immunoassays (Jelkmann, 2001), as this is a 
strong signal for angiogenic growth (Gerhardt et al., 2003). However, growth factors such 
as VEGF may also play a role in arteriogenesis (Lanahan et al., 2013)(section 1.8). 
Therefore, this analysis would not have provided conclusive results about whether 
collateral vessel formation in the chick occurs by angiogenesis or not. 
Other indications the collateral vessel formation in the chick embryo occurs by an 
arteriogenic rather than angiogenic process could have come from studies into the 
presence of arteriogenic factors such as MMPs, macrophages or arteriogenic genes such as 
MCP1 (Hoefer et al., 2001) (as discussed in section 1.4). Later work shed more light on the 
genetic profile of the area of collateral vessel formation in the embryo and will be 
discussed in the next chapter (Chapter 4). The data from this chapter taken together 
provided good evidence to suggest that collateral vessels do not form de novo in this 
model, and that the driving force was haemodynamic force rather than an angiogenic 
stimulus. 
PIV measurements of the distal vitelline branches, at early timepoints following ligation (T0 
and 2 hour intervals) could have helped to assess whether the vessels carrying more flow 
were the ones that persisted to become established collateral vessels. I had not yet 
discovered PIV at the time of this study and future work could utilise this method. I did 
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however go on to generate proof-of-principle that PIV represents a viable tool to examine 
blood velocity in chick collateral vessels. Although preliminary data, PIV analysis did show 
that even at early timepoints, collateral vessels carried arterial flow across the midline to 
unperfused tissue (Figure 3.9, 3.10). It is important to note that time matched observations 
could not be made in the sham-ligated embryo. In the area of collateral vessel remodelling 
the sham-ligated model maintains its symmetrical distribution of vitelline branches either 
side of the vitelline vein (midline). The flow profiles of the vitelline vein are physiologically 
different to the arterial profiles of collateral vessels and cannot therefore be compared. 
From my PIV experiments I have shown that serial PIV is possible in chick embryo collateral 
vessels at two timepoints. I have also shown that blood velocity can be measured in both 
developing and established collateral vessels. Technical limitations (which could not be 
optimised in the length of visit to our collaborators in Delft) prevented me from acquiring 
sufficient data to draw any firm conclusions about haemodynamics in my model. Some of 
these shall next be discussed: 
A short window of time existed at which PIV analysis was optimal in my model; at early 
developmental stages, vessel boundaries were difficult to visualise, at later stages veins 
obscured arteries. Flow at high velocities in proximal vessels, was difficult to record with 
the camera and light source available. Occasionally due to movement of the embryo or 
debris on the yolk sac, images could not be processed.  Processing took ~6 hours for each 
dataset, which also limited my ability to generate replicate datasets. One significant 
limitation was that embryos did not tolerate repeated imaging. Kloosterman (2014) had 
previously performed PIV on chick embryos at two points:  HH st 13 and HH st 17 (a gap of 
4 hours) (Kloosterman et al., 2014), however, it is worth noting that these embryos had not 
undergone surgery prior to imaging and had not been subjected to more than two 
observations. Due to the limited amount of time I had working in Delft (7 working days) I 
147 | E m i l y  C l a r e  H o g g a r  
 
was not able to investigate why the embryos were perishing where usually they would 
survive (e.g. Timecourse analysis over 48 hours Figures 3.5, 3.7).  
I next went on to examine vitelline and collateral vessel architecture. The vitelline vessels 
were found to be composed of endothelial cells and VE-cadherin successfully labelled 
endothelial cells in these vessels (Figure 3.14). Smooth muscle has been investigated by 
other groups previously and has not been found in these vessels at this development stage 
in the chick embryo (Taber et al., 2001, Lucitti et al., 2005). There is little requirement for 
vitelline vessels to regulate vascular tone as the entire network is maximally expanded to 
increase the surface area to the yolk sac (le Noble et al., 2004) allowing oxygen and 
nutrient uptake. 
 VE-cadherin immunolabelling of endothelial cells of the extra-embryonic vasculature 
represented a marker which could be used for examination of the area of collateral 
development, to distinguish endothelial cells from non-vascular structures. 
Immunohistochemistry can be technically challenging in this model (see later studies in 
chapter 5). Lectins have been used by other groups to label the vasculature of chick 
embryos and have benefits over immmunohistochemical antibodies as they bind to specific 
glycoproteins on the luminal surface of blood vessels. Jilani et al., (2003) investigated 9 
different lectins to find the most selective option for vessel visualisation and found Lens 
culinaris agglutinin, concanavalin A to bind most successfully to endothelial cells (Jilani et 
al., 2003). The drawback to using lectins in my model is the intra-vascular delivery required. 
My attempts at microvascular injection often ended in death of the embryo due to 
haemorrhaging. This was why I opted to use immunohistochemical techniques instead. 
My finding that collateral vessels in the chick embryo are mainly endothelial in structure 
can be seen as an advantage or a potential limitation of the model when compared to 
mammalian models. Arguably, the initiation of arteriogenesis in mammals appears to 
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derive from activated endothelial cells and given that the chick extra-embryonic vessels 
appear endothelial in nature; this suggests that the chick could provide a means to examine 
the role of the endothelium in isolation. However, native collateral vessels in higher species 
classically have a tunica intima of endothelial lining; a tunica media composed of smooth 
muscle cells; and elastic tissue and a tunica adventitia of collagen and elastic lamina (Cai et 
al., 2003). Following occlusion and elevated shear stress in these models, the activated 
endothelial cells release factors which initiate remodelling (Arras et al., 1998, Heil and 
Schaper., 2005). The internal elastic lamina ruptures, which separates the smooth muscle 
layers (Heil and Schaper., 2007). The intima and adventitia thicken as smooth muscle cells 
proliferate (Buschmann and Schaper, 2000). Therefore the process of collateral remodelling 
in the chick embryo is not comparable from an architectural viewpoint. 
Conversely, the chick model could provide valuable insights into an exclusive endothelial 
response to changes in flow, in vivo, not possible in mammalian models. Further, it could 
be argued that this in vivo system provides information about the endothelial cell response 
to changes in flow which are difficult to reproduce in vitro.   In vitro assays have benefits in 
that they produce rapid, reproducible and quantifiable results. External stimuli can be 
strictly controlled. However, physiological in vivo conditions are difficult to replicate 
accurately in vitro; endothelial cells behave differently in static vs. flow conditions. Isolation 
of cells in vitro, may give the benefit of studying an isolated reaction to a drug. Further, 
indirect effects from surrounding cells, such as endodermal or ectodermal cells in the extra-
embryonic tissue  in vivo, which may influence the response to a drug, would not be 
captured in in vitro assays. It has also been shown that endothelial cells in culture change 
their active state, chromosome number, cell surface antigens and growth properties 
(Jackson and Nguyen., 1997).  In vitro experiments must therefore be interpreted with 
caution and validated with multiple tests with either more than one cell type, tested on 
different matrices with different compounds (Staton et al., 2004). 
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There is also evidence to suggest that endothelial cells differ, for example HUVECs and 
endothelial cells from the microvasculature(Jackson & Nguyen 1997). These differences 
(phenotypic or structural) may affect behaviour (Jackson & Nguyen., 1997). It is therefore 
difficult to know which cell line best recapitulates the in vivo situation. Although a valid 
method, these in vitro limitations support the utility of the chick embryo as a model to 
investigate flow-induced remodelling. The chick allows analysis of an in vivo endothelial 
system, with further benefits of real-time vessel observation, easy access for vascular 
manipulation and pharmacological assays.  
Further characterisation of the endothelial behaviours of remodelling collateral vessels in 
my model came from in situ hybridisation studies of arterial/venous markers, post-ligation.  
This data revealed that endothelial cells appeared to adopt an arterial identity as the 
expanding collateral network extended across the midline into venous territory. This was a 
time-dependent process as nrp1 expression increased over time, not previously reported 
by other groups. Arterial markers were upregulated from at least 4 hours post-ligation and 
were more strongly expressed at 12 hours in the collateral vessels (Figure 3.18).  
My data was predominantly concerned with flow-induced arterial expression patterns. In 
the literature, there is debate about whether arterial expression is pre-determined 
genetically and determined by Notch signalling (Lawson et al., 2001) or if expression is 
plastic and can be altered by flow (le Noble et al., 2004). Although our findings agreed with 
those of le Noble et al., (2004) as flow appeared to drive nrp1 expression, I could 
investigate some of the findings of Lawson et al., (2001) to validate these results.  
Notch has been found to be required for arterial/venous patterning (Lawson et al., 2001). 
This group investigated expression of ephrinB2 (arterial marker) and ephB4 (venous 
marker) in the blood vessels of zebrafish embryos. They disrupted Notch signalling by 
inhibiting DNA binding proteins of downstream Notch targets and created mutants 
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defective in Notch signalling. In both of these models vessel architecture did not develop 
normally and expression of ephrinB2 and ephB4 was affected. The group concluded that 
activation of Notch represses venous differentiation in developing arteries which leads to 
changes in vessel patterning (Lawson et al., 2001).  
My data gave an indication that changes in haemodynamic force were driving expression of 
arterial markers and the resulting pattern of vessel networks post-ligation. This implies that 
a) collateral vessels can respond to changes in altered demand by modulating gene 
expression – a hypothesis I later investigate in Chapter 4, and b) that changes in 
haemodynamic force may be the stimulus driving collateral vessel remodelling.  
Final experiments in this chapter attempted to determine if endothelial proliferation was 
required for collateral vessel remodelling.  Proliferation was investigated because studies 
have shown that in mammalian models outward remodelling of collateral vessels involves 
smooth muscle cell and endothelial cell proliferation (Scholz et al., 2002). The literature 
suggests that proliferation might be required for flow-induced vessel remodelling (Schaper 
et al., 1971) but there are currently no investigations in the chick model into proliferation 
and collateral vessel growth.  
I hypothesised that developing collateral vessels would require more proliferation early on 
at a time when the process is dynamic. However, at an early 4 hour timepoint following 
ligation there was no significant difference in the number of proliferating cells in the area 
of collateral vessel development between sham and tied-ligated embryos (Figure 3.19). VE-
cadherin double staining was performed alongside BrdU labelling to aid analysis of 
proliferating endothelial cells. The sham-ligated control allowed for an estimation of any 
differences in proliferation due to collateral vessel formation, but none were observed. 
Although the n numbers were not sufficiently high to be entirely confident, this data 
supports the hypothesis that collateral vessels do not form de novo by a sprouting 
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angiogenic process, which would require proliferation (Gerhardt et al., 2003). Further, 
Buschmann et al., (2010) reported that intussusceptive angiogenesis, which was likely to 
play a role in collateral vessel formation in the chick embryo, was a process requiring little 
proliferation (Djonov et al., 2000, Buschmann et al., 2010). My data does not provide 
sufficient evidence to draw conclusions as to whether proliferation is or is not required for 
collateral vessel remodelling as it could be argued that there is a trend towards tied-ligated 
chick embryos showing more proliferation in this area. Increasing the n number would 
increase the statistical power which could help to detect significant differences. It is 
possible that since the entire chick is growing rapidly, the baseline level of proliferation is 
high enough to mask the effect of collateral remodelling, which will only represent a 
proportion of proliferation in the area assessed. 
The evidence for increased proliferation in collateral vessel formation comes from early 
studies in canine models (Schaper et al., 1971). The group found that following constriction 
of the left circumflex coronary artery, consequent collateral vessels showed increased 
proliferation. Radioactively labelled thymidine was titrated into the vessels and DNA 
synthesis and mitosis in coronary collateral vessels was measured. The tunica media and 
tunica intima of collateral vessels showed most proliferation. They could not distinguish if 
proliferation was occurring in endothelial or smooth muscle cells so did not draw 
conclusions about the contribution of endothelial cell proliferation to collateral vessel 
remodelling (Schaper et al., 1971). However, Odori et al., (1983) showed increased 
proliferation of endothelial cells after renal artery stenosis was induced by clipping the 
artery in rats. The proliferative response was assessed by coded reading of images showing 
positive labelled nuclei of endothelial cells following titration of thymidine, 5 days after the 
stenosis. Compared to sham-ligated models which showed no change in proliferation, 12 
out of 18 rats showed a significant proliferative response. The group concluded that 
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increased proliferation led to increased number of collateral vessels during remodelling 
(Odori et al., 1983).  
Other studies have shown that peaks in proliferation of endothelial/smooth cells occurs at 
different timepoints following vessel occlusion, in different species: Scholz et al., (2000) 
showed mitosis of smooth muscle and endothelial cells was present 24 hours after femoral 
artery occlusion in rabbits (Scholz et al., 2000). One study found a peak to occur at 3 weeks 
in dogs (Schaper et al., 1971) whilst another group found the peak at 1-4 days in rats (Ilich 
et al., 1979). Similarly the number of proliferating cells that contributes to collateral vessels 
may be species dependent. In collateral vessels of the canine model it ranges from 2.6-3.5% 
(Schaper et al., 1971), 5-6% in rodents (Ilich et al., 1979) and <1% in porcine models (White 
et al., 1992). My results showed a general level of proliferation which was higher (~10%). 
This difference could be species dependent or reflective of the fact that a developing chick 
embryo may require increased proliferation for growth. 
BrdU labelling and assessment requires an antigen retrieval step. This procedure often 
damaged tissue and made identification of specific cellular staining of VE-cadherin/BrdU 
difficult. A second proliferation marker could validate the result acquired with BrdU 
labelling. This would also further validate that BrdU was successfully incorporated into cells 
during the remodeling period in vivo – an especially technically challenging procedure 
(section 2.22.1). For example, Ki67 would be a good antibody to test as it can be detected 
at all phases of the cell cycle and would provide a more stringent analysis of all the 
proliferating cells. It is possible that increases in proliferation may occur after 4 hours. In 
later studies I therefore investigated proliferation during later timepoints (chapter 5).  
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In summary, the data in this chapter suggests the following: 
 Unilateral arterial ligation causes changes in haemodynamics which remodel the 
pre-existing vitelline vessel network into collateral vessels 
 Collateral vessel number rises and falls, implying active selection of a favourable 
configuration via an unknown mechanism 
 Collateral vessels are endothelial in nature and adopt an arterial identity as they 
remodel to perfuse a venous territory 
 Proliferation is limited in collateral vessels at early timepoints 
 
Future work 
The PIV technique could be developed to be used in future studies to enhance and support 
data from static images (for example, in Figure 3.5).  When optimised, PIV would allow 
comprehensive blood velocity mapping in the collateral vessels of this model. Future work 
could investigate whether Notch signalling increases in ‘developing’ collateral vessels as 
they adopt an arterial fate when crossing the venous territory at the midline. 
Immunohistochemistry could be used to analyse Notch receptor (Notch 1, 3, 4) or ligand 
expression (delta-like4, jagged 1, 2) in collateral vessels. These results could be compared 
to my previous nrp1 findings (Figure 3.18). Inhibition of Notch signalling with a gamma 
secretase inhibitor could confirm a role for Notch in collateral vessel formation. Inhibition 
of ephrinB2 could be tested to see if this resulted in impairment of the patterning of the 
collateral vessel architecture. 
In conclusion, the vitelline network remodels after occlusion in a similar way to mammalian 
models. The chick model has technical advantages over higher model systems: easy 
accessibility of the vessels; simple visualisation methods; ease of manipulation. Although 
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the vessel architecture between species differs, the chick embryo model provides 
mechanistic similarities to collateral vessel formation in mammals. The chick embryo 
provides a unique platform from which to identify novel endothelial cell responses to 
changes in haemodynamic alteration. I exploited these advantages in the next chapter to 
characterise the gene expression profile during collateral remodelling. 
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Chapter 4 
Characterising the transcriptional profile during flow-induced vessel 
remodelling in the chicken embryo 
 
Summary 
In this chapter I used microarrays to assess the transcriptional response at two timepoints 
during collateral development in the chicken embryo.  
My aims were to: 
 characterise transcriptional changes during different phases of flow-induced vessel 
remodelling  
 identify candidate genes which may contribute to collateral development 
 
Figure 4.1 shows a flowchart of the experimental groups and timepoints. In addition to the 
sham-ligated and tied-ligated groups, I included a ‘baseline’ group of uninstrumented HH st 
17 embryos (the stage at which other groups underwent tied-ligation/sham-ligation) 
(section 2.6.1).  
To examine the gene expression changes detected, I undertook the following analysis 
pipeline. Using PUMA, I identified genes that were differentially expressed in the following  
comparisons; 
4 hours post tied-ligation vs. 4 hours post sham-ligation 
12 hours post tied-ligated vs. 12 hours post sham-ligation 
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Data from each array was normalised before being analysed, to make sure signals between 
different array chips were distributed evenly and any variations due to technical issues 
were removed to make the data comparable (section 2.6.1). This data was then used for 
clustering.  
It is important to understand the ‘normal developmental’ programme in chick embryos as it 
develops from HH st 17 to the timepoints observed for the tied-ligated embryos. This gives 
an idea of the genes which are required for growth and which may be expressed as a result 
of experimental conditions. I therefore also performed comparisons between baseline vs. 4 
hours post sham-ligation and baseline vs. 12 hours post sham-ligation. These data are 
included in the appendix due to space considerations (Figure A4 and A5). Further, despite 
needing knowledge of normal development, these genes are biologically less relevant as 
my focus is a comparison of differentially expressed genes in tied-ligated and sham-ligated 
embryos.   
4.1 A priori expectations of relevant gene expression changes 
Microarrays generate a large amount of data that often require a priori assumptions about 
what gene expression changes might be relevant. As I showed in the previous chapter, the 
tissue at the site of collateral vessel remodelling is complex. Even in sham-ligated embryos, 
there is ongoing development of the vitelline vasculature over the timepoints assessed 
(Appendix figures A4, A5). During collateral vessel remodelling, there are highly dynamic 
changes in vessel morphology (Figure 3.5) that would be predicted to correlate with 
significant alteration in transcription. I therefore chose to focus my efforts on identifying 
two key groups of genes (that encode known proteins with homologues in mammalian 
species).  
The first group were genes that are differentially expressed both 4 hours and 12 hours 
after tied-ligation. These genes showed more or less expression in the area of collateral 
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vessel formation compared to sham-ligated embryos, but expression was also detected in 
the sham-ligated embryos. These genes might be expected to include genes that are 
generally required for collateral development (or at least vascular remodelling). The second 
group were genes that were expressed only in tissue undergoing collateral vessel 
remodelling (at either 4 or 12 hours after tied-ligation). These genes showed little to no 
expression in sham tissue or at baseline, but appeared specific to the area of collateral 
vessel remodelling. These genes could therefore be specific to vessels undergoing 
remodelling and might represent mediators of collateral vessel transcriptional response, 
rather than more general vascular remodelling or growth. Focusing on these genes would 
exclude those whose expression was simply delayed or accelerated by ligation, or whose 
expression was simply a function of the amount of vascular tissue at the site of remodelling 
(which appears to be greater during collateral remodelling). 
4.2 Assessment of the transcriptional changes during normal development and 
collateral vessel development in the chicken embryo 
As discussed in the previous chapter, collateral development following unilateral vitelline 
artery ligation proceeds over at least 48 hours. I chose to study gene expression at 4 hours 
and 12 hours post-ligation. I chose these timepoints because at 4 hours the vessels have 
been exposed to altered blood flow for sufficient time to induce a biological response but 
collateral vessel development is in an early stage. Figure 3.7 showed numbers of collateral 
vessels and their diameter remained low at 4 hours and at 12 hours collateral vessel 
number had peaked and a process of selection of the most favourable configuration 
seemed to have commenced. Examining these timepoints might therefore identify drivers 
of the initial expansion of collateral number (at 4 hours) and genes that contribute to the 
selection of persisting collateral vessels (at 12 hours). 
158 | E m i l y  C l a r e  H o g g a r  
 
 
  
Figure 4.1 Schematic of microarray experimental protocol 
 
Tissue was excised from the same medial posterior area in sham and tied-ligated 
embryos (represented by box). A indicates the excised area in a sham-ligated embryo. B 
indicates excised area in a tied-ligated embryo. C The timeline shows the timepoints 
selected for microarray analysis. Tissue was taken from embryos pre-surgery for a 
baseline measurement (HH st17). At T0 either a tied-ligation or a sham-ligation was 
performed. Tissue was then removed from groups of 3 embryos at 4h and 12h post-
ligation/sham. RNA from each group was pooled. Each experiment was repeated 3 times 
(i.e. 9 embryos per timepoint per group, n=3 arrays per timepoint per group). 
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4.3 The transcriptional profile during collateral vessel development 
My key aim was to compare gene expression at the site of collateral vessel development in 
tied-ligated embryos compared with sham-ligated embryos. I therefore next compared the 
transcriptional profile at both 4 hours and 12 hours post tied-ligation. At 4 hours post tied-
ligation, 158 transcripts were differentially expressed between sham-ligated and tied-
ligated embryos by more than 1.5 fold with a PPLR of >0.8 or <0.2 (see Materials and 
Methods). At 12 hours post tied-ligation, 187 transcripts were differentially expressed 
between sham-ligated and tied-ligated embryos by more than 1.5 fold with a PPLR of >0.8 
or <0.2 (Figure 4.2). 
 
 
 
 
 
 
Figure 4.2 Venn diagram showing number of differentially expressed genes at 4 h post-
tied-ligation compared to 4h sham-ligation and 12h post tied-ligation compared to 12h 
sham-ligation. 
 
The circle on the left represents 158 differentially expressed genes at 4 hours post tied-
ligation compared to 4 hours post sham-ligation. The circle on the right represents 187 
differentially expressed genes at 12 hours post tied-ligation compared to 12 hours post 
sham-ligation. The overlapping section of the circles represents 13 shared genes 
differentially expressed at both timepoints compared to the sham operated embryos. 
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After excluding 81 hypothetical genes at 4 hours post tied-ligation, this left 77 differentially 
expressed genes: 33 upregulated and 44 downregulated in tissue undergoing collateral 
vessel development. After excluding 100 hypothetical genes at 12 hours post tied-ligation, 
this left 87 differentially expressed genes: 61 upregulated, 26 downregulated in tissue 
undergoing collateral vessel development. Only 13 genes were differentially expressed at 
both 4 and 12 hours after tied-ligation. These are listed in table 4.1. Although potentially 
playing a role in general vascular remodelling, I chose not to focus on most of these genes 
as I ultimately would focus my efforts on genes that were more specifically altered as a 
result of tied-ligation (i.e. only showed differential expression in the area of collateral 
vessel remodelling). However, the genes in table 4.1 are discussed at the end of this 
chapter. 
 
 
(Gene information from Gene cards www.genecards.org and Ensembl www.ensembl.org) 
Table 4.1; The 13 genes differentially expressed at both 4h and 12h after tied-ligation 
compared with sham-ligation. Blue shows genes downregulated at both timepoints. 
Red indicates genes upregulated at both timepoints. 
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4.5 Hierarchical clustering of genes differentially expressed during collateral 
development 
Large sets of microarray data can be organised into hierarchical clusters using programmes 
such as TreeView (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). Data sets are 
assembled into a tree which indicates the mean expression of the different groups.  
Branches of the dendrogram connect clusters of genes with similar expression changes. I 
used TreeView to cluster genes that were differentially expressed between tied-ligated and 
sham-ligated embryos at 4 hours or 12 hours post-ligation. Data is expressed as expression 
level relative to baseline (unligated, HH st 17). Figure 4.3 shows a dendrogram with genes 
coloured purple if downregulated compared with baseline, or yellow if upregulated 
(intensity proportional to expression). The four columns allow a direct comparison of the 
expression profiles between the four different groups (4 hours sham-ligated, 4 hours tied-
ligated, 12 hours sham-ligated, 12  hours tied-ligated). 
Figure 4.3 A-F show individual clusters of genes with similar expression profiles, separated 
into related nodes. Node A shows genes downregulated during collateral development at 
both 4 hours and 12 hours post-ligation. Node B shows genes whose expression falls after 
sham-ligation but either does not fall as much or is upregulated at 12 hours in tied-ligated 
embryos. Node C shows genes upregulated in sham-ligated embryos at 4 hours. Node D 
genes upregulated at 4 hours post-ligation with very little expression in any other group. 
Genes in node E are generally upregulated in the sham-ligated group at 12 hours, while 
node F shows genes that are upregulated in tied-ligated embryos at 12 hours post tied-
ligation, with little or no expression in other groups. 
To observe the genes that were only expressed at the sites of collateral vessel development 
(with little or no expression in the sham-ligated group) I focussed on genes in nodes D and 
F, and those with most specificity to tied-ligated tissue (little or no expression in baseline or 
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sham-ligated groups). These are indicated by red boxes on Figure 4.3. The known functions 
of these genes are described in table 4.2.  
To confirm differential gene expression, of selected candidate genes identified by the 
microarray, I then went on to perform quantitative real-time polymerase chain reaction 
(QRTPCR). 
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Figure 4.3 Hierarchically clustered heatmaps of  the fold changes of the differentially 
expressed genes during flow-induced vessel remodeling 
 
Data is expressed as fold change from baseline (yellow indicates an increase in 
expression, purple is a down-regulation from baseline). Genes were clustered to describe 
related expression profiles of up or down-regulation at each time-point. Red boxes 
indicate genes specifically expressed at 4h or 12h post tied-ligation.  Red stars indicate 
genes selected for QRTPCR analysis (section 4.6). 
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Table 4.2 Genes specifically expressed during collateral vessel development 4h or 12h 
post tied-ligation 
These genes were differentially expressed in embryos remodelling the vitelline vasculature 
in response to changes in haemodynamic forces, with little or no expression in baseline or 
sham-ligated embryos at either timepoint.  
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4.6 Selection of candidate genes for quantitative analysis by QRTPCR 
From the heatmap clusters (Figure 4.3), 151 genes were identified which were differentially 
expressed in tissue from chicks undergoing collateral vessel development (tied-ligated). To 
select a realistic number of genes with which to perform validation of expression using 
QRTPCR, I chose to examine expression the sub-set of selected genes (boxed region of 
nodes D and F in figure 4.3). These genes were most highly differentially expressed 
between sham-ligated and tied-ligated and therefore I hypothesised that expression was 
likely to be specific to vessels undergoing remodelling. I also investigated genes whose 
known functions made their involvement in collateral vessel development plausible and 
genes that only showed expression either exclusively in tied-ligated or sham-ligated 
embryos. 
To validate the expression profiles observed in the microarray I used QRTPCR to assess 
transcription of the following genes: ADAMTSL1 (node D, boxed region), PDE10A (node D, 
boxed region), MMP9 (node B), STC2 (node F, boxed region), PSCA (node F, boxed region), 
FAT4 (node F, unboxed), IRX4 (node F, unboxed), and CC2D1B (node A). Table 4.3 lists the 
differential expression detected by the microarray and some of the known functions of 
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each gene. However, only 4 primer sets were successfully optimised (section 2.8.3 and 
discussed at the end of this chapter); ADAMTSL1, PDE10A, STC2 and PSCA. Table 4.4 shows 
the QRTPCR results for the four genes whose primers were successfully optimised. The 
QRTPCR results showed similar (though not identical) patterns of differential expression to 
the microarray.  
Of the four candidate genes whose differential expression was confirmed by QRTPCR, 
PDE10A seemed most suitable for further assessment (discussed at the end of this 
chapter). This selection was based on the criteria above, the roles of other PDE family 
members in the vascular system (section 1.15.3) and the availability of reagents that allow 
manipulation of pathways influenced by PDE10A . The next chapter of this thesis focuses 
on the regulation of PDE10A expression and its role during collateral vessel development. 
 
Table 4.3 Relative gene expression in tied-ligated compared with sham-ligated embryos 
in the area of flow-induced vessel remodelling (Red indicates genes whose differential 
expression was confirmed using QRTPCR (primer sets for others could not be optimised) 
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Table 4.4 Comparison of the expression levels detected using microarray analysis and 
QRTPCR. 
 
 
4.8 Discussion 
In this chapter I used microarrays to assess the transcriptional response at two timepoints 
during collateral development in the chicken embryo (Figure 4.1). I clustered the data into 
heatmaps which helped to analyse groups of genes with similar expression profiles (Figure 
4.3). I used the data to identify candidate genes with which to validate expression profiles 
using QRTPCR (Table 4.1). 
My more general aim was to identify genes that were differentially expressed in tissue 
from tied-ligated compared with sham-ligated embryos (section 4.5). The ultimate aim was 
to finally select a gene which was appropriate and relevant for further investigations using 
functional assays in my model, which could be used for assessing a role in flow-induced 
collateral vessel remodelling (section 4.6).  
There were three options to clustering my microarray data into heatmaps. Option 1 would 
be to compare sham and tied-ligated differentially expressed genes in a direct 2-way 
comparison; however, this does not give an idea of expression relative to baseline. Option 
2 would be to compare tied-ligated data from 4 and 12 hours post-ligation directly with the 
baseline measurement; however, this would not reveal information about the gene in the 
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sham-ligated model. These 2 methods have merits but I wished to answer the specific 
question about the differentially expressed genes between sham and tied-ligated models. I 
therefore analysed expression of the genes which were differentially expressed over time 
between sham and tied-ligated models, in terms of relative expression to baseline (Figure 
4.3). 
Before analysing the transcriptional profile of tied-ligated embryos undergoing vessel 
remodelling, it was necessary to first assess the ‘normal developmental’ gene expression 
profile. I therefore first identified genes that were differentially expressed between a 
baseline, uninstrumented measurement (genes expressed at T0), and 4 hours after sham-
ligation. This was repeated for data at 12 hours after sham-ligation. A heatmap of the 
‘normal developmental’ programme can be found in the appendix (Figure A5). This allowed 
me to better interpret and put into context data from the tied-ligated embryos and allowed 
me to confirm that the differentially expressed genes in tissue from these embryos were 
not simply an amplification, delay, or acceleration of the normal developmental 
transcriptional response. 
Comparisons of the heatmaps from the sham and tied-ligated microarrays showed that a 
large number of genes were shared between these two groups (Appendix, table A1 and 
table A2). Some had similar expression profiles, suggesting that these genes were required 
for normal development of the tissue. Some had contrasting expression profiles which 
suggested a need to alter normal developmental signals and react to the tied-ligation and a 
change in flow. These shared genes hold less interest for this study as they may be either a 
result of a delayed expression due to the ligation or an amplification of a normal 
developmental process. I therefore focussed on the genes in the heatmap of the tied-
ligated microarray data which was separated into nodes of genes with most similar 
expression profiles (as had been performed in the heatmap of the sham-ligated data).  
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Although differential expression is neither necessary nor sufficient to confirm a functional 
role in collateral vessel formation, some of these differentially expressed genes may be 
involved in the process. Below are some speculations about how the differentially 
expressed genes I identified in these studies may be related to the process of collateral 
vessel remodelling. However, at this point in my studies I took no position as to whether 
they truly play such a role, particularly as the array data does not allow identification of 
genes specifically expressed in the vasculature. Discussed below are the 13 genes 
differentially expressed at both 4 hours and 12 hours after tied-ligation compared with 
sham-ligation. Some of these 13 genes were expressed in the sham-ligated model and 
therefore, although interesting, did not show a specific response to ligation and may have 
just been an amplification of the normal developmental signal. However, of the three 
transcription factors identified in the table (CC2D1B, ZFPM2, IRX4), two of these were 
expressed specifically in the tied-ligated embryos (CC2D1B and IRX4), indicating that they 
may play specific roles during collateral vessel remodelling. Given what is known about 
collateral vessel development, it is possible to hypothesise what broad mechanisms and 
pathways might be reflected in transcriptional changes. These would include 
mechanotransduction, cytoskeletal rearrangement, vasoregulation, inflammation, 
migration, proliferation, and increased transcriptional activity. Some of these are discussed 
below.  
It could be expected that transcriptional activity would be a common activity to cells 
undergoing remodelling at both 4 and 12 hours post-ligation. For example, Coiled-coil and 
C2 domain containing 1B (CC2D1B) is a transcriptional repressor. In my microarray this 
gene was downregulated in tied-ligated compared with sham ligated embryos at both 4 
and 12 hours post tied-ligation. Little is known of the targets of CC2D1B although it is 
known to negatively regulate expression of the serotonin 1A receptor in brain 
(Hadjighassem et al., 2009). Serotonin exerts a range of vascular effects mediated by the 
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family of serotonin receptors. The serotonin 1, but not the serotonin 2 receptor, has been 
shown to mediate migration of endothelial cells (Matsusaka and Wakabayashi, 2005). 
Although I did not detect upregulation of the serotonin 1A receptor in my array data, it is 
possible that down regulation of CC2D1B enhances vascular sensitivity to serotonin activity 
via effects on receptor expression. Since serotonin positive cells have been shown to be 
present at sites of coronary collateral vessel development in canine models, it would be 
interesting to pursue the effects of serotonin signalling in collateral vessel development, 
especially given the availability of reagents that can block serotonin receptors 
experimentally (Wolf et al., 1998). However, it is possible CC2D1B is a transcriptional 
regulator of other genes within the chick vasculature, including those that influence 
arterial/venous identity or other processes involved in collateral development. Chromatin 
immunoprecipitation of CC2D1B, or microarray comparisons of endothelial cells with and 
without siRNA knockdown of CC2D1B might identify genes that are regulated by this 
repressor and reveal unexpected roles for CC2D1B in vascular development. 
Dipeptidyl peptidase-6 (DPP6) was downregulated at both 4 hours and 12 hours in tissue 
from chicks undergoing collateral vessel development (tied-ligated) compared with sham-
ligated embryos. DPP6 is a peptidase which changes expression of voltage gated potassium 
channels (Xiao et al., 2013). It has been recorded that potassium channels may play a role 
in the endothelial cell mechanotransduction of signals, following changes in blood flow 
(Davies, 1995). It is possible that DPP6 is downregulated during collateral vessel formation 
to allow potassium channels to transduce flow-induced signals inside the cell. To further 
analyse a role for potassium channels in my model of collateral vessel formation, patch 
clamp recordings could be used to measure activity during changes in flow following 
ligation or potassium channel blockers could be used to test if this inhibited collateral 
formation. 
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Titin (TITIN), was also downregulated in tissue from chicks undergoing collateral vessel 
development (tied-ligated) compared with sham-ligated at 4 and 12 hours post-ligation. 
This protein is involved in the structural integrity of cells, including the alignment and shape 
of cardiomyocytes (May et al., 2004). There is evidence from the shrunken-head phenotype 
in mice, which results from a Titin mutation, that suggests this gene also helps endothelial 
cells to maintain their cell shape (May et al., 2004). A downregulation of this structural 
protein may be required for endothelial cells to morphologically adapt to the change in 
flow conditions. 
More specific functions to the process of collateral vessel formation may explain the 
regulation of genes at both timepoints following ligation. For example, E-selectin (SELE) 
was downregulated at both timepoints. SELE is a receptor expressed on activated 
endothelium and plays a role in monocyte adhesion, essential for arteriogenesis (Hoefer et 
al., 2004). This gene may therefore be expected to be upregulated in my model, however 
collateral vessel formation can be selectin independent (Hoefer et al., 2004).  It is also 
possible that this gene was initially upregulated at earlier timepoints but was then 
downregulated to modulate a response and was therefore missed by my timepoints. This 
early response is supported by studies which show a narrow time window for endothelial 
responsiveness to attraction of monocytes during arteriogenesis (Hoefer et al., 2001). 
Further, flow-sensitised HUVECs in vitro show early induction of MCP1 followed by swift 
downregulation and do not show upregulation of SELE at any timepoint (Diamond et al., 
1990). 
Increased signalling may also be expected in an activated cell. Regulator of G protein 
signalling (RGS7), was downregulated at both timepoints. The reason for this may be that 
RGS7 inhibits signal transduction via G proteins. For example, RGS7 may be downregulated 
to relieve its inhibitory effect on signalling pathways or transcription factors which have 
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been stimulated by external factors such as inflammation (Winsauer and de Martin., 2007) 
or changes in flow. We can speculate that RGS7 may usually prevent signals which 
determine cell fate, such as an endothelial cell adopting an arterial fate. Its downregulation 
may therefore lead to cells becoming arterial during collateral vessel formation. 
Formin homology protein (FHOD3) was downregulated at both 4 and 12 hours in the tied-
ligated model. FHOD3 has been found to be involved in actin organisation. This was 
observed in cardiomyoctes of the heart (Taniguchi et al., 2009). Growth-arrest specific 2 
(GAS2) was upregulated at both timepoints post-ligation. Phosphorylation of GAS2 has 
been shown to result in the reorganisation of the actin cytoskeleton in mouse fibroblasts. It 
is possible that this gene may have a similar role in organising the cytoskeleton in activated 
endothelial cells (Brancolini and Schneider., 1994). Considering the strong implications that 
the cytoskeleton is important to mechanotransduction of flow-induced signals in activated 
endothelial cells of collateral vessels (Helmke and Davies., 2002), it would be interesting to 
further investigate genes related to the cytoskeleton and actin organisation in my model. 
Another cellular function which may be required at both timepoints following ligation and 
changes in flow is increased cell communication to allow endothelial cells to coordinate a 
response to changes in flow. Collagen type VIII, type 1 (COL8A1) was also upregulated at 
both timepoints and is thought to be involved in forming gap junctions and maintaining the 
structure of the endothelial cell (May et al., 2004). Gap junction proteins have been 
implicated in endothelial responses to flow. Connexin 40 (Gja5) has been identified in chick 
and mice collateral vessels and found to be involved in flow-induced arterial remodelling 
(Buschmann et al., 2010). 
It is possible that some genes which showed similar expression profiles at both timepoints 
may determine endothelial cell characteristics important to the formation of collateral 
vessels such as regulating an arterio/venous identity. Iroquois homeobox gene (IRX4) was 
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upregulated at 4 and 12 hours post ligation. IRX4 is a transcription factor which activates 
gene transcription and may regulate other key genes (Hatcher and Basson, 2009). 
Conversely, zinc finger protein (ZFPM2) was downregulated at both timepoints and acts 
with GATA genes to also regulate gene expression. IRX4 has been found to be involved in 
patterning chambers of the heart in development (Bruneau et al., 2000). ZFPM2 has been 
shown to be involved in patterning the valves of the developing heart (Tan et al., 2012). 
Although there is little other information in the literature about these two genes and their 
roles in an endothelial context, it is possible that due to their involvement with gene 
transcription, they may be involved with regulating endothelial cell change of fate during 
collateral vessel formation. For example IRX4 may promote arterial fate and is therefore 
upregulated, whilst ZFPM2 may work to inhibit an arterial fate and is downregulated. 
Sperm antigen with calponin homology and coiled-coil domains 1-like, (SPECC1L) was 
upregulated at both timepoints. This cytoskeletal, structural protein is involved in actin 
cytoskeleton re-organisation (Saadi et al., 2011). This gene has been suggested to also play 
a role in cell migration and adhesion which may have implications for endothelial cells in 
contributing to collateral vessel formation in my model and could be further analysed with 
in vitro studies. 
It is likely that some genes were expressed at both timepoints to carry out generic 
functions required by an activated endothelial cell, for example, Solute carrier (SLC35B3) 
which was upregulated at 4 and 12 hours post-ligation. It is likely that increased solutes, 
including amino acids, glucose and signalling molecules would be required for the increased 
metabolic needs of the activated cell, and for functions such as phosphorylation of proteins 
or cross-talk between signalling pathways (Mann et al., 2003). 
Junctophilin 1 (JPH1) was upregulated at both 4 and 12 hours in the tied-ligated model. 
Junctional proteins may be involved in mechanotransduction (Davies, 1995).  Junctophilins 
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are important components of junctional complexes which mediate cross-talk between the 
cell surface and intracellular ion channels (Takeshima et al., 2000). Junctional complexes 
allow direct exchange between neighbouring cells of signalling molecules or electrical 
signals to allow cells to communicate and adapt to changes such as alterations in 
haemodynamic forces (Haefliger et al., 2004, Wagner., 2008).  
Although genes differentially expressed at both timepoints are interesting, data from 
Chapter 3 showed that the processes occurring post-ligation are complex. There are 
regressing vessels as well as remodelling vessels in the tissue of interest which rely on 
complex signalling. I therefore needed a stringent selection process to identify genes most 
likely to be relevant and only expressed in collateral vessels. The most relevant portion of 
the heatmap was therefore a sub section of genes exclusively expressed at 4 or 12 hours 
post-ligation (boxed regions in Figure 4.3). These genes were either not expressed or 
expressed at very low levels in sham-ligated embryos. Clearly, these stringent requirements 
exclude many genes that may be relevant to collateral development but the number of 
genes differentially expressed in embryos undergoing flow-induced vascular remodelling 
(Figure 4.3) prevented investigation and discussion of all of these individually.  
Some of the genes which showed more specific upregulation at 4 hours (node D) or 12 
hours (node F) in the microarray shall now be discussed in an attempt to interpret 
expression profiles in the context of collateral vessel remodelling; they are  discussed 
speculatively and would require further experiments to determine their actual role in the 
process.  
In node D, genes of interest within this node (i.e. upregulated in tied-ligated at 4hours 
only), could play a role in activated endothelial cell signalling. Claudin 11 (CLDN11) is 
involved in tight junctions (Morita et al., 1999) which have been reported to be involved in 
endothelial cell response to changes in flow (Davies, 1995). Discs-large homolog 2 (DLG2) is 
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a variant of discs-large protein which plays a role in cell proliferation and cell polarity of 
smooth muscle cells (Mahoney et al., 2006).  DLG2 may play a role in endothelial cell 
orientation during changes in flow. Interestingly FAT4, another polarity molecule (Saburi et 
al., 2008) was upregulated in the microarray at 4 hours post tied-ligation (node F). A 
Disintegrin And Metalloproteinase with Thrombosponidn Motif- like1 (ADAMTSL1) was 
upregulated. Other studies have shown that ADAMTSL1 may facilitate cell-matrix 
interactions (Hirohata et al., 2002). Upregulation of Adhesion Molecule with Ig-like domain 
2 (AMIGO2) may also suggest a role in collateral vessel formation; as discussed previously, 
adhesion molecules are known to play a role in arteriogenesis (Hoefer et al., 2004, Hoefer 
et al., 2001). Finally, PDE10A was also upregulated. PDE10A is known to degrade cAMP and 
cGMP and has been shown to play a role in pulmonary vascular remodelling (Tian et al., 
2011). As a note of interest, Adenylate cyclase activating polypeptide 1 (ADCYAP1) was 
downregulated in group C. This polypeptide increases levels of cAMP which is a molecule 
involved in signal transduction. cAMP is discussed later in the context of vessel remodelling 
in my model in chapter 5. 
Node F shows the genes which are upregulated at 12 hours post-ligation. A Disintegrin And 
Metalloproteinase with Thrombosponidn Motif 8 (ADAMTS8) disrupts angiogenesis 
(Campbell et al., 2010) and may be necessary for arteriogenesis to occur. Interleukin 12B 
(IL12B) is a cytokine that has been studied in tumour biology and has been found to inhibit 
angiogenesis (Lee et al., 2002). A Disintegrin And Metalloproteinase with Thrombosponidn 
Motif like-3 (ADAMTSL3) is involved in MMP activity (Porter et al., 2005); as discussed 
before, ECM breakdown is an important feature of collateral vessel formation. Sperm 
Antigen with Calponin homology and Coiled-coil domains (SPECC1L) regulates actin 
cytoskeleton rearrangement (Saadi et al., 2011) and may therefore be important in 
endothelial mechanotransduction of a flow-induced signal or a change in cell shape due to 
changes in flow. 
176 | E m i l y  C l a r e  H o g g a r  
 
Known flow responsive regulator of endothelial gene expression, Klf2, (Dekker et al., 2006) 
was a gene which I expected to see differentially expressed in tied-ligated compared to 
sham-ligated tissue, but was not detected. I had also previously detected nrp 1 and nrp2 
RNA transcripts in the area of flow-induced remodelling using whole mount in situ 
hybridisation in Chapter 3 (Figure 3.18). In the microarray data nrp1 and nrp2 are 
expressed, but show uniform levels of expression across timepoints in tied and sham-
ligated embryos. I suggest that these genes might be highly dynamically regulated and that 
expression of these genes is exquisitely sensitive to haemodynamic forces. In this model it 
is possible that sustained haemodynamic forces are required to reveal or maintain 
expression profiles. In the time taken to dissect the tissue for the microarray, this exquisite 
regulation could be lost. Future experiments could be designed to test this. By excising 
small pieces of tissue from the area of collateral vessel formation at the two timepoints and 
performing whole mount in situ hybridisation expression of these two genes could be 
compared to the results in Figure 3.18. In support of this idea, ongoing studies in the lab of 
Professor Marysia Placzek show that cell cycle regulated genes are dynamically regulated. 
Unless the tissue being investigated is fixed within one minute, expression patterns of cell 
cycle genes are lost (Placzek et al. data unpublished). Such dynamic maintenance could 
explain why other markers I expected to see in the microarray did not appear, but clearly 
more experiments are needed to test this theory.   
Dynamic regulation does not account for all examples where flow-sensitive genes were not 
detected and could be explained instead by the timepoints selected. It was obvious that 
between 4 and 12 hours many temporal changes in gene expression occurred. Shear stress 
responsive genes have a small window of expression (Resnick and Gimbrone, 1995). 
Previous microarray data has shown that certain shear stress responsive genes are 
expressed with an early elevation which quickly returns to baseline. This includes genes 
such as c-jun, PDGF-B, MCP1,TGF-B, bFGF and ICAM1. Genes such as endothelin 1 and 
177 | E m i l y  C l a r e  H o g g a r  
 
thrombomodulin have been seen to briefly increase expression, then become significantly 
downregulated during the shear stress response (Resnick and Gimbrone, 1995). Other 
studies in mice have shown distinct phases of gene expression during collateral 
development which have been divided into early induction, mid-phase induction and late-
phase induction (Lee et al., 2004b). Early induced genes include transcription factors, 
followed by genes involved in angiogenesis and inflammation as well as stress-related 
genes. Mid-phase includes genes involved in cell cycle and cytoskeleton regulation and 
inflammation genes. Late-phase includes genes associated with anti-inflammatory and 
extracellular matrix effects (Lee et al., 2004a). This data suggests that one reason I did not 
see differential expression of these predicted genes is that my timepoints may have missed 
temporally expressed ‘shear stress’ genes (including Klf2). To test this earlier timepoints 
could have been analysed or endothelial tissue extracted from the proximal vitelline vessels 
where shear stress is highest. Despite this, my data did show evidence of key genes such as 
ECM remodelling MMPs, inflammatory genes, certain adhesion molecules and genes 
involved in cytoskeletal rearrangement, all known to be involved in arteriogenesis in 
mammalian models (Lee et al., 2004a). This suggests that certain processes involved in 
flow-induced remodelling are universal to species and a requisite for successful 
remodelling. 
Another reason for the lack of shear stress responsive genes observed in the microarray 
data could be due to species as it cannot be ignored that the chick has a different vessel 
architecture to that of mammals (as discussed in Chapter 3). Further, this relates to the 
different flow profiles the chick embryo extra-embryonic collateral vessels experience 
compared to that in mammalian models. Different flow profiles are known to activate 
different genes (Chiu et al., 2009). It has also been shown that the surrounding cellular 
environment can effect gene transcription in flow-treated cells. For example, Chiu et al., 
(2009) showed the different expression profiles of flow treated endothelial cells when 
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cultured next to either smooth muscle cells or fibroblasts. The cells were separated by a 
porous membrane in a parallel flow chamber and received either shear stress induced 
levels of flow or remained static. In the shear stress environment, smooth muscle cells 
were found to inhibit endothelial expression of adhesion molecules such as ICAM1, VCAM1 
and E selectin. The authors concluded that smooth muscle cells regulate shear stress 
induced genes in endothelial cells (Chiu et al., 2009). As the chick embryo collateral vessels 
do not contain smooth muscle at this stage, endothelial cells would not be regulated in this 
way and therefore may express different genes. 
The microarray was performed using heterogeneous tissue from the chick model, 
containing ectoderm and endoderm as well as blood vessels. Sham-ligated tissue was 
extracted from the same region to correct for any changes in gene expression which were 
not driven by, or not effected by, flow. However it is possible that gene expression profiles 
may not have been exclusively endothelial and may therefore have masked endothelial 
shear stress responses.  
Although some of the ‘expected’ arteriogenic genes were not detected in my array, I 
believed that the results of the transcriptional analysis could provide a useful platform to 
discover novel genes involved in collateral vessel formation. To select candidate genes for 
validation of the microarray I prioritised analysis of genes based on the following criteria: 
only expressed in the area of collateral vessel remodelling (boxed regions of nodes D and 
F); a known function related to vessel remodelling in the literature; easily investigated 
pharmacologically with in vivo study; those with high enough expression that they could be 
detected by QRTPCR. Based on these criteria, genes were selected to take forward to the 
validation stage using a second, QRTPCR technique, to confirm the expression profiles 
observed in the microarray and identify a gene to investigate in vivo. 
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Four genes were successfully optimised for QRTPCR and which reflected expression profiles 
observed in the microarray. A disintegrin and metalloproteinase with thrombospondin 
motif (ADAMTSL1), phosphodiesterase 10A (PDE10A), stanniocalcin 2  (STC2) and prostate 
stem cell antigen  (PSCA). ADMATSL1 and PDE10A could be found in the boxed region of 
node D, suggesting specific upregulation in collateral vessel tissue at 4 hours post tied-
ligation. STC2 and PSCA were found in the boxed region of node F, suggesting a specific 
upregulation in collateral vessel tissue at 12 hours post tied-ligation. I selected a gene to 
take forward into functional analyses which were necessary to further validate gene 
expression in the context of collateral vessel formation. 
I chose not to pursue studies into ADAMTSL1 expression as this gene had already been 
investigated for an involvement in vessel remodelling due to its role in the extra-cellular 
matrix (Jonsson-Rylander et al., 2005). Therefore it was a likely possibility that ADAMTSL1 
was enabling collateral vessel development in my model and so did not offer an 
opportunity to identify a novel contribution to the field.   
PDE10A had not previously been investigated in the remodelling vasculature. Since 
beginning my studies on PDE10A Tian et al., (2011) published a role for PDE10A in 
pulmonary vascular remodelling and linked levels of cAMP to vascular smooth muscle cell 
proliferation (Tian et al., 2011). However, this did not explain the up-regulation of PDE10A 
in the chick model during the early phase of collateral vessel growth in the area of extra-
embryonic vasculature, which lack smooth muscle and apparently show little need for cell 
proliferation.  An interesting possible interaction between PDE10A’s degradation of cAMP 
and flow-induced remodelling is implied by White (White et al., 2011). This group used 
transcriptomics and functional assays to compare HUVECs exposed to laminar shear stress 
(15dynes/cm2) with elevated shear stress (75dynes/cm2). Both flow profiles regulated 
different gene expression profiles. In this study ATF transcription factors, which are highly 
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enriched in shear responsive genes, were regulated by levels of cAMP which fluctuated as a 
result of shear stress. Further, shear induced changes reduced cAMP levels. cAMP activity 
(and PKA activation) usually causes ATF4 (which can be an activator or a repressor of 
transcription) to repress gene transcription. Reduced cAMP (and PKA activity) increased 
ATF4 gene activation. Interestingly, ATF4 binding sites are enriched in genes upregulated in 
elevated shear stress (White et al., 2011). This study provides an intriguing link to PDE10A’s 
up regulation and function (to reduce levels of cAMP), to the role PDE10A may play in flow-
induced vessel remodelling in the chick embryo. 
STC2 was another interesting gene. STC2 has recently been investigated in vascular biology 
in the cancer field (Chang et al., 2003, Buckanovich et al., 2007). STC2 transduction by 
lentiviruses into HUVECs showed increases in cell cycle regulators, MMPs and junctional 
proteins like Ve-cadherin. STC2 was also found to mediate VEGF pathways. Once again, for 
functional validation of expression and investigative experiments, lentiviral transfections 
and in vivo studies in the chick would have been difficult. It was therefore logical to begin 
with investigations into PDE10A, as this was an enzyme with inhibitors readily available. 
Other technical considerations directed my choice of focus on particular candidate genes . 
PSCA encodes a glycoprotein and has never been associated with the remodelling 
vasculature. To investigate its functional role in my model, agents which would block PSCA 
function such as blocking antibodies would have to be designed or genetic studies to 
silence the gene would be required which were not possible at the time.  
I chose to pursue functional studies to investigate a role for PDE10A expression in collateral 
vessel formation. This was a gene that was highly expressed at 4 hours post-ligation. 
Pharmacological inhibitors were readily available to investigate the effect of PDE10A 
inhibition on collateral vessel formation 
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Microarrays provide a powerful tool for the analysis of a whole genome transcriptome. This 
approach can be used to examine the transcriptional profile induced by a treatment or 
disease state (Duggan et al., 1999). However, although microarrays have provided a means 
to identify novel mechanisms of disease or potential therapies, limitations of using this 
genetic profiling technique cannot be ignored. 
In both microarray and QRTPCR technology, technical limitations exist however, these can 
be diminished by a number of factors: template quality and variability; flaws in 
protocol/assay design and optimisation steps; ineffective data normalisation, which all 
effect results (Dallas et al., 2005, Morey et al., 2006). Control parameters correct for these 
factors and are now widely used as standard procedure: biological and technical replicates; 
use of probabilistic or statistical approaches (Liu et al., 2005); standardised calculations 
such as 2-∆∆ct (Nolan et al., 2006) and careful selection of a non-fluctuating housekeeping 
gene. 
Although the validation of my candidate genes did support the expression profiles in the 
microarray, there were differences in the relative amounts of gene expression. This may be 
partly explained by cross hybridisation of microarray probes binding to related sequences, 
which mask true expression levels (Rajeevan et al., 2001). Sample quality at the time of 
QRTPCR analysis may have degraded compared to when the microarray was conducted. 
Other contributing factors may be amplification errors and mis-priming, which leads to 
primer dimers affecting QRTPCR results (Rajeevan et al., 2001). I attempted to check and 
decrease the amount of error. The samples were checked for quality first by nanodrop and 
then by the RNA Integrity Number (RIN) which is assessed by a computer algorithm. I chose 
to have 3 biological replicates per sample and ensured that each sample was of a similar 
quality and yield. The microarray itself consisted of a chip with many copies of the same 
PM/MM probes which reduced error. PUMA analysis also increased integrity of results by 
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using computer algorithms and normalisation to increase accuracy of probe level data. 
QRTPCR was performed with primers optimised for temperature, cDNA concentration and 
primer concentration. 3 biological replicates were run to increase accuracy of results and 
reduce pipetting error. Technical runs were repeated to ensure reproducibility. To extract 
fold change data from the results a well characterised formula was applied to the ct value 
data (delta delta ct method (Nolan et al., 2006). Despite differences in gene expression 
levels, the gene expression profiles observed in the microarray were reproducible with 
QRTPCR at both 4 hour and 12 hour timepoints for PDE10A, ADAMTSL1, STC2, PSCA. This 
gives me confidence that these genes are regulated by flow in the chick embryo model.  
It is important to recognise that important mediators of collateral vessel development may 
not be transcriptionally altered, or that the complex nature of the tissue and processes 
involved could mask real changes in gene expression  (Kerr et al., 2000).  There are 
different approaches to extracting relevant data from the large datasets (Duggan et al., 
1999). There is some discrepancy over the best method of estimating probe level data to 
select differentially expressed genes, which include: implementing fold change limits 
(Duggan et al., 1999); cut offs determined by P-values (O'Donovan et al., 2008) or 
probabilistic approaches which asses PPLR (Milo et al., 2003). Analysis of our microarray 
data was conducted using PUMA to identify the PPLR value for each gene. This probabilistic 
approach accounts for variance between chips and samples and error at the probe level 
and has been found to improve detection of differentially expressed genes (Liu et al., 
2005).  
Future work 
Future work could include performing the microarray on the collateral vessel tissue at a 
wider range of timepoints. Collateral vessels could attempt to be isolated from surrounding 
tissue with a Dispase enzyme that might make the results more specific. A microarray could 
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be performed more proximally to the chick. For example, a microarray on tissue extracted 
from the unligated proximal vitelline artery immediately following contralateral artery 
ligation might show regulation of more specifically flow-responsive genes.  
 
In conclusion, my study revealed a number of interesting, novel differentially expressed 
genes, some of which appeared to be both temporally regulated and/or flow-regulated. A 
number of the genes which differentially expressed between sham and tied-ligated 
embryos at both 4 and 12 hour timepoints included those involved in the structure of the 
cell or the cytoskeleton. There were also many shared genes involved in cell 
communication and signalling, which could be expected due to the complicated 
coordination of events involved in the endothelial response to changes in flow. 
The next chapter focuses on the functional role of PDE10A, to attempt to uncover a 
functional role for this gene in flow-induced vessel remodelling 
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Chapter 5 
Examining the role of phosphodiesterase 10A in collateral vessel 
development 
 
Summary 
In this chapter I examined the transcriptional regulation of PDE10A in flow-treated HUVECs 
in vitro and confirmed expression of PDE10A protein in the area of collateral vessel 
formation in the chick embryo. I used pharmacological assays to show that PDE10A is 
required for flow-induced vessel remodelling. This effect could be rescued by blocking the 
downstream effects of PDE10A inhibition. 
The aims of this chapter were; 
 To confirm expression of PDE10A in endothelial cells in vitro and to determine 
whether this is affected by altered fluid forces 
 To determine the temporal and spatial  expression of PDE10A protein in the extra-
embryonic vitelline vasculature during flow-induced remodelling in the chick 
 To establish the effect of pharmacological inhibition of PDE10A on flow-induced 
remodelling 
 To examine mechanisms whereby PDE10A may influence flow-induced remodelling 
 
5.1 The effect of altered flow on PDE10A expression in human endothelial cells 
My microarray data suggested PDE10A is upregulated at the site of collateral vessel 
development, an upregulation which I considered most likely to be in endothelial cells in 
response to altered blood flow. I therefore wished to confirm that endothelial cells express 
PDE10A and that this expression changes under conditions of altered flow. 
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I therefore examined PDE10A expression in human umbilical vein endothelial cells (HUVEC, 
the endothelial cell line most commonly used and available in my department). PDE10A 
expression was quantified by QRTPCR on RNA from HUVECs extracted from 7 different 
umbilical cords (Section 2.9). HUVECs were either cultured in static conditions or on an 
orbital shaker. In the plates on the orbital shaker, cells in the centre of the well are exposed 
to disturbed flow, while those at the periphery are exposed to non-disturbed flow (Dardik., 
2005). The cells in the centre display a ‘cobblestone’ appearance with high levels of 
proliferation whereas cells at the periphery have an elongated shape and align with the 
direction of flow with little proliferation (Dardik., 2005). Endothelial cells exposed to 
different flow patterns have been shown to express different genes based on an 
atheroprotective or atheroprone requirement (Partridge et al., 2007). 
I detected PDE10A mRNA in all HUVEC samples, confirming my hypothesis that endothelial 
cells express this gene. PDE10A mRNA expression was significantly higher in cells at the 
periphery of wells exposed to orbital shaking compared with either cells exposed to static 
conditions (p=0.02) or cells in the centre of the same wells (disturbed flow) (p=0.03) (Figure 
5.1). This data suggested that PDE10A expression in HUVECs is regulated by altered flow. 
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Figure 5.1 PDE10A gene expression in flow treated or static HUVECs 
HUVECs extracted from 7 different umbilical cord veins were cultured in 6 well plates to 
~400,000 cell density. Following orbiting QRTPCR was performed on extracted RNA. 
(n=6) Relative fold change was calculated using the delta Ct equation. Ct of each sample 
was normalised to a non-flow responsive housekeeping gene A. shows QRTPCR results 
from HUVECs exposed to disturbed (centre) or non-disturbed (periphery) flow for 72 
hours in culture. PDE10A mRNA was upregulated in cells exposed to non-disturbed flow 
at the periphery compared to cells at the centre. QRTPCR was performed on 2 
occasions, Unpaired Student’s t-test  p=0.03  B. Expression of PDE10A in HUVEC 
cultured under static conditions or at the periphery of wells on orbital shaker. QRTPCR 
was performed on 2 separate occasions) Unpaired Student’s t-test p=0.02 (∆∆ct 
calculated as described in Section 2.8.8) 
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5.2 Temporal analysis of PDE10A protein expressed in the area of flow-induced 
vessel remodelling 
In the previous chapter I showed by microarray and QRTPCR that PDE10A mRNA is 
upregulated during collateral vessel development 4 hours after ligation. This did not 
confirm whether PDE10A protein was upregulated, as some mRNA transcripts are not 
translated into proteins (Jayapal and Melendez, 2006). I therefore performed Western 
blots on protein lysates extracted from the area of collateral vessel formation in ligated and 
sham-ligated chicks (Section 2.20), to analyse PDE10A protein expression in groups of 
pooled embryos, across different timepoints, including those used in the microarray. 
Figure 5.2 shows a representative blot (n=3) of PDE10A protein expression at the site of 
collateral development at 4, 8, 12 and 24 hours in sham or tied-ligated embryos. Although 
PDE10A is expressed in the testis and brain it is also expressed in the heart (Bender and 
Beavo, 2006). I therefore used chick embryo heart tissue from the same stage (HH st 17) as 
a positive control to confirm PDE10A protein expression.  
The blot shows a number of different bands. This is most likely to be due to the non-
specific nature of a polyclonal antibody and unfortunately, due to cost it was not possible 
to purchase a second, more specific antibody. PDE10A has a molecular weight of 95kDa. 
There were two bands at the correct protein size for PDE10A, one of which was also 
detected in the positive control tissue. The top band was the band of interest (as shown in 
the positive heart tissue, indicated by the arrow at 95 kDa). The presence of two bands may 
be due to post-translational modification such as phosphorylation or glycosylation. It is 
possible that there are more than one isoform of PDE10A although there is only 1 predicted 
splice variant of the gene in the Gallus gallus species, according to Ensembl  
(http://www.ensembl.org/Gallus_gallus/Gene/Evidence?db=core;g=ENSGALG00000011537;r=3:42463951-
42626252;t=ENSGALT00000018810). 
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Figure 5.2 Western blot analysis of tissue dissected from the area of flow-induced 
remodelling at different timepoints following sham or ligation surgery shows up-
regulation of PDE10A protein during early time-points in tied-ligated embryos 
 
A HH st 17 embryo. The black box at the posterior midline of the embryo shows the 
area from which protein lysates were extracted for analysis. B PDE10A protein 
expression appears upregulated in ligated tissue compared to sham at both 4 and 8 
hours post-ligation. At 12 and 24 hours, PDE10A expression appears downregulated 
in tied-ligated embryos. Black box indicates bands that show PDE10A protein up-
regulation at early timepoints in tied-ligated embryos, compared to sham-ligated 
embryos. PDE10A protein is recognised at the top band at 95kDa which is expressed 
in positive control heart tissue. Actin loading controls are below the PDE10A blot. 
Actin is recognised by a band at 42 kDa. In each group, lysates from 8 embryos were 
used and experiment performed three times. An unstained Precision Plus Protein 
Standard ladder was used to identify molecular weights. 
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This PDE10A protein data reflected the PDE10A mRNA expression profiles observed in the 
microarray (table 4.4). Having confirmed that PDE10A protein was also upregulated in the 
area of collateral vessel development 4 hours after ligation, I next wanted to test whether 
PDE10A protein could be detected in the vessels themselves.  
5.3 Immunohistochemistry for PDE10A in proximal vitelline and developing 
collateral vessels 
In the microarray, PDE10A mRNA expression was detected in a heterogeneous sample of 
extra-embryonic tissue (area of collateral vessel remodelling). I therefore next used 
immunohistochemistry to attempt to detect expression of PDE10A at a more specific 
resolution. 
I used the same PDE10A antibody as for my Western blot analysis and optimised the 
concentration for immunofluorescence (section 2.17). PDE10A has not before been 
investigated in chick in the literature, but in the mouse, expression is highest in the brain 
and testis (Omori and Kotera, 2007). I therefore first tested the PDE10A antibody in mouse 
brain tissue sections, over a range of concentrations, to act as a positive control (Appendix, 
Figure A9). A concentration of 1:500 was found to give optimal labelling on mouse tissue. 
Recognising that the antibody was not designed against mouse tissue I therefore also 
tested the antibody on chick brain tissue (Appendix, Figure A10). Sections were taken from 
chick embryo brain tissue at the same stage as my experimental stage embryos (HH st 17) 
and tested over the same range of concentrations. In fact, a concentration of 1:250 was 
found to be optimal for labelling chick tissue (Appendix figure A10). 
VE-cadherin was used as a positive control for endothelial cells (following analysis in 
section 3.6.1, Figures 3.14 -3.16). Tissue incubated with no primary antibody and a 
secondary antibody alone acted as a negative control to check that the secondary antibody 
had specifically bound to the primary antibody. Dual labelling of PDE10A and VE-cadherin 
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was not possible since both primary antibodies were raised against the same species. 
Adjacent sections were therefore separately labelled to detect PDE10A and VE-cadherin 
proteins. Serial sections through the area of collateral vessel remodelling were cut to a 
thickness of 12m to allow the adjacent cells to align to approximate PDE10A expression 
and location.  
I examined PDE10A protein expression in the area of collateral vessel development 4 hours 
after ligation (Figure 5.3). I hypothesised that I would detect PDE10A expression in the 
collateral vessels at early time-points, given the microarray and QRTPCR validation data. 
Figure 5.3 shows preliminary evidence of PDE10A protein expression in collateral vessels at 
4 hours post-ligation. A punctate expression pattern of PDE10A labelling was detected in 
regions which expressed VE Cadherin in adjacent sections (Figure 5.4). PDE10A punctate 
expression patterns have been observed before in striatal neurons (Nishi et al., 2008). I did 
not examine tissue from sham-ligated tissue as there are very few vessels in this region at 
the midline, making comparisons to sham-ligated embryos, difficult. 
Taken together with my results from the western blotting, my immunohistochemical data 
suggest that PDE10A protein expression is increased in the area of collateral vessel 
development, and that this is localised closely to VE-cadherin positive structures, i.e. blood 
vessels. I cannot conclude from the histology that these blood vessels are collateral vessels, 
although since sham-ligated vessels possess very few vessels in this area at this timepoint, 
this does appear likely. 
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Figure 5.3 PDE10A can be detected by immunohistochemistry in the collateral vessels 4 
hours post tied-ligation 
 
A Representative micrograph of HH st 17 embryo. Boxed region indicates area of tissue 
dissected for immunohistochemistry. B Brightfield image of a cross-section of tissue 
taken from the boxed area in A. Arrows indicate possible collateral vessels within the 
tissue. C Confocal image of PDE10A immunofluorescent labelling of cross-sectioned 
tissue containing  collateral vessels. D shows adjacent section and VE-cadherin labelling. 
E shows adjacent section and secondary antibody only as negative control. All tissues 
were labelled with DAPI. (n=20 not including those used in optimisation, section 2.17) 
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Figure 5.4 Higher magnification images revealed punctate staining patterns of PDE10A 
labelling 
 
A High power image of a section through the extra-embryonic tissue in the area of 
collateral vessel formation showing DAPI labelling. B Split channel of the same section 
showing PDE10A labelling. C Merged image showing PDE10A and DAPI labelling of the 
tissue. 
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5.4 Investigating the effect of PDE10A inhibition on collateral vessel formation  
I next wanted to test whether PDE10A plays a role collateral vessel formation in the chick 
embryo. Papaverine hydrochloride is the most potent and widely used PDE10A inhibitor, 
although it is also able to inhibit other PDEs with lower affinity (Siuciak et al., 2006a). It is 
used clinically (topically during vascular surgery) as a vasodilator, due to its effects on 
vascular smooth muscle (Evans et al., 1997, Gherardini et al., 1998). 
I hypothesised that papaverine application to the site of flow-induced remodelling would 
inhibit PDE10A function and thus impair collateral vessel formation. Filter paper discs were 
a suitable drug delivery mechanism (Section 2.21). For all pharmacological assays, discs 
were positioned over the midline vitelline veins at the site of collateral vessel development 
at the anterior and posterior poles of the HH st 17 embryo (Figure 2.5). Drugs were tested 
on 6 embryos per group with experiments repeated on separate occasions to test 
reproducibility. Concentrations of papaverine were selected based on previous studies. 
Tian et al. (2011) used papaverine to assess the effect of PDE10A  inhibition on pulmonary 
remodelling in hypertensive rats (as described in section 1.16.1) and used a concentration 
of 25M  (Tian et al., 2011). I therefore used this as a starting point and tested a range of 
concentrations from 5-20M, hypothesising that the chick would tolerate a reduced 
concentration compared to the mouse. 
5.5 The effect of papaverine on normal vitelline vessel development 
I wished to establish the effect of papaverine treatment on normal vessel development to 
see if it was toxic, or inhibited all vessel formation. I applied papaverine to the proximal 
vitelline vessels whilst the vasculature was still forming, at an earlier stage (HH st 15) to 
embryos that underwent ligation in previous studies (HH st 17). Filter paper discs soaked in 
papaverine or PBS were positioned over the vitelline vessels, lateral to the embryo body. 
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The vitelline vessels were imaged 24-28 hours following application of papaverine or PBS 
(Figure 5.5A).  
The mean diameter of the control treated vitelline vessels was 233+16m. The mean 
diameter of vessels treated with 20M papaverine was 302m+ 47 (p=non-significant). 
Heart rate of the embryos was also not affected by papaverine application (Figure 5.5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.5 PDE10A inhibition was not toxic to HH st 15 embryos and did not affect the 
diameter of developing proximal vitelline vessels 
 
Papaverine was applied to the developing left and right proximal vitelline vessels at HH 
st 15 for 24h. After 24 hours discs were removed and vitelline vessel diameter 
quantified. A Papaverine did not significantly affect the diameter of vitelline vessels 
compared to PBS. B Papaverine did not adversely affect heart rate of embryos (n=12 
per group) 1 way ANOVA with Dunnett’s multiple comparisons test. 
 
195 | E m i l y  C l a r e  H o g g a r  
 
5.6 Inhibition of PDE10A reduces collateral vessel diameter but does not affect 
collateral vessel number 
I next applied filter paper discs of papaverine or PBS to the extra-embryonic tissue at the 
site of subsequent collateral vessel development (HH st 17, Figure 5.6A) immediately 
following sham or tied-ligation surgery, for 24 hours (as described in section 2.21). After 
this time discs were removed and vessels beneath imaged (method explained in section 
2.24).    
Figure 5.6B shows the number of collateral vessels at the midline 24 hours after ligation in 
chicks treated with filter paper discs loaded with PBS, 5M, 10M, or 20M papaverine. 
Although there was a trend to an increase in collateral vessel number in the 5M treated 
group, there were no significant differences between any group and PBS. 
Figure 5.6C shows the diameter of the collateral vessels in the same chicks. I found that 
papaverine treatment statistically significantly reduced collateral vessel diameter in all 
concentrations, in a concentration-dependent manner. This led to a similar reduction in 
total cross sectional area of collateral vessels in papaverine treated embryos (Figure 5.6D). 
Figure 5.7 shows representative micrographs of the area of collateral vessel formation 
following PBS or papaverine treatment, 24 hours post-ligation. In PBS treated chicks, 
collateral vessels appeared quite large and red, and extend from left to right across the 
midline. With increasing concentrations of papaverine collateral vessels reduced in size.  
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Figure 5.6 PDE10A inhibition significantly impaired collateral vessel formation after 24 
hours tied-ligation 
 
Papaverine was applied at the anterior and posterior poles of HH st17 embryos over the 
area of collateral vessel formation immediately post tied-ligation. After 24h collateral 
vessel number and mean diameter were quantified: A Representative 
photomicrographs of the position of the filter paper discs at the poles of the embryo for 
both papaverine and PBS treated embryos. Black box indicates sites of collaterals B 
Effect of papaverine on collateral vessel number, no significant differences between PBS 
and any concentration of papaverine C Effect of papaverine on collateral vessel 
diameter D Effect of papaverine on total cross-sectional area of collateral vessels after 
(n=12 per group). 1 way ANOVA with Dunnett’s multiple comparisons test. *=0.05, 
**=0.001, ****<0.0001 
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Figure 5.7 Representative micrographs show that PDE10A inhibition impairs collateral 
vessel development after 24 hours at the anterior and posterior poles of the embryo 
 
Embryos received right proximal vitelline vessel tied-ligation and either PBS, 5, 10, 20 
M doses of papaverine on filter paper discs at anterior and posterior poles, over the 
area of collateral vessel formation, for 24h. Representative photomicrographs (as 
shown here) were analysed to assess the effect of papaverine on collateral vessel 
formation (described in section 2.24 and Figure 5.6). Increased concentrations of 
papaverine increasingly impaired collateral vessel formation at both poles of the 
embryo. When shown at a higher magnification collateral vessels appeared smaller in 
diameter (as measured in figure 5.6) with increasing concentrations of the drug (5, 10, 
20M), compared to controls (n=12 per group). 
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The data showed that application of papaverine for 24 hours significantly reduced collateral 
vessel diameter. However, I had detected upregulation of PDE10A as early as 4 hours after 
tied-ligation in the region of collateral development. I therefore examined at what stage 
papaverine could be detected to affect collateral formation. Filter paper discs treated with 
PBS or 20M papaverine were applied to the area of collateral vessel remodelling as before 
(section 5.6) but embryos were imaged every 2 hours after ligation. At each timepoint, 
discs were removed, a micrograph was taken and fresh discs replaced.  
 The results, shown in figure 5.8, showed that 20M papaverine induced a statistically 
significant reduction in collateral vessel diameter. These data fit with the Western blot and 
immunohistochemistry results which showed expression of PDE10A protein at early 
timepoints following ligation. In these regions, application of papaverine reduces vessel 
diameter. In comparison, the diameter of these vessels was unaffected by papaverine 
(Figure 5.5). 
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  Figure 5.8 Timecourse analysis of the effect of papaverine treatments showed PDE10A 
inhibition significantly impaired collateral vessel formation from 6 hours post tied-
ligation 
 
A Embryos underwent right proximal vitelline vessel tied-ligation and application of 
20M papaverine or PBS vehicle on filter paper discs at anterior and posterior poles 
(sites of collateral vessel formation). Serial photomicrographs were performed and 
collateral vessel diameter quantified. 2way ANOVA showed an overall significant 
difference between groups over the time-course (** indicates p=0.005). Further analysis 
using an unpaired t-test to compare the means between groups at each timepoint 
revealed that papaverine significantly impaired collateral vessel formation from 6 hours 
post tied-ligation. (Student’s t-test ; 6h p=0.05; 8h p=0.005; 11h p=0.005)(n=6 per 
group). 
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5.7 PKA inhibition rescues the effect of PDE10A inhibition in vivo 
Rp-8-Br-cAMPS are cAMP analogues (Gjertsen et al., 1995). The molecular structure is 
modified from the cAMP structure by replacing a hydrogen atom with a bromine atom, and 
an oxygen atom is modified by sulphur (Gesellchen et al., 2006). Whereas PDE10A 
hydrolyses cAMP to control cAMP levels, Rp-8-Br-cAMPS competes with cAMP for PKA 
binding sites and cannot be metabolised by phosphodiesterases (Gjertsen et al., 1995). On 
the basis that PDE10A and Rp-8-Br-cAMPS act in a similar way – both work to prevent 
downstream cAMP signalling, I therefore hypothesised that RP-8-Br-cAMPS may rescue the 
effect of PDE10A antagonism.  
Rp-8-Br-cAMPS can penetrate cell membranes when given extra-cellularly and do not 
degrade during incubation as the structure is hydrolytically stable (Gjertsen et al., 1995). 
Rp-8-Br-cAMPS are a combination of well-accepted PKA inhibitor and a widely used 8-
bromo cAMP. The molecule works by occupying cAMP binding sites preventing PKA 
activation thus acting as a competitive inhibitor of downstream cAMP/PKA signalling 
(Dostmann et al., 1990). When PKA is active it is composed of two catalytic subunits bound 
to a regulatory subunit dimer. With increased levels of cAMP each regulatory subunit binds 
two cAMP molecules. This causes a conformational change and dissociation of the catalytic 
subunits. Catalytic subunits can then phosphorylate target molecules (Gesellchen et al., 
2006). As cAMP antagonists occupy the cAMP binding site of the regulatory subunit, 
catalytic subunits cannot dissociate and become active. 
Rp-8-Br-cAMPS have been studied in various models in the literature. RP-8-Br-cAMPS have 
been used at 30M to investigate the effect on calcium channels in monocytes of a portal 
vein taken from a rabbit (Ruiz-Velasco et al., 1998). In vivo zebrafish studies by a colleague 
used Rp-8-Br-cAMPS at concentrations of 0.35-1.4mM to study cAMP levels (Nikolay 
Ogryzko, unpublished data). In rat models Rp-8-Br-cAMPS was used at 100nM to observe 
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the effect on cAMP signalling via EPAC (Liebenberg et al., 2011). There was little indication 
of what concentration would be optimal for chick embryo studies. I therefore tested a 
range of concentrations from 30M- 500M as I expected the vessels in my model to 
require a higher concentration that that used in cells but less than mammalian or zebrafish 
studies given the direct application. 
5.8 Rp-8-Br-cAMPS does not affect normal vessel development, heart rate or 
collateral vessel development 
As with the papaverine assays I first wanted to assess the toxicity of the drug or any 
adverse effect on vascular development. I therefore applied a range of concentrations 
(30M- 500M) on chick embryos whose extra-embryonic vasculature was not yet fully 
mature and still developing (HH st 15). Filter paper discs soaked in Rp-8-Br-cAMPS were 
applied to the developing vitelline vessels for 24 hours (Figure 5.9); 30-500M of Rp-8-Br-
cAMPS had no statistically significant effect on the diameter of the vitelline vessels 
(Controls, 240±10m; 50M Rp-8-Br-cAMPs, 239±26m; 1 way ANOVA n.s) These 
concentrations did not affect heart rate (Figure 5.9B). 
I next examined the effect of Rp-8-Br-cAMPS on collateral vessel development in the same 
assay as described in section 5.6. Figure 5.10A shows that there were no significant 
differences in number of collateral vessels in Rp-8-Br-cAMPS treated groups compared to 
controls. Although most concentrations had no effect on collateral vessel diameter, 30M 
Rp-8-Br-cAMPS did significantly increased this compared to PBS (Figure 5.10B). However, 
this was not reproduced in subsequent studies (Figure 5.11), and overall I did not detect an 
increase in collateral vessel diameter with Rp-8-Br-cAMPS treatment. 
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Figure 5.9 Rp8-Br-cAMP application to the vitelline vessels did not affect vessel 
diameter or heart rate 
 
Rp8-Br-cAMP was applied to both (unligated) proximal vitelline vessels at HH st 15 for 
24h to observe any adverse effects on the development of the vitelline vasculature. 
After 24h the discs were removed and the vitelline vessel diameters were quantified. A 
Rp8-Br-cAMP did not significantly affect the diameter of vitelline vessels compared to 
PBS treated embryos. B Rp8-Br-cAMP did not adversely affect heart rate of embryos 
(n=6 per group). 1 way ANOVA with Dunnett’s multiple comparisons test. (n.s) 
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Figure 5.10 When applied to HH st17 tied-ligated embryos, Rp-8-Br-cAMPS did not 
affect collateral vessel number, but at 30M did increase mean diameter of collateral 
vessels compared to controls. 
 
A Increasing concentrations of Rp-8-Br-cAMPS to the anterior and posterior poles of 
ligated embryos at the area of collateral vessel formation for 24h did not affect 
collateral vessel number. B The mean diameter of collateral vessels significantly 
increased, compared to controls at  30M Rp-8-Br-cAMPS (n=6 per group). Statistical 
analysis used 1 way ANOVA and Dunnett’s post-test. p=0.005 
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5.9 Rp-8-Br-cAMPS is able to rescue the effect of papaverine on collateral vessel 
diameter 
I hypothesised that a PKA inhibitor would counteract the effect of PDE10A inhibition and 
improve the diameter of collateral vessels treated with papaverine. As in figure 5.6, filter 
paper discs of PBS, 30M Rp-8-Br-cAMPS, 20M papaverine, or both were placed at the 
anterior and posterior poles of the embryo for 24 hours following ligation. 
As before, 20M papaverine had no effect on collateral vessel number but significantly 
reduced collateral vessel diameter (Figure 5.11). Treatment with 30M Rp-8-Br-cAMPS had 
no effect on collateral vessel development, and was unable to rescue the effect of 
papaverine treatment. 
There were many factors which could have prevented a rescue effect, particularly an 
insufficient concentration of Rp-8-Br-cAMPS. I therefore next tested whether 100M of Rp-
8-Br-cAMPS could rescue the effect of papaverine on collateral development. Repeating 
the assays with this concentration completely rescued the effect of papaverine on 
collateral vessel diameter (Figure 5.12B). 
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Figure 5.11 30M Rp-8-Br-cAMPS did not affect collateral vessel number, and had no 
effect on the mean diameter of collateral vessels when co-treated with papaverine for 
24 hours post tied-ligation 
 
A No significant difference was observed between groups treated with either PBS, Rp-8-
Br-cAMPS (30M alone), papaverine (20M alone) or Rp-8-Br-cAMPS (30M) with 
papaverine (20M) (ns) B The mean diameter of the collateral vessels of the 
papaverine treated group and the group co-treated with papaverine and Rp-8-Br-cAMPs 
were significantly reduced compared to PBS controls and Rp-8-Br-cAMPS (30M alone) 
(n=8 per group). Statistics were performed with 1 way ANOVA and Bonferroni’s multiple 
comparisons post-test. (**** p<0.0001) 
 
. 
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  Figure 5.12 100M Rp-8-Br-cAMPS did not affect collateral vessel number, but did 
rescue the mean diameter of collateral vessels when applied to collateral vessels with  
papaverine for 24 hours post-ligation 
 
A No significant difference was observed between groups treated with either PBS, Rp-8-
Br-cAMPS (100M alone), papaverine (20M alone) or Rp-8-Br-cAMPS (100M) with 
papaverine (20M) B The mean diameter of the collateral vessels of the papaverine 
treated group were significantly reduced compared to all other groups  after 24h post 
tied-ligation (n=8 per group). Statistics were performed with 1 way ANOVA and 
Bonferroni’s multiple comparisons post-test. (** p<0.05, *** p<0.005) 
 
. 
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5.10 Investigating a functional role for PDE10A in collateral vessel remodelling 
I next sought to investigate how PDE10A inhibition impairs collateral vessel formation in 
vivo. A previous investigation of PDE10A inhibition in hypertensive rats showed that 
papaverine administration induced increased activity of cAMP and phosphorylation of CREB 
(Tian et al., 2011). One effect of this was reduced remodelling of pulmonary vasculature 
due to a reduction in proliferation.  My previous attempts to assess a role for proliferation 
in flow-induced vessel remodelling in sham and tied-ligated embryos showed a trend 
towards an increase in proliferation in the area of flow-induced remodelling 4 hours 
following ligation (Figure 3.19). Some studies state that proliferation in this extra-
embryonic tissue should be minimal during remodelling due to the intussusceptive growth 
of the vessel network (Buschmann et al., 2010). Other studies of arteriogenesis in 
mammalian models show that endothelial cell proliferation is required for outward 
remodelling of the vessel lumen ( Scholz et al., 2000, Heil and Schaper, 2004). I examined 
the effect of PDE10A inhibition on proliferation in the area of collateral vessel remodelling 
6 and 8 hours after ligation. These timepoints were selected because in figure 3.19 
proliferation at 4 hours showed a trend towards being increased in the ligated embryos. I 
therefore wanted to test if this trend became significant at later timepoints. Further, in 
figure 3.7, collateral vessel diameter increased most between 4-12 hours, which could 
suggest proliferation was occurring or contributing to the outward expansion. My Western 
blot results (Figure 5.2) also showed up-regulation of PDE10A protein at early timepoints 
but prominent bands were observed particularly at 8 hours after ligation. 
I assessed proliferation using BrdU (Section 2.22). BrdU is technically difficult to administer 
in vivo (Table 2.5). Following ligation, 25l of 1mM BrdU injected over the vitelline membrane 
in the area of collateral vessel remodelling. Filter paper discs of 20M papaverine were 
then applied to the area of collateral vessel remodelling as before (section 5.6). Tissue was 
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dissected at 6 and 8 hour timepoints and processed for analysis by immunohistochemistry 
labelling of the nuclear localised BrdU epitope on cryo-sectioned tissue (section 2.22).  
My results showed that papaverine did not significantly affect proliferation in the area of 
flow-induced remodelling at either 6 hours or 8 hours after tied-ligation. Figure 5.13A 
showed that at 6 hours post tied-ligation only 1% of cells treated with PBS, compared to 
1.5% of cells treated with papaverine were BrdU positive. In Figure 5.13B, at 8 hours post-
ligation more cells were labelled by BrdU (4.5%±1 of control treated cells; 5.6%±0.8 of 
papaverine treated cells). The results suggest that PDE10A inhibition did not affect 
proliferation during vessel remodelling, although the statistical power of the assay would 
not be sufficient to detect a small alteration in proliferation. These data suggest collateral 
vessel remodelling was impaired by PDE10A inhibition due to some other mechanism than 
proliferation, which was low even in untreated embryos.  
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  Figure 5.13 PDE10A inhibition does not affect proliferation in the area of collateral 
vessel formation at 6 hours and 8 hours post tied-ligation 
 
Collateral vessels were treated with papaverine and BrdU for 6 or 8 hours in vivo, post 
tied-ligation, then dissected and assayed for proliferation with anti-BrdU and by 
quantification of proliferation index (positive cell area/DAPI positive area x 100). A 
Papaverine did not significantly alter proliferation in collateral vessels at 6 hours post 
tied-ligation, compared to controls  B Papaverine did not significantly affect 
proliferation in vivo at 8 hours compared to control (n=8 per group) (Student’s T-test = 
n.s) 
 
 
. 
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5.11 Discussion 
In this chapter I attempted to investigate the role of PDE10A in collateral vessel 
development. I confirmed expression of PDE10A mRNA in human endothelial cells, and that 
this was increased by exposure to altered flow. I also detected PDE10A protein 
upregulation in the area of collateral vessel development in the chick. I have shown that 
pharmacological inhibition of PDE10A impairs collateral vessel formation (in terms of vessel 
diameter, but not vessel number). The mechanism for the contribution of PDE10A to 
collateral vessel development remains unclear, and appears not to involve proliferation, 
but my observation that the effect of PDE10A inhibition can be rescued by Rp-8-Br-cAMP 
points to an effect that could be mediated by cAMP via effects on PKA. 
My first observation in this chapter was that PDE10A was expressed in HUVECs and 
regulated by altered flow (Figure 5.1). This data supported the suggestion that at least 
some of the expression changes detected by my microarray were likely to have been 
induced by the alterations in blood flow induced by vitelline artery ligation. This data could 
therefore be taken as evidence to support the findings of the microarray. However, the 
altered flow conditions induced by orbital shaking do not accurately mimic the more 
complex changes during collateral vessel development. For example, in in vitro models such 
as the cultured HUVECs exposed to orbital flow conditions, complex re-circulation currents 
occur (Dardik et al., 2005). This may not give a true reflection of flow-related PDE10A 
expression in vivo. Due to the benefits of studying the chick embryo in vivo, to investigate 
an endothelial response to flow (previously discussed in section 3.9), I continued the study 
of flow-induced PDE10A expression, and its contribution to collateral vessel formation, in 
my original model.  
211 | E m i l y  C l a r e  H o g g a r  
 
To determine upregulation of PDE10A protein in my model I used Western blotting (Figure 
5.2) and to investigate an endothelial location for PDE10A in collateral vessels I used 
immunohistochemistry (Figures 5.3-5.4).  
I first used Western blot techniques to compare PDE10A expression in the area of collateral 
vessel formation in sham-ligated and tied-ligated embryos (Figure 5.2). Western blotting 
also allowed me to semi-quantify changes in PDE10A protein expression over different 
timepoints. Results showed that PDE10A expression was increased at early timepoints in 
the tied-ligated embryos compared to the sham-ligated embryos. 
On the Western blots, prominent double bands were observed at the 95kDa which 
corresponds to the molecular weight of PDE10A protein (Fujishige., 1999). The doublet 
bands could indicate modified PDE10A protein due to phosphorylation, acetylation, 
methylation or other post-translational events (Seo and Lee., 2004). Phosphorylation of 
PDE10A by PKA has been show to alter its cellular location in PDE10A isoforms in the rat 
(Kotera et al., 2004), indicating that this modification does occur. Double bands could also 
imply splice variants that share the same epitopes. In the chick there is predicted to be only 
1 transcript of PDE10A (Ensembl). A third reason for multiple bands could be due to non-
specific binding of the polyclonal antibody. From my results, the positive control (heart 
tissue), supported that the top band at 95kDa was likely to be PDE10A. Ideally a second 
antibody (preferably monoclonal) would have allowed confirmation of this result. However, 
the results of the Western blot data matched the pattern of up-regulation of PDE10A 
mRNA expression in the microarray (section 4.5) and was consistent with the effects of 
PDE10A inhibition (Figure 5.8). PDE10A was upregulated in tissue from chicks undergoing 
collateral vessel development (tied-ligated) compared to the sham-ligated at 4 and 8 hours 
post-ligation and this appearance was seen on three separate gels, confirming its 
reproducibility. 
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I next used immunohistochemistry to attempt to discover if PDE10A protein was expressed 
in endothelial cells, as the Western blotting data supported, but did not confirm, an 
endothelial location of flow-regulated PDE10A. 
Despite technical challenges, I acquired preliminary immunohistochemical data about 
PDE10A protein expression in collateral vessels. Although subjective, there appeared to be 
punctate expression of PDE10A in collateral vessel tissue at 4 hours post-ligation - an 
expression pattern observed before in mouse striatal tissue (Nishi et al., 2008). This gave 
me confidence in my results; however, immunohistochemistry was inconclusive in this 
model at demonstrating exactly which cell type expresses PDE10A during flow-induced 
remodelling. 
In the literature, PDE10A expression has been previously observed in the cardiovascular 
system. Northern blots revealed PD10A transcripts to be expressed in the heart and aorta 
in human tissue (Fujishige et al., 1999). Immunohistochemistry has also shown PDE10A 
expression in pulmonary arteries from human lung tissue (Tian et al., 2011). It has also 
been shown that PDE10A can be expressed in different cellular compartments such as the 
nucleus or cytoplasm.  This compartmentalisation of PDE10A was identified in a 
recombinant system which investigated splice variants of PDE10A in an in vitro study using 
COS-7 cells. An expression plasmid containing PKA catalytic subunit was co-transfected with 
PDE10A plasmids. Subcellular localisation of PDE10A was analysed by immunoblotting. The 
group found one PDE10A isoform (PDE10A2), was predominantly membrane-bound, but 
translocated to the cytosol when a particular amino acid was phosphorylated (threonine 
16) by protein kinase A (PKA) (Kotera et al., 2004).  
My data showed that PDE10A protein is upregulated at early timepoints in tied-ligated 
embryos in the area of collateral vessel formation. It is likely that the location of PDE10A is 
endothelial but no solid conclusions can be drawn from the data due to the limitations of 
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the immunohistochemistry results. However, taking together my microarray, QRTPCR, 
Western blot, immunohistochemistry and HUVEC data, PDE10A expression appears to be 
upregulated in vessels undergoing flow-induced remodelling and that the likeliest source of 
PDE10A expression is the endothelium. 
Having confirmed PDE10A protein expression in the area of collateral vessel formation and 
upregulation in tissue from chicks undergoing collateral vessel development (tied-ligated) 
compared with sham-ligated, I next assessed whether PDE10A plays a functional role 
during collateral development, using a PDE10A inhibitor.  
To perform pharmacological assays, I used a simple method of drug delivery by pipetting a 
set volume of solution onto uniform cut filter paper discs and applied these directly to the 
vitelline membrane on the surface of the extra-embryonic tissue over the area of interest 
(collateral vessel remodelling), at both poles of the embryo. Embryos treated with discs of 
PBS controlled for any adverse reactions due to the filter paper application onto the 
vitelline membrane surface. This was not observed, further suggesting that for my model 
filter papers were a useful tool for drug delivery. I used papaverine as the most widely used 
and most specific PDE10A antagonist available. I chose to use papaverine in a range of 5-
20M.  
At a concentration of 20M, papaverine impaired collateral vessel remodelling. Collateral 
vessel diameter was significantly reduced in papaverine treated chicks compared to 
controls after 24 hours (Figure 5.6). No studies have looked at metabolism of papaverine in 
the chick model, but my results suggested that papaverine was having an effect on the 
remodelling vessels and was not degrading over time. The published IC50s (half maximal 
inhibitory concentration) against PDE3A and PDE5 suggest that at this concentration there 
may be effects against these isoforms present in smooth muscle (Ritschel and Hammer., 
1977). This was not an issue in my model as at HH st 17, in the chick embryo there is no 
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smooth muscle present in the extra-embryonic vasculature (Lucitti et al., 2005).  Further, 
evidence to support this comes from the fact that no vasodilation was observed. 
My assay was robust, rapid and reproducible despite the difficulty in quantifying diffusion 
and subsequent dose released from it, but it is important to recognise limitations of this 
assay.  
Papaverine, although widely used as a specific inhibitor of PDE10A, is not selective for 
PDE10A inhibition only. It is possible some of my results are due to effects on other PDEs. 
However, the later rescue of the effect of papaverine by Rp-8-Br-cAMPS, coupled with the 
lack of effect of papaverine on normal vessel development makes it unlikely that 
papaverine is simply exerting its effect through toxicity or non-specific inhibition.  
The kinetics of release of solutions from filter paper in ovo is unknown. I attempted to 
investigate solution diffusion from filter paper to the vitelline membrane by applying food 
colouring solutions to the filter paper and observing release of the dye after 24 hours 
(Appendix, Figure A11). The solution did appear to transfer to the vitelline membrane and 
therefore suggested that liquid diffusion was possible. It would be more sufficient to 
measure the size of particles in different solutions, and to measure how much solution 
actually reaches the endothelial cells of the vasculature. Due to the challenges in collecting 
this information, I was not able to calculate the exact concentration of papaverine which 
reached the endothelial cells in vivo. The highest possible local concentration experienced 
by the extra-embryonic tissue would be the concentration applied to the filter paper. 
Matrigel would be an alternative method of drug delivery which allows slow release of a 
substance over time (Staton et al., 2004). This would have been useful in my assays, but 
matrigel contains growth factors and cytokines it contains which may have affected the 
results and caused an angiogenic response (Staton et al., 2004). Solutions can also be 
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pipetted onto the surface of the embryo (le Noble et al., 2004), but this does not allow for 
localised delivery to a targeted area. The filter paper discs, provide a more localised drug 
delivery to a specified area and have been used in other studies. One such study 
demonstrated the benefit of using filter paper to focus on an area of vessel distribution 
after application of a drug (Miller et al., 2004). The group used the discs to target drug 
delivery of an angiogenesis stimulator (bFGF) to a specified the area on the CAM surface 
and then used this area to quantify the vascular density beneath the discs (Miller et al., 
2004). It is unlikely that topical application alone would have been suitable for my 
experiments which required localisation of the drug to a targeted area.  
I next wished to understand at which point after ligation, PDE10A inhibition began to have 
an effect on collateral vessel remodelling. Analysis of papaverine inhibition over time 
identified that the effect of PDE10A inhibition was apparent from 6 hours post-ligation 
(Figure 5.8). These results showed that PDE10A inhibition caused detectable impairment of 
collateral vessel diameter at early timepoints following ligation and treatment with 
papaverine, compared to PBS treated controls. These results were consistent with the 
Western blot data that suggested PDE10A was upregulated at early timepoints in tied-
ligated chicks (Figure 5.2). Since papaverine had no effect on normal vessel development 
and PBS treated embryos controlled for external influences, the differences between 
groups observed in this study were likely to be due to the specific effect of the drug.  
Vessel measurements were performed as previously described (section 2.24) but for this 
experiment, vessels were imaged every two hours. This involved removing the embryos 
from the incubator, therefore exposing the embryos to a reduction in temperature. A 
cooling effect could have affected development of the embryo slightly and therefore the 
size of the vessel measured. Cooling of the eggs was unlikely to cause vasoconstriction (as 
discussed previously chapter 3.2).  As the measurements were consistent and all embryos 
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received the same procedure, I can be confident in my results. To eliminate any concerns in 
the future, a heated light source to prevent cooling could be used during imaging.  
To reduce the risk of evaporation of the drug from the filter paper during imaging of the 
vessels (which might alter the concentration of the drug), fresh discs were applied to the 
embryos. There is a possibility that the cumulative effect of replacing discs with fresh drug 
after each imaging session may have affected the results (i.e. the total dose received might 
be higher). However, the data was consistent with other experiments and thus supported 
the hypothesis that papaverine treatment impaired collateral vessel formation from early 
timepoints, leading to collateral vessels with significantly reduced diameter. 
Papaverine inhibition of PDE10A has been show to increase PKA signalling by elevating 
levels of cAMP (Giralt et al., 2013). In the Tian study papaverine caused increases in cAMP 
levels which consequently impaired outward remodelling of pulmonary arteries (Tian et al., 
2011). I therefore next investigated if the effect of papaverine inhibition on collateral vessel 
formation could be rescued with an inhibitor of PKA signalling, which would stop 
downstream effects of elevated cAMP levels. I used the PKA antagonist, RP-8-Br-cAMPs, 
which competitively binds to PKA preventing downstream signalling and is more PKA 
specific than forskolin (Karege et al., 2004). To test this I applied both the PDE10A inhibitor 
and PKA antagonist to embryos undergoing collateral vessel development after tied-
ligation. RP-8B-r-cAMPs successfully rescued the effect of papaverine at 100M and 
restored collateral vessel diameter (Figure 5.12). At this dose, Rp-8-Br cAMPs alone did not 
affect the diameter of collateral vessels. This strongly suggests that papaverine reduces 
collateral vessel diameter by increasing PKA signalling. This response could lead to changes 
in gene transcription which may contribute to the impaired collateral vessel growth 
observed when collateral vessels were treated with papaverine. 
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In the literature Rp-8-Br-cAMPs have previously been used to rescue the effects of PDE 
inhibition. A study by Lu et al. discovered that a PDE1 inhibitor, zaprinast, inhibited 
excitation of rat neurons by increasing levels of cAMP and consequent PKA signalling. 
However, Rp-8-Br-cAMPs prevented downstream effects of zaprinast by inhibiting PKA 
signalling (Lu et al., 2004). A second study used a PDE inhibitor and Rp-8-Br-cAMPs to 
investigate immunological disorders related to T lymphocyte function. Mouse T-cells were 
stimulated with anti-CD3 antibody and Il-12 induced IFN-gamma production was measured. 
PDE7A was proposed to be involved with regulation of T lymphocyte function as PDE7A 
inhibition impaired T lymphocyte function. This was further demonstrated to be related to 
cAMP levels as addition of forskolin (Adenylate cyclase activator) also impaired T-cell 
function. However, Rp-8-Br-cAMPs reduced the suppressive effect of both the PDE7A 
inhibitor and Forskolin induced increases in cAMP levels (Kadoshima-Yamaoka et al., 2009). 
Image analysis and quantification was conducted in the same way as for previous 
experiments (as described in section 2.24) and was therefore consistent within these 
studies. However, the collateral vessel diameters of PBS and papaverine treated collateral 
vessels were measured to be slightly larger in the rescue assays than in previous 
experiments (Figure 5.6 Controls: 63±4; Figure 5.11 Controls, 113±8m, Figure 5.12, 
Controls 95±7m) (Figure 5.6 papaverine, 30±3m Figure 5.11 papaverine 38±4m; Figure 
5.12 papaverine 51±4m). This may have been due to the practicalities of the experiment. 
As described in section 2.21, it took time to operate on each embryo and then to image 
each individual embryo. It should therefore be taken into consideration that all embryos 
could not physically be analysed at once and therefore some embryos may have been 
incubated for slightly longer than others. The group sizes may have needed to be higher to 
see more consistent results between experiments. Another reason for the slight difference 
in recorded vessel size could be due to calibration issues which may have occurred from 
using a different type of camera for the latter experiments. Importantly, the vessel 
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diameters measured in previous experiments compared with the vessel diameters 
measured in the rescue experiments, showed a consistently significant difference between 
papaverine and control treated embryos. Therefore I am confident that my experiments 
show a rescue of collateral vessel diameter with 100M Rp-8-Br-cAMPS following 
papaverine treatment. In summary, papaverine inhibition of PDE10A consistently caused 
impaired collateral vessel remodelling. Further, regardless of the experimental limitations, 
inhibition of PKA signalling with Rp-8-Br-cAMPS restored impaired collateral vessel 
diameter.  
Having found some evidence that PDE10A plays a role in collateral vessel remodelling in the 
chick embryo, I decided to investigate a possible mechanism for this effect. There is little 
known about how PDE10A is regulated or what its function is. There is also little data available 
on the vascular effect of PDE10A inhibition. Other than being investigated in the brain, the 
only study showing a vascular function for PDE10A was published during the course of my own 
research (Tian et al., 2011). This study showed that PDE10A played a role in regulating 
proliferation of smooth muscle cells during remodelling of pulmonary vasculature in 
hypertensive rats (Tian et al., 2011).  I had identified only very low levels of proliferation in 
collateral vessel remodelling at 4 hours post-ligation previously (Figure 3.19). However, taken 
with the evidence in the literature, it was logical that proliferation may have been prevented by 
PDE10A inhibition which impaired the size of collateral vessel diameter. 
To test whether PDE10A contributed to outward remodelling during collateral vessel formation 
by influencing proliferation I attempted to determine whether PDE10A inhibition was associated 
with any alteration in markers of cellular proliferation during collateral vessel development.  I 
tested for BrdU incorporation into the DNA of cells in the area of collateral vessel remodelling 
following ligation and in the presence of PDE10A inhibitor in vivo. I examined 6 and 8 hour 
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timepoints, post-ligation, as at these early timepoints in vivo, PDE10A is highly expressed 
(Figure 5.2) and papaverine significantly impaired vessel remodelling (Figure 5.6).  
My results showed that there was no significant difference in proliferation in the area of vessel 
remodelling when vessels were treated with papaverine compared to PBS. There was much less 
proliferation detected at 6 and 8 hours post-ligation, compared to the data from 4 hours 
after ligation previously studied (Figure 3.19) (4 hours an average of ~10% proliferating 
cells; 6 hours ~1% proliferating cells; 8 hours ~4% proliferating cells). This result could have 
been due to the difference in developmental stages between embryos, perhaps the 
embryo is growing more rapidly at earlier timepoints. Another possibility is that collateral 
vessel development is associated with a very early increase in proliferation that was not 
detected by my studies and that had subsided by 4 hours after ligation, although this seems 
less likely given the progressive increase in collateral vessel diameter for many hours after 
ligation.  
The difference in the levels of proliferation, of cells in the area of collateral vessel 
remodelling, between experiments (between 4 hours (Figure 3.19) and 6 and 8 hours 
(Figure 5.13) could be explained by the use of filter paper and the addition of 
papaverine/PBS solution. This could have affected the results as the discs may have soaked 
up some of the BrdU which was applied topically to the area prior to adding the discs. This 
may have impeded the amount/concentration of BrdU which reached the endothelial cells. 
The BrdU/PBS solution on the discs may have diluted the concentration of BrdU therefore 
also affecting how much BrdU was incorporated into the DNA. Nevertheless, I was able to 
detect proliferation in my control (PBS treated) groups; therefore I do not consider these 
assays to be sufficiently flawed to entirely discount their results.  
Finally, it should be noted that PDE10A is a dual PDE; therefore cGMP levels may have also 
been affected. However, due to the lack of vascular smooth muscle in these vessels at this 
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stage, it is unlikely that any cGMP mediated vasodilatory responses would have been the 
cause of reduced collateral diameter (if present it would have led to an increase in 
diameter). I therefore conclude that I found no evidence to support a role for PDE10A in 
promoting proliferation during collateral vessel development, and since proliferation seems 
low even in my earlier studies it seems likely that PDE10A mediates its effects in other 
ways. 
Discovering a single mechanism of action for PDE10A is difficult due to the many different 
roles of cAMP in mediating many different signalling pathways. For example, in neurons, 
cAMP levels have been found to regulate growth cone remodelling and axon guidance. 
cAMP levels in neurons are responsible for a cell’s attractive or repulsive response to 
stimuli by mediating extracellular signals and cytoskeletal interactions (Lohof et al., 1992). 
In endothelial cells, increased cAMP has been found to affect proliferation, cell cycle 
progression and migration (Favot et al., 2003).  
Since so little is known about PDE10A, speculation about its possible roles requires 
extrapolation from what is known about other PDE family members. It is worth noting that 
PDEs of different subtypes are affected and respond differently to inhibition dependent on 
their vascular location (Netherton and Maurice, 2005). Favot et al., (2003) investigated the 
effect of inhibiting PDEs to prevent endothelial migration and proliferation response to 
VEGF in angiogenesis (Favot et al., 2003). The group used a chick CAM assay to inhibit PDE2 
and PDE4 in HH st 25 embryos and found that PDE inhibition reduced vessel density and 
angiogenesis (an effect I did not see in my own studies antagonising PDE10A in earlier stage 
uninstrumented chicks, Figure 5.5).  
Further experiments investigating PDE2,3,4 and 5 inhibition in HUVECs have confirmed that 
PDE inhibition reduces vascular cell migration during angiogenesis but this was vessel type 
and PDE type specific (Netherton and Maurice, 2005). This information has clinical 
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implications as PDE inhibition could potentially therefore prevent VEGF induced 
angiogenesis in tumours and be used to develop novel anti-cancer therapies. 
Future Work 
Future work could further investigate the effect of different types of flow on PDE10A 
expression in cultured flow-sensitised endothelial cells. Although I used HUVECs for my 
experiments (as these were available) future investigations could use human microvascular 
endothelial cells (hMVEC) which more accurately represent the microvasculature and could 
therefore give insights in clinical problems. 
Cryosections were used to collect immunohistochemical data; however, tissue processing 
of the fragile extra-embryonic vessels was difficult and challenging. My attempts to 
optimise sectioning did not improve the quality of sections taken from tissue. Future work 
could experiment with different cutting techniques such as vibrotome sectioning.  
A second antibody raised in a different species could allow dual labelling with an 
endothelial marker to confirm PDE10A endothelial expression. Individual collateral vessels 
could not be isolated from surrounding tissue and other cell types using fine dissection 
alone and due to these technical challenges, I sought to identify endothelial cells in this 
heterogeneous tissue. VE-cadherin acted as a marker of endothelial cells with which to co-
localise PDE10A expression but could only be performed in adjacent sections due to cross-
reactivity of the secondary antibody (Figures 5.3-5.4).  
A second antibody would also have confirmed specific PDE10A labelling of collateral vessel 
tissue as the PDE10A antibody used was not confirmed by the antibody manufacturer to be 
specific for chick tissue. I checked the amino acid sequence of this antibody by Clustal 
analysis (Appendix A5) and optimised concentration and blocking steps on tissue known to 
be positive for PDE10A (Appendix, Figures A6, A7). 
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To further explore and confirm PDE10A protein expression it would be interesting to 
perform immunohistochemistry or in situ hybridisation for PDE10A in mammalian models. 
PDE10A protein studies could be performed on hind-limb ligation models to look for 
evidence of flow-induced endothelial expression of PDE10A in collateral vessels. PDE10A 
immunohistochemistry could then also be investigated at other sites of altered blood flow 
in vivo, such as arterial bifurcations, to observe any subtle changes in PDE10A expression 
which might be due to different types of flow (disturbed/non-disturbed).  
To further validate the in vivo observations that PDE10A inhibition has most effect at early 
timepoints following ligation, I could test if papaverine treated embryos could recover their 
collateral vessel diameter over time. Filter paper discs containing PDE10A inhibitor could be 
applied to the embryo following ligation but removed at later timepoints, from 12-24 
hours. I would hypothesise that this recovery of vessel diameter would be unlikely based 
on the Western blot results. Downregulation of PDE10A protein was observed in Western 
blots from 12-24 hours and it is likely that papaverine would have less effect if less PDE10A 
protein was present, but it would be interesting to confirm this. Filter paper was a cheap 
and effective drug delivery system for my in vivo model, however there are other 
tools/methods available which might have had advantages. These could be considered for 
future experiments. 
The mechanism of PDE10A in the chick embryo during flow-induced remodelling could be 
further investigated by testing the role of cAMP in this process and confirming cAMP 
involvement with a more specific PDE10A inhibitor. A second PDE10A inhibitor such as 
IBMX (Soderling et al., 1999) could confirm my findings. I attempted to acquire TP-10, a 
more specific PDE10A inhibitor manufactured by Pfizer, during my studies, but my request 
to the company was not approved. 
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Further investigations of PDE10A inhibition on collateral vessel formation could include PIV 
recordings, to confirm an impairment of collateral vessel diameter and the consequent 
effect on collateral blood flow.  
Changes in gene expression, as a result of any impaired blood flow/consequences of 
reduced vessel diameter could be investigated by RNA analysis of endothelial cells in the 
collateral vessels following papaverine treatment. This could be compared to normal 
collateral vessel gene profiles. To observe any positive effects of enhancing PDE10A on 
collateral vessel formation an alternative assay could involve application of PDE10A protein 
to the area of vessel remodelling, following arterial ligation. Conversely, PDE10A gene 
silencing in the chick model by SiRNA or PDE10A knockout mouse models could be used to 
see if impaired collateral vessel formation resulted from the absence of PDE10A gene 
expression. PDE10A knockout mouse models already exist and have been generated to 
investigate the neurological implications of PDE10A expression (Siuciak et al., 2006b).  
Finally, as proliferation was not found to be the mechanism by which PDE10A was 
influencing collateral vessel formation in my model,  a migratory mechanism, or other 
known processes of arteriogenesis in mammalian models, could next be tested. 
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Chapter 6 
General discussion 
Cardiovascular disease is one of the primary causes of death worldwide (Aschwanden et al., 
2014). Negating the need for invasive vascular surgery by developing novel therapeutic 
agents to promote collateral vessel remodelling would have huge clinical applications. 
However, clinical trials of agents to promote collateral development have failed to 
reproduce the promising data from animal models. Understanding more about the process 
of collateral vessel development and the mechanisms underlying the factors which drive 
remodelling is vital in advancing this research. 
 Current mammalian models have provided much knowledge on the subject, yet there are 
many disadvantages to using these. Mouse, rat and rabbit models have been widely used 
to investigate collateral formation (Scholz et al., 2000, Herzog et al., 2002, Stabile et al., 
2003, Terry et al., 2011) , but the hind-limb model involves invasive surgery under general 
anaesthesia (Ito et al., 1997a, Herzog et al., 2002). Laser Doppler or angiography are used 
to quantify blood flow or to visualise collateral vessels (Limbourg et al., 2009) but do not 
allow for real-time observation of collateral development and are expensive and time-
consuming. In the porcine coronary model there are few pre-existing coronary collateral 
vessels and these do not remodel in response to increased fluid shear stress (Voskuil et al., 
2003). Therefore this model does not lend itself well for research in this field. The gridlock 
zebrafish could be used as an alternative to mammalian models of collateral vessel 
formation. The mutant is a model of aortic occlusion and has been shown to develop 
collateral vessels in response to aortic occlusion (Gray et al., 2007). However, compared to 
the chick embryo, the zebrafish has less homology to mammalian genes and 
pharmacological assays cannot be localised to specific vessels and may lead to off-target 
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effects. The chick embryo’s extra-embryonic network of blood vessels provide insight into 
flow-induced vessel remodelling which can provide clues about important genes to 
investigate further in higher models. Although differences in vessel architecture exist 
between species, the vitelline vessel network of the chick embryo remodels in response to 
changes in blood flow in a manner that is anatomically similar to its mammalian 
counterparts, even though the lack of investing pericytes and smooth muscle cells will 
undoubtedly impact on the ability to compare results between these model species.  
The first aim of my project was to assess if the chick embryo could be used as a model of 
collateral vessel formation, at a time when no such study had been performed. I first 
established a system to assess collateral vessel formation in the chick embryo.  I performed 
a longitudinal quantification of developing collateral/collateral number and diameter 
following unilateral vitelline artery ligation. Studies of collateral vessel development in 
mammalian models, following arterial occlusion, show the process occurs in two distinct 
phases: an initial increase in collateral vessel number, followed by a “pruning” selection 
process (Duvall et al., 2004). This selection process allows the more efficient vessels to 
persist and those carrying less flow to be pruned from the system (Hoefer et al., 2001). My 
data showed that collateral vessel formation in the chick embryo model also involved an 
initial expansion of the remodelling vascular network which was refined over time to 
become more haemodynamically efficient. Although I have not identified the mechanisms 
driving this selection, its conservation between chick and mammal suggests that studies 
using the chick model would be likely to contribute to a better understanding of what 
governs selection of collateral vessels for persistence or regression. 
Evidence from mammalian models suggests that therapeutic strategies for alleviating the 
consequences of arterial occlusive disease should be targeted to improving arteriogenesis 
(collateral vessel development) rather than angiogenesis (as discussed in section 1.8). My 
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data suggested that the chick embryo remodels collateral vessels from a pre-existing 
source in a process more akin to arteriogenesis than angiogenesis. Examination of various 
vascular markers in developing collateral vessels histologically and histochemically showed 
that flow in these remodelling collateral vessels was capable of regulating gene expression 
to induce an arterial identity. In situ hybridisation data of nrp1 and nrp2 markers showed 
that endothelial cells in remodelling collateral vessels adopted an arterial identity over time 
as collateral vessel extended into a previous venous territory to deliver arterial blood to an 
unperfused area. However, in the chick embryo the window of plasticity is brief and once 
cells become committed to an arterial or venous fate, they are no longer influenced by 
flow. The ability to induce collaterals to an arterial identity would be optimal for the 
requirements of carrying large volumes of blood at high pressure and velocity. Placing 
venous origin vessels in arterial flow conditions (such as coronary artery bypass grafting) 
this leads to intimal hyperplasia and a significant graft failure rate (Owens., 2010). Thus, 
understanding how to therapeutically influence endothelial identity, or induce plasticity of 
arterial/venous marker expression, might be a strategy to promote graft patency as well as 
promote collateral vessel development.  
It can be viewed as either an advantage or a disadvantage to use a model which only gives 
a read out of the endothelial mechanisms involved in collateral formation depending on 
the specific question to be addressed. I believe that the chick model may provide some 
fundamental insights into the endothelial response to changes in flow which will add novel 
knowledge to the field. In my studies to investigate an endothelial response to changes in 
flow, the chick model had clear advantages over higher species. However, the collateral 
vessel architecture of the chick does not match that of mammalian species. Most obvious is 
the absence of smooth muscle in chick collateral vessels at early developmental stages 
(Lucitti et al., 2005). For this reason, the chick model alone will never be sufficient for 
discovering new therapeutic targets to enhance collateral vessel formation in patients with 
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cardiovascular diseases. However, the chick model does provide an adequate platform 
from which to identify potential candidate genes or processes to investigate further in 
higher species and therefore could provide invaluable contributions to the field.  
Due to the accessibility of the vitelline vasculature, previous groups have manipulated 
blood flow to observe morphological patterning and genetic changes following induced 
vessel occlusion. For example, Buschmann et al., (2010) identified collateral vessels in the 
chick embryo and used this model to identify a gene which was taken forward into gene 
knockout studies in mouse models (Buschmann et al., 2010). This gene, originally identified 
in the collateral vessel of the chick embryo, was found to contribute to collateral vessel 
remodelling in the mouse, demonstrating the ability of chick studies to identify candidate 
genes which drive or regulate collateral vessel formation in higher species.  However, a 
microarray analysis of the genes differentially expressed during collateral vessel 
development in the chick model has not previously been described. The next part of my 
project was to identify potential candidate genes which may play a role in the remodelling 
process. My hypothesis was that flow-induced collateral vessel remodelling in my model is 
associated with a unique transcriptional profile that could be discriminated from the profile 
of “normal” vascular development that would be taking place in the same region in a 
developing embryo. I used microarrays to characterise transcriptional changes during 
different phases of flow-induced vessel remodelling. I used probabilistic data analysis as 
well as QRTPCR to identify candidate differentially expressed genes which may contribute 
to collateral development. I focussed on genes which were differentially expressed, above 
a fold change threshold, in tied-ligated embryos compared to the sham-ligated embryos- 
which did not develop collateral vessels.  The transcriptional profile of the area of flow-
induced remodelling showed an active response to changes in flow which reflected the in 
vivo pattern of remodelling and identified a large number of interesting differentially 
expressed genes.  
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The gene identified in the Buschmann study (2010) (Gja5) was present in the data from my 
chick microarray but showed no change in expression over the timepoints or between 
sham-ligated and tied-ligated models at the timepoints I focussed on. The absence of 
upregulation of this gene in my model could be explained by the window of time observed.  
Gja5 was detected in collateral vessels at 20 hours in chick collateral vessels and although 
the group observed expression of Gja5 at a 4 hour timepoint, this was in the vitelline artery 
and not the collateral vessels (Bushmann et al., 2010). This study perhaps suggests that a 
microarray performed at later timepoints on chick collateral vessels may reveal different 
candidate genes which may be interesting to investigate. One unexpected result was that 
genes upregulated during arteriogenesis in mammalian models were not differentially 
expressed in the chick model microarray profiles. Genes found to be upregulated in 
response to changes in flow both in vivo and in vitro in previous studies include those 
involved in proliferation, vascular tone, cytoskeleton and inflammation such as MCP1, 
VCAM1 and ICAM1 (Ito et al., 1997b, Scholz et al., 2000, McCormick et al., 2001, Pipp et al., 
2004) but were unchanged in the chick array. This may be due to the heterogeneity of the 
tissue analysed (and not specific collateral vessel tissue). Expression of some genes is more 
dynamic; particularly flow-induced genes which are exquisitely regulated and sensitive. As 
tissue was taken out of the flow environment in my experiment, this may have led to lost 
expression of these flow-sensitive genes. This could explain the reason why some of the 
expression profiles of these genes were not captured by microarray.  
Certain transcriptional responses may be universal to endothelial cells exposed to altered 
flow. Expression of other key genes may differ due to differences in species, windows of 
expression, environment and flow patterns. For example, Lee et al., (2004) investigated 
temporal expression of flow-responsive genes in mice following ligation or sham-ligation. 
The group found early up-regulation of transcription factors and DNA binding proteins, 
followed by a mid-phase of upregulated inflammatory genes, along with cell cycle genes 
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and cytoskeletal genes (Lee et al., 2004a). Although MCP1 was upregulated, other adhesion 
molecule genes which were reported to be expressed in other mammalian species 
(reviewed by Schaper, 2003) were not observed. It is also noteworthy that in vitro studies 
examining the effect of altered flow on endothelial cells also often identify largely non-
overlapping lists of differential gene expression. For example one study conducted by 
McCormick et al., (2001) looked at the genes that were differentially expressed after 
HUVECs were exposed to laminar shear stress (25 dynes/cm2) for 24 hours (McCormick et 
al., 2001). Genes encoding cyctochromes P450 1A1 and 1AB, glucocorticoid-induced 
leucine zipper protein, argininosuccinate synthase and human prostaglandin transporter 
were most significantly altered in gene expression analysis. Most dramatically decreased 
were MCP1 and ET1 (McCormick et al., 2001). Some genes, such as eNOS, c-jun 
transcription factor, PDGFA, TGFB, bFGF and ICAM1. MCP1 and ET1 have been shown to be 
initially upregulated but then significantly downregulated expression over time (Resnick 
and Gimbrone., 1995).  
My data did however identify candidate genes for further study and of these I selected 
PD10A for functional analysis. Upregulation of RNA transcripts does not confirm a 
functional role for the protein of the gene; therefore further analysis is required. I began 
my functional analysis of PDE10A by confirming PDE10A upregulation at the protein level. 
Temporal and spatial expression of PDE10A protein was identified in the extra-embryonic 
vitelline vasculature during flow-induced remodelling at early timepoints post-ligation. 
Pharmacological assays showed that inhibition of PDE10A impaired flow-induced collateral 
vessel remodelling at early timepoints following vessel ligation. The mechanism whereby 
PDE10A contributes to flow-induced remodelling remains to be elucidated. However, since 
these studies confirmed a functional role for PDE10A in collateral development (a role 
unsuspected by any previous work or known function of PDE10A) it justifies my microarray 
approach for the relatively unbiased discovery of drivers of collateral vessel development. 
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Although PDE10A is not well characterised in the literature it is known to hydrolyse both 
cAMP and cGMP (Beavo., 1995). PDE10A contains two adenylyl cyclases and FhlA (GAF) 
domains in the N-terminal and a catalytic domain in the C-terminal portions of the 
molecule (Fujishige et al., 1999, Soderling et al., 1999). Direct activation of PDEs can be 
achieved by cyclic nucleotide binding to the GAF domain (Gross-Langenhoff et al., 2006). 
PDE agonists and antagonists can modulate catalytic activity by binding to and stabilising 
either the 'closed' or 'open' form of GAF domains of PDE proteins. This is likely to be how 
papaverine inhibits PDE10A function; however I was unable to test an exact mechanism of 
action. Further, PDE10A function is still not well understood and further investigations are 
needed to determine whether factors such as phosphorylation or membrane attachment 
control GAF-dependent regulation of PDE10A catalytic activity (Gross-Langenhoff et al., 
2006). 
PDE10A acts to regulate cAMP activity. Cyclic nucleotides act as intracellular second 
messengers to convey and amplify complex signals from outside to inside the cell (Essayan., 
2001, Francis et al., 2001) and regulate important mediators of cell signalling such as PKA. 
Protein kinases are cyclic nucleotide binding proteins consisting of two regulatory and two 
catalytic subunits (Seino and Shibasaki., 2005). PKA binds two cAMPs to its regulatory 
subunits which cause a conformational change to release two catalytic subunits. These 
catalytic subunits catalyse the phosphorylation of proteins such as PDEs (Christina., 2010). 
Protein kinases activate PDEs by transferring a terminal phosphate group from an ATP 
molecule to a hydroxyl group on the PDE (Christina., 2010).  PDEs in turn inactivate cyclic 
nucleotides to reduce the cAMP/cGMP signal (Beavo., 1995).  I hypothesise that inhibition 
of PDE10A subsequently increases cAMP levels and ameliorates downstream activation of 
PKA signalling pathways. PKA has many phosphorylation targets and further studies are 
required to elucidate what these targets are in case of impairing collateral vessel 
remodelling when PDE10A is inhibited. Pharmacological assays with a PKA antagonist, Rp-8-
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Br-cAMPS, were able to rescue the effect of PDE10A inhibition on collateral vessel 
remodelling.  This result implied that the relationship between PDE10A, PKA and cAMP 
signalling may be important to collateral vessel formation. A summary of the proposed 
pathway can be seen in Figure 6.1. 
 
  Figure 6.1 Proposed pathway occurring after proximal vitelline artery ligation in the 
collateral vessels undergoing flow-induced remodelling 
This schematic proposes the pathway which occurs in the collateral vessels of the chick 
embryo following vessel ligation. Changes in flow upregulate PDE10A. PDE10A 
hydrolyses cAMP preventing binding to PKA. This reduced PKA activity reduces 
phosphorylation of PKA targets. Although the mechanism is unknown, this process 
allows collateral vessels to develop normally. Papaverine inhibits PDE10A.  
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Although I did not have time to measure the levels of cAMP to confirm degradation by 
PDE10A, increased levels of cAMP following PDE10A inhibition by papaverine has been 
previously documented (Tian et al., 2011). Hypertensive rat models were assessed for a 
role of PDE10A in pulmonary vascular remodelling. PDE10A mRNA and protein levels were 
upregulated in the nuclei of remodelling pulmonary vascular smooth muscle. When these 
rats were infused with papaverine, pulmonary vascular remodelling was impaired. 
Increased cAMP levels and increased cAMP response binding protein (CREB transcription 
factor) phosphorylation levels were detected in remodelling pulmonary arterial smooth 
muscle cells. Papaverine appeared to inhibit proliferation of the vascular smooth muscle 
cells which prevented normal vessel remodelling in response to hypertension (Tian et al., 
2011). The response of PDE10A inhibition in my model did not affect proliferation and was 
unlikely to influence vessel tone, due to the lack of smooth muscle in the embryo at this 
stage. Therefore, I speculate that the effect of papaverine may disrupt the regulation of 
vital signalling pathways or prevent flow-induced changes in gene expression. This might in 
turn, disrupt downstream processes involved in vessel remodelling, such as inflammation, 
attraction of monocytes or cell migration.  
A PKA mediated effect that reduces collateral vessel formation may explain why PDE10A 
would be upregulated to regulate PKA signalling. As introduced in section 1.15.2, in the 
vasculature, cAMP/PKA signalling has been linked to certain activities that would require 
regulation by PDE10A, to allow an endothelial cell response to changes in flow.  
In endothelial cells, PKA signalling has been shown to be involved in activating an arterial 
fate and arterial gene expression (Chiu and Chien., 2011). Developing collateral vessels 
have been shown to adopt an arterial fate over time (Figure 3.18). However, it is just as 
important to inhibit arterial fate of endothelial cells in regressing vessels which are not 
destined to become collateral vessels. Therefore, it could be hypothesised that PDE10A is 
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upregulated early on during collateral vessel formation to control cAMP/PKA signalling; 
thus inhibiting arterial determination of some endothelial cells, enabling the selection 
process we know to be important to collateral vessel network formation (section 3.3). 
cAMP/PKA signalling has also been shown to increase ERK1/2 and MAPK signalling, which 
leads to actin cytoskeleton rearrangement (Liu et al., 2001). Actin cytoskeletal 
rearrangement is thought to be involved in an endothelial response to changes in flow 
(Davies, 1995, Ingber, 2003). This would be expected to occur immediately following 
altered haemodynamics. Genes involved in actin cytoskeletal rearrangement have indeed 
been detected in vivo (Lee et al., 2004a) and in vitro (Peters et al., 2002) at early 
timepoints. PDE10A could be hypothesised to be upregulated, following ligation, to reduce 
the increased levels of cAMP/PKA signalling which were initially required during the 
endothelial response to changes in haemodynamic flow. Other PKA mechanisms which 
might hinder collateral vessel formation and therefore require an upregulation of PDE10A 
need to be further investigated. Due to the many targets and different signalling pathways 
involving PKA this would be difficult to assess.  
Given the variety of cAMP target effects, including cell signalling, it may be that PDE10A is 
involved in mechanotransduction to regulate remodelling vessels. Changes in flow 
modulate the behaviour and transcriptome of endothelial cells (Peters et al., 2002). 
Further, it has been proposed that development of normal collateral vessels, induced by 
changes in flow, may be mediated by signalling pathways such as RAS-ERK and Rho 
(Eitenmuller et al., 2006). Vossler et al., (1997) showed that agents that increased 
intracellular cAMP, through PKA, activated MAPK and ERK pathways (Vossler et al., 1997). 
Or, given PKA involvement in gene transcription, it may be that PDE10A helps to regulate 
shear responsive genes which may regulate other processes necessary for collateral vessel 
remodelling. For example in an in vitro study a reduction in cAMP decreased PKA activity, 
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which in turn increased ATF4 DNA binding sites in shear stress induced genes. This 
increased expression of shear stress responsive genes in endothelial cells exposed to 
elevated shear stress (White et al., 2011). Future work would include finding a mechanism 
for PDE10A function in flow-induced vessel remodelling by investigating mechanisms other 
than proliferation such as endothelial cell migration which is affected by inhibition of other 
PDEs (Netherton and Maurice, 2005). 
Investigations into siRNA knock downs of PDE10A in the chick embryo could reveal a 
mechanism of action for PDE10A in collateral vessel remodelling. I have previously 
attempted electroporation to introduce DNA constructs into my vessels of interest. Due to 
the fragility of the extra-embryonic vasculature at this stage, embryos did not survive this 
technique. However, I would be keen to see the effect of PDE10A knockdown on the 
remodelling process, following vessel ligation.  
Mouse knockout models of PDE10A have currently, only been used to investigate 
behaviour and locomotive effects (Siuciak et al., 2006b, Siuciak et al., 2008). Given time and 
resources it would be interesting to observe the vasculature in the mammalian models and 
analyse the response to flow-induced vessel remodelling following hind-limb ischaemia. 
My results would be greatly strengthened by confirmation using another antagonist. 
Although the contribution of PDE10A to flow-induced vascular remodelling was supported 
by rescue experiments, and the control embryos confirmed that there were no off target 
effects or toxicity, I would have preferred to use an entirely selective inhibitor to rule out 
any uncertainty. Nevertheless, it is worth noting that the effect of papaverine in 
mammalian models is to induce vasorelaxation via effects on smooth muscle cells. 
Therefore my observation that papaverine reduces collateral vessel diameter in the chick 
(while not affecting vessel size in unligated embryos) underlines the fact that my results 
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point to a role for phosphodiesterases in collateral vessel formation that is not simply an 
extension of their role in normal vascular physiology. 
I would like to investigate the role of cAMP in more detail. I had previously tried an assay 
with Forskolin, a compound which increases levels of cAMP, but this was unsuccessful due 
to the high amounts of DMSO required for the solution on the embryos. Other PKA 
inhibitors would have also validated a role for cAMP signalling in collateral vessel 
remodelling and allowed further insight into the pathway and mechanism involved in 
collateral vessel development. 
To further investigate cAMP signalling following ligation, cAMP levels could be measured 
with an enzyme-linked immuno-absorbent assay (ELISA) on cell lysates. Chromatography 
analysis could have been performed to validate PDE10A/cAMP binding in my model. 
Further, it would be interesting to measure the exact amounts of cAMP following PDE10A 
up-regulation (4 hours post-ligation) and after PDE10A inhibition. This would confirm the 
action of PDE10A and rule out any contribution of cGMP to the process of remodelling. 
Increased cAMP/PKA signalling leads to phosphorylation of cAMP dependent substrates 
(Nishi et al., 2008); Tian et al., (2011) measured this by monitoring CREB phosphorylation 
following systemic infusion of papaverine into hypertensive rats (Tian et al., 2011). I could 
have investigated this by checking for phosphorylation using phosphorylation state specific 
antibodies in the presence and absence of papaverine by Western blot. To determine 
whether cAMP was regulating shear stress response genes via ATF4 binding sites 
transcriptomics could be used to look for enriched ATF4 transcriptor binding sites in flow-
induced upregulated genes (White et al., 2011). 
A mechanism for the role of PDE10A in collateral development could have been 
investigated in in vitro systems. If PDE10A protein expression was confirmed in flow-
treated HUVEC cells, migration assays could be performed to see if PDE10A up-regulation 
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or inhibition reduces endothelial migration. siRNA could then be applied to cells in culture 
to observe cell behaviour following PDE10A knock down. Further research could investigate 
a pharmacological stimulant of collateral vessel formation as opposed to investigating 
inhibitors which impair the remodelling process. This might reveal results which would be 
more relevant to developing potential clinical applications. 
In conclusion, PDEs are involved in complex pathways, regulating cyclic nucleotide 
pathways with many variable targets which affect a variety of systems. The function and 
regulation of cAMP and cGMP pathways in the vascular system depend on location, cellular 
compartmentalisation, PKA or EPAC activation, signalling cascades and a variety of PDEs. 
This is therefore a difficult pathway to dissect. My data suggests involvement of PDE10A to 
the process of flow-induced vessel remodelling, via effects on PKA, however much more 
evidence and research is required to pinpoint how this enzyme is involved before it 
becomes therapeutic target with clinical implications.  
Should PDE10A be identified as a target for therapeutic development, the focus of the 
research would be to enhance PDE10A function in people unable to utilise and remodel 
collateral vessels. PDE inhibitors which impair vessel remodelling could be developed for 
use in the clinic as anti-cancer therapeutics. For this study the purpose of using a PDE10A 
inhibitor has been to investigate a role and validate PDE10A expression during collateral 
vessel remodelling. The chick embryo could also potentially be used as a model to 
investigate targets to enhance PDE10A function and improve collateral formation.  
To conclude, by using global transcriptional profiling in a chick model I have identified 
PDE10A as a novel regulator of collateral vessel development. The translational potential of 
this finding remains to be examined. 
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Appendix 
Chapter 3 
 
 
 
 
 
Figure A1. Following tied-ligation, over an 8h timecourse collateral vessels 
could be seen to develop from a pre-existing distal branch of the unligated 
left vitelline artery. 
Following right proximal vitelline artery tied-ligation, a plastic disc was placed 
over the left vitelline artery to follow one field of view over time. The panels 
show micrographs from one representative chick embryo from T0 post tied-
ligation to 8 hours. Scale bar = 1000m 
254 | E m i l y  C l a r e  H o g g a r  
 
 
Figure A2. A representative PIV image of the blood velocity in the left proximal 
vitelline vessel of a HHst 17 chick embryo  
The heatmap on the side of the image shows average velocity of the vectors recorded 
in the vessel. The highest velocity is indicated by red vectors. 
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Figure A3. The parabolic curves to show the blood flow was fastest at the centre of 
the vessel in collateral vessels recorded at 24h using PIV  
For vessels recorded at 24 hours LaVision processing software also produced parabolic 
curves from the data which showed blood velocity was highest at the centre of the 
vessel. Each of the vessels shown in the panels on the left are individual collateral 
vessels from one chick embryo (Figure 3.12). The corresponding parabolic flow data is 
shown in the graphs on the right. 
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Chapter 4 
 
 
 
 
 
  
Figure A4. Venn diagram showing number of differentially expressed genes at 4 hours 
and 12 hours post-sham-ligation, compared to the baseline measurement. 
The circle on the left represents the number of differentially expressed genes at 4 hours 
post-sham surgery compared to baseline (HH st17). The circle on the right represents 
the number of differentially expressed genes 12 hours post sham-ligation compared to 
baseline. The overlapping section of the circles represents 69 genes which are 
differentially expressed at both timepoints compared to baseline. 
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Figure A5. Hierarchically clustered heatmaps of  the fold changes of the differentially 
expressed genes during normal development 
 
Shows normalised expression over time. Black indicates no expression, intensity of red is 
proportional to expression level. The tree has been separated out into nodes (A-G). Each 
represents a cluster of genes with similar expression profiles. The tree map to the left of 
each coloured node represents the relatedness of genes in each nodel.  
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Table A1. The shared differentially expressed genes which were expressed in both tied-
ligated (L)and sham-ligated (sh) models (taken from the heatmap data) 
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Table A2. The gene functions of the shared differentially expressed genes which were 
expressed in both tied-ligated (L)and sham-ligated (sh) models (as in Table A1) 
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Figure A6. Gene ontology was used to cluster differentially expressed genes by 
biological processes and molecular function from the data analysed at 4 hours after 
tied-ligation 
 
A Biological processes which were statistically significantly over/under represented at 
4h. Complement activation was most hihly over-represented.  B Molecular functions 
which were statistically over/under represented at 4h, included protein binding. 100% 
indicates the same number as expected by chance. P<0.05 
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Figure A7. Gene ontology was used to cluster differentially expressed genes by 
biological processes and cellular components from the data analysed at 12 hours after 
tied-ligation 
 
A Gene ontology showed the biological processes statistically significantly over/under 
represented at 12h based on the number of differentially expressed genes observed, 
compared to the number of genes expected in that process in the chicken genome. B 
Cellular components which were over-represented at 12h post tied-ligation included 
components involved with the exracellular matrix and extracellular region. 100% 
indicates the same number as expected by chance. P<0.05 
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Chapter 5 
 
 
 
 
 
 
 
 
 
Figure A8. Clustal alignment of the PDE10A antigen peptide sequence in human 
and chick  
 The PDE10A antibody binds to the region of human PDE10A protein shown above 
(peptide sequence incl. amino acids 547-739) -this was the species the antibody was 
raised against. The alignment with the peptide sequence in the chick PDE10A protein 
suggested that the similarity of antigen sequence in both species was sufficient for 
the anti-human PDE10A antibody to react with the chick tissue and bind to PDE10A 
protein. 
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Figure A9. PDE10A immunohistochemistry of a transverse section through embryonic 
mouse brain tissue  
Mouse brain tissue aimed to serve as a positive control.The panels show representative 
examples of a panel of different concentrations tested.  The first panel shows the 
merged labelling patterns of DAPI(blue) and PDE10A (green). These images could then 
be split into separate colour channels to view the individual staining patterns. 
Representative image from 3 embryos. 
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Figure A11. Dye assays showed diffusion from the filter paper to the vitelline 
membrane 
Food dye solution was able to freely diffuse from the filter paper placed oer the left 
vitelline artery. 24h after the disc was removed the food dye had transferred to the area 
of the disc, suggesting that at least this solution was able to leave the filter paper. 
Figure A10. PDE10A immunohistochemistry of a transverse section through chick 
embryo brain tissue (HH st 17) 
Chick brain tissue aimed to serve as a positive control. The white box shows the 
magnified region in B. The green arrow indicates positive PDE10A labelling in neurons 
positive for PDE10A. DAPI labelling of cell nuclei is indicated by blue stain. 
Representative image from 6 embryos. 
